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SUMMARY 
Diabetes mellitus (DM) is a metabolic disorder that results from a 
dysfunction of insulin secretion (type 1) and/or sensitivity (type 2). Type 1 
and in many cases type 2 diabetic patients require daily insulin injections to 
control blood glucose levels and retard the appearance of diabetes-related 
complications. The liver plays a central role in the context of whole-body 
glucose homoeostasis and fuel management in general. Under physiological 
conditions, insulin is released by the pancreas into the portal vein and 
reaches the liver along with the nutrient flow absorbed in the 
gastrointestinal tract (GIT). Under these conditions, the actions of insulin on 
liver metabolism play a key role in promoting glucose and lipid storage. 
DM is characterized by impairment of these actions resulting in abnormal 
levels of blood glucose and lipids that, if left untreated, provoke widespread 
secondary complications. With current therapies, insulin is delivered 
subcutaneously and this results in a predominantly peripheral uptake, in 
contrast with the physiological release profile. The experimental work 
described on this thesis addressed the pathways for glucose disposal and 
storage in the liver under two experimental settings representing the fasted 
to fed transition and the fed state. The studies were performed in non-
diabetic control rats and in a rat model for type 1 DM, the streptozotocin 
(STZ)-diabetic rat. The delivery of insulin by alternative liver-targeted 
routes was also explored. 
A general introduction is presented in chapter 1. Diabetes and its 
therapy are briefly addressed and the STZ-diabetic rat model for the study 
of type 1 DM is introduced. Hepatic glucose and lipid metabolism are 
overviewed with emphasis to its regulatory aspects, and molecular 
mechanisms of insulin signaling are integrated with the metabolic 
regulation. In the last section of this chapter the use of stable isotope tracers 
for the study of hepatic metabolism is briefly overviewed.  
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In the studies described in chapter 2, rats were challenged with a 
carbohydrate load after a 24-hour fast and glucose disposal was addressed 
by carbon 13 (13C) and deuterium (2H) nuclear magnetic resonance (NMR) 
spectroscopy. One group of animals was given a glucose load and the other 
a mixture consisting of 9 equivalents of glucose and 1 equivalent of 
galactose. Hepatic glycogen was depleted with fasting and increased 8-10 
times after the carbohydrate loads. The gluconeogenic flux dominated both 
glycogen synthesis and endogenous glucose production (EGP). Galactose 
hepatic metabolization resulted in a decreased contribution of load glucose 
to glycogen but apparently had little effect on the clearance of load glucose 
from the blood. 
Chapter 3 presents the glucose challenge study performed in STZ-
diabetic rats after a 24-hour fast. One group of animals was injected insulin 
by the subcutaneous (s.c.) route prior to receiving the glucose load. In 
another group insulin was delivered to the intraperitoneal (i.p.) cavity to 
provide a higher portal/peripheral ratio and target the liver. In a last group, 
rats did not receive any treatment. Glucose disposal was traced by 13C and 
2H NMR methods. There was no net hepatic glycogen synthesis during the 
test, not even in the insulin-treated rats. The untreated STZ-diabetic rats 
showed increased EGP coupled with reduced clearance of load glucose. The 
absolute contribution of EGP to blood glucose in the insulin-treated rats was 
reduced to control levels, regardless of the route of insulin administration. 
Glucose clearance was highly enhanced in the insulin-treated rats even 
when compared to controls. These studies indicate that in the context of a 
glucose challenge, the stimulatory effect of insulin on glucose uptake is 
much higher than its inhibitory effect on EGP. 
The absorptive state was addressed in chapter 4, and hepatic 
metabolism was studied in ad libitum fed STZ-diabetic and non-diabetic 
control rats with the deuterated water (2H2O) tracer approach. In controls, 
net glycogen synthesis during an overnight feeding accounted for one third 
of the hepatic stores and was equally derived from the direct and indirect 
(gluconeogenic) pathways. The amount of glycogen synthesized by diabetic 
|xxiii 
rats was similar to controls in all stages of the disease but the hepatic 
glycogen content was lower 10 and 20 days after the induction by STZ, 
indicating that those animals had higher glycogen turnover rates. There was 
a progressive increase of the indirect pathway contribution to hepatic 
glycogen synthesis from 70% 4 days after diabetes induction to 90% at 10 
and 20 days of the disease. Parallel to the disruption in glycogen synthesis, 
the contribution of gluconeogenesis to EGP was profoundly increased 10 
and 20 days after diabetes induction but not in the earlier stage (4 days). The 
lipogenic pathway was promptly reduced 4 days after the induction of 
diabetes but the hepatic triglyceride (TG) content was similar to controls. 
With the progression of the diabetic condition, the contribution of the 
lipolytic flux increased, resulting in elevated hepatic TG content. 
Chapter 5 describes the insulin replacement experiments in STZ-
diabetic rats. The treatment protocol consisted in two daily injections by the 
s.c. or i.p. route and was carried out for 10 days. Hepatic metabolism was 
then addressed by the 2H2O method under natural feeding conditions. Gene 
expression and enzyme activity assays were also performed in liver samples 
from those rats. With both treatments there was a restoration of the direct 
pathway to glycogen synthesis and of the pathways to EGP. In the i.p.-
treated rats glycogen stores could be recovered to control levels. The 
lipogenic pathway was also enhanced but was still lower than controls in 
both s.c.- and i.p.-treated groups. Despite the improvements on glycogen 
and TG synthesis in the liver, the gluconeogenic and lipolytic fluxes could 
not be efficiently suppressed with the insulin-replacement protocols. 
Chapter 6 explores the use of novel nanoparticle-based delivery 
systems in insulin therapy. Experiments in control rats showed that the 
hypoglycemic response following s.c. injection of insulin was enhanced by 
the use of nanoparticles from poly-lactide-co-glycolide (PLGA), especially 
when γ-cyclodextrin esters with 10 carbon alkyl chains (γ-CDC10) were 
present in the formulation. The oral route was also investigated but the 
nanoparticles were ineffective even after coating with an enteric polymer. 
Experiments in STZ-diabetic rats did not demonstrate any benefit of the 
xxiv| 
 
nanoparticle formulation relative to a standard insulin solution in terms of 
the hypoglycemic response following the s.c. injection nor in the context of a 
glucose challenge.  
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RESUMO 
A diabetes mellitus constitui um perturbação metabólica que resulta 
de uma disfunção na secreção (tipo 1) e/ou sensibilidade (tipo 2) à insulin. 
Os doentes do tipo 1, e em muitos casos também do tipo 2, necessitam de 
injecções diárias de insulina para controlar os níveis plasmáticos de glucose 
e retardar o aparecimento de complicações relacionadas com a doença. O 
fígado é um órgão central na regulação da homeostase da glucose e na 
gestão energética em geral. Em condições fisiológicas, a insulina é secretada 
pelo pâncreas para a veia porta e chega ao fígado de forma consertada com 
a absorção de nutrientes no tracto gastrointestinal. Nestas condições, os 
efeitos da insulina no metabolismo hepático são fundamentais para 
promover o armazenamento de glucose e lípidos. A diabetes é caracterizada 
por perturbações nestes efeitos, que se refletem em níveis anormais de 
glucose e lípidos no sangue, os quais, não corrigidos, provocam o 
alastramento de complicações secundárias. Na terapêutica tradicional, a 
insulina é administrada por via subcutânea (s.c.), o que resulta numa 
insulinização predominantemente periférica, por oposição ao perfil de 
libertação fisiológico. O trabalho experimental descrito nesta tese estudou a 
captação e consumo de glucose pelo organismo e seu armazenamento no 
fígado em dois contextos experimentais representando a transição do jejum 
para o estado prandial e o estado prandial propriamente dito. Os ensaios 
foram realizados em ratos controlo e ratos tornados diabéticos por indução 
com estreptozotocina (STZ), um modelo animal para a diabetes tipo 1. 
Foram ainda estudadas vias alternativas para administração de insulina 
direccionada ao fígado. 
O capítulo 1 apresenta uma indrodução geral. A diabetes e o seu 
tratamento são abordados de forma breve e o modelo animal de diabetes 
induzida por STZ é apresentado. O metabolismo hepático da glucose e dos 
lípidos é analizado sendo dado ênfase ao seu controlo e regulação. Aspectos 
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moleculares da transdução do sinal da insulina, com relevância para a 
regulação metabólica, são abordados. Por último, a aplicação de substratos 
enriquecidos com isótopos estáveis ao estudo do metabolismo hepático é 
apresentada. 
Nos ensaios descritos no capítulo 2, os ratos receberam uma dose 
massiva de açúcares após 24 horas de jejum e o consumo de glucose foi 
seguido por espectroscopia de ressonância magnética nuclear de carbono 13 
(13C) e deutério (2H). A um grupo de animais foi administrada uma dose de 
glucose e a outro uma mistura que consistiu em 9 equivalentes de glucose e 
1 equivalente de galactose. As reservas de glicogénio no fígado foram 
consumidas no período de jejum e aumentaram 8-10 vezes após a ingestão 
das doses de açúcares. Tanto a produção endógena de glucose como a 
síntese de glicogénio hepático foram dominadas pelo fluxo da 
neoglucogénese. A metabolização hepática da galactose reduziu a 
contribuição da glucose exógena para a síntese de glicogénio mas pouco 
alterou a captação de glucose do sangue. 
O capítulo 3 descreve a prova de tolerância à glucose realizada em 
ratos diabéticos por indução com STZ, após 24 horas de jejum. Um grupo de 
animais recebeu insulina por via s.c. antes da dose de glucose. Num outro 
grupo, a insulina foi injectada na cavidade intraperitoneal (i.p.) para 
aumentar a razão portal/periférica e direccionar a insulina para o fígado. 
Um último grupo não recebeu qualquer tratamento. O consumo de glucose 
foi avaliado por técnicas de RMN de 13C e 2H. Não houve síntese líquida de 
glicogénio no fígado, nem mesmo nos ratos injectados com insulina. Os 
ratos diabéticos que não foram injectados com insulina apresentaram um 
aumento da produção endógena de glucose acompanhado por uma redução 
da captação de glucose plasmática. A contribuição absoluta da produção 
endógena para a glucose plasmática nos ratos diabéticos injectados com 
insulina foi igual à observada nos controlos não diabéticos, 
independentemente da via de administração. O consumo de glucose 
proveniente da dose administrada foi bastante aumentado, mesmo em 
comparação com os controlos. Estes ensaios indicam que, no contexto de 
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uma prova de tolerância à glucose, a acção da insulina é mais notória na 
estimulação da captação de glucose do sangue do que na inibição da 
produção endógena de glucose. 
O estado prandial propriamente dito foi abordado no capítulo 4. 
Ratos controlo e diabéticos por indução com STZ alimentados ad libitum 
foram estudados e o seu metabolismo hepático avaliado pelo método da 
água deuterada (2H2O). Nos ratos controlo, a síntese líquida de glicogénio 
durante uma noite de alimentação representou um terço do conteúdo 
hepático e seguiu as vias directa e indirecta (neoglucogénica) de forma 
equivalente. Os ratos diabéticos sintetizaram uma quantidade de glicogénio 
similar aos controlos em todos os estádios da doença avaliados, mas o 
conteúdo hepático total diminui 10 e 20 dias depois da indução da diabetes, 
significando que nestes casos houve uma maior renovação do glicogénio 
hepático. Verificou-se um domínio progressivo da via indirecta para a 
síntese de glicogénio, que aumentou de 70% 4 dias após a indução da 
diabetes para 90% 10 e 20 dias depois. Paralelamente às alterações no 
metabolismo do glicogénio, a contribuição da neoglucogénese para a 
produção endógena de glucose foi profundamente aumentada 10 e 20 dias 
após a indução de diabetes mas manteve-se igual à dos controlos aos 4 dias 
da doença. A via lipogénica foi imediatamente reduzida 4 dias depois da 
indução da diabetes mas o conteúdo hepático de triglicerídeos manteve-se 
igual ao dos controlos. Com a progressão da doença, a contribuição do fluxo 
lipolítico aumentou, levando ao aumento do conteúdo hepático de 
triglicerídeos. 
O capítulo 5 relata as experiências de reposição da insulina em 
animais diabéticos. O protocolo de tratamento consistiu em duas injecções 
diárias por via s.c. ou i.p. durante 10 dias. O metabolismo hepático foi, 
então, seguido com 2H2O em condições de alimentação ad libitum. Foram 
ainda feitos ensaios de expressão genética e actividades enzimáticas em 
amostras de fígado destes animais. Ambos os tratamentos proporcionaram a 
recuperação das vias de síntese hepática de glicogénio bem como das vias 
para a produção de glucose para valores controlo. Os animais injectados 
xxviii| 
 
com insulina por via i.p. apresentaram níveis de glicogénio no fígado 
semelhantes aos controlos. A via lipogénica também foi potenciada mas 
manteve-se abaixo dos valores dos controlos com ambos os tratamentos. 
Apesar das melhorias na síntese hepática de glicogénio e triglicerídeos, os 
fluxos da neoglucogénese e lipólise não foram suprimidos com os 
protocolos de reposição de insulina. 
O capítulo 6 explora o uso de novas formulações de nanopartículas 
na terapêutica com insulina. As experiências em ratos controlo mostraram 
que a acção hipoglicémica da insulina foi potenciada através do uso de 
nanopartículas de um co-polímero de ácido láctico e glicólico (PLGA), 
mormente com a inclusão de esters da γ-ciclodextrina com cadeias alquílicas 
de 10 carbonos (γ-CDC10). A via oral também foi investigada mas a 
formulação não se mostrou eficaz, nem quando as nanopartículas foram 
revestidas com um polímero entérico. Nas experiências em ratos diabéticos 
por indução com STZ não ficou demonstrado qualquer benefício da 
formulação de nanopartículas em relação a uma solução padrão de insulina 
em termos de acção hipoglicémica após administração s.c. nem no contexto 
de uma prova de tolerância à glucose. 
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1                                                                                                            
GENERAL INTRODUCTION 
All life forms exist in a state of dynamic equilibrium. Life relies on 
the flux of matter and energy through the cellular metabolic pathways and 
during these processes the balance between nutrient intake and the release 
of excretory products must be maintained (Fell 1997). Several levels of 
control including biochemical, endocrine, physiological, neuronal and 
behavioral are involved in the interplay between energy intake, storage and 
expenditure (Friedman 1995). The liver is a central organ in the context of 
energy balance and fuel management and hence plays an important role in 
whole-body metabolism.  
Glucose is a universal source of energy for cells in the organism. The 
liver is responsible both for glucose production during fasting and its 
disposal and storage in the fed state. Those pathways are connected to the 
processing of other fuels like lipids and proteins in the intricate network of 
whole-body metabolism. Glucose, protein and lipid metabolism are 
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regulated, among other factors, by the pancreatic hormone insulin. Diabetes 
melittus (DM) is characterized by a dysfunction of insulin secretion and/or 
sensitivity, which results in metabolic disruptions.  
The following sections address briefly DM pathology and treatment 
as well as an experimental animal model for its study. Hepatic glucose and 
lipid metabolism is overviewed with focus on its regulatory aspects and 
integration with insulin action. Finally, tracer-based approaches to the study 
of these metabolic pathways are generally discussed.  
 
1.1 Diabetes mellitus 
The World Health Organization (WHO) describes DM as “a 
metabolic disorder of multiple etiology characterized by chronic 
hyperglycemia with disturbances of carbohydrate, fat and protein 
metabolism, resulting from defects in insulin secretion, insulin action or 
both” (WHO 1999). The WHO report from 2006 recommends as diagnosis 
criteria fasting plasma glucose ≥ 7.0 mM (126 mg/dL) or 2-hour1 plasma 
glucose ≥ 11.1 mM (200 mg/dL) (WHO 2006).  
The current classification of DM is based on the clinical stages as 
well as the etiology of the disease (WHO 1999). Type 1 DM results from β 
cell destruction secondary to idiopathic or auto-immune factors; whereas 
type 2 DM may range from predominantly insulin resistance with relative 
insulin deficiency to predominantly insulin deficiency with relative insulin 
resistance. The previous types constitute the basic forms of diabetes and 
while there may be several therapeutic options for type 2 diabetic patients, 
the treatment of type 1 DM relies completely on the administration of 
exogenous insulin. With insulin administration (to type 1 and in some cases 
also type 2 diabetic patients) hyperglycemia is prevented and when a strict 
metabolic control is followed (Atkinson et al. 2001), the diabetes-related 
                                                     
1 Refers to the oral glucose tolerance test (OGTT) where plasma glucose is measured 2 hours 
after the ingestion of a 75 g oral glucose load following an overnight fast. 
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complications (retinopathy, nephropathy, neuropathy, heart disease, among 
others) are delayed, with benefits for the patients’ quality of life.  
 
1.1.1 Insulin therapy and formulation 
Before the discovery of insulin in the 1920s the life span of people 
diagnosed with diabetes was rarely beyond childhood. Although insulin 
doesn’t cure diabetes, its value in the treatment of diabetic patients was 
immediately recognized by the attribution of the Nobel Prize in Physiology 
and Medicine to Banting and Macleod in 1923 for “The discovery of insulin” 
(Nobelprize.org 2010).  
Following the discovery of insulin many advances were made 
concerning its isolation and purification. In the 1980s the technology of 
recombinant deoxyribonucleic acid (DNA) allowed for the industrial 
production and commercial expansion of human insulin and, in the last 15 
years, modified insulins (with altered amino acid sequences) produced by 
biotechnology engineering techniques resulted in enhanced stability and/or 
modulation of the duration of action (Pillai et al. 2001).  
Despite the huge amount of improvements on insulin therapy, its 
administration often requires multiple daily injections via the subcutaneous 
(s.c.) route. This is unpleasant for the patients, thus compromising their 
compliance to the treatment. Furthermore, delivery by the s.c. route is 
unable to mimic the physiologic portal to peripheral gradient resulting in 
deficient hepatic insulinization. This may limit the metabolic performance of 
insulin-treated diabetic patients compared to that of healthy individuals, 
particularly in the case of hepatic-specific actions such as glycogen kinetics 
(Bischof et al. 2002).  
Presently, research on insulin formulation is focused on exploring 
more patient-friendly routes such as the oral (e.g. Chalasani et al. 2007; 
Damgé et al. 2007; Reis et al. 2008) or pulmonary (e.g. Johansson et al. 2002; 
Aguiar et al. 2004). The oral route has the advantage of delivering insulin to 
the portal vein, resembling the physiological release and appropriately 
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targeting the liver. Therefore, effective oral delivery may constitute an 
important strategy for optimizing the metabolic effects of insulin. This can 
be achieved by the use of specialized delivery systems such as nanoparticles 
(explored in chapter 6).  
Alternatively to the insulin supplementation therapy, providing 
diabetic patients with functional β cells constitutes the ultimate goal of DM 
treatment. Pancreas and isolated islet transplantation has allowed for 
diabetic patients to produce their own insulin (Shapiro et al. 2000; 
Sutherland et al. 1998). In the context of β cell replacement, the liver is 
commonly used as a surrogate for the pancreatic function. For example, in 
islet transplantation protocols the portal vein is used to graft the β cells 
(Shapiro et al. 2000). Moreover, with advances in stem cell technology, cells 
in the liver have been reprogrammed to express the β cell phenotype 
(Aguayo-Mazzucato et al. 2010; Halban et al. 2010; Wagner et al. 2010). In 
addition, using virus as gene delivery vehicles has allowed for the basal 
hepatic insulin expression in diabetic rats and translated into improved 
glycemic control (Dong et al. 2002).  
 
1.1.2 The STZ-diabetic rat as a model for type 1 diabetes 
The diabetogenic action of streptozotocin (STZ) was discovered in 
the 1960s (Junod et al. 1969) and ever since this drug has been widely used 
in the experimental setting to induce diabetes in rodents.  
 In rats, type 1 DM is induced by a single intravenous injection of 
STZ at a dose no lower than 45 mg/kg (Junod et al. 1969). Alternatively, STZ 
can be delivered to the intraperitoneal (i.p.) cavity at a dose no lower than 
50 mg/kg (Szkudelski 2001). Typically, doses of 50-65 mg/kg lead to 
chronic hyperglycemia and higher doses cause severe ketosis and death 
within days (Wei et al. 2003). Additionally, STZ can induce type 2 DM if rats 
are injected a high dose of the drug (~100 mg/kg) in the first days that 
follow birth (Szkudelski 2001). 
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Structurally, STZ is a nitrosouria derivative with a hexose moiety 
that allows it to enter the cells by the same transporter as glucose. Uptake of 
STZ occurs specifically via the glucose transporter 2 (Glut-2), which is the 
principal glucose transporter in rodent β cells (Wollheim et al. 2004), and 
this seems to be essential for its toxic action (Hosokawa et al. 2001). In 
addition, STZ is also toxic to other tissues expressing Glut-2, like the liver or 
the kidney, and the damage on extra pancreatic cells may also account for 
the pathology that characterizes the STZ-diabetic rat (Lenzen 2008). 
Several cytotoxicity mechanisms, ultimately leading to cell death, are 
described for the deleterious action of STZ in β cells. Streptozotocin causes 
direct damage on DNA by alkylation (Bolzán et al. 2002). In addition, STZ 
acts as a nitric oxide donor leading to the production of reactive oxygen 
species that also account for the DNA damage (Szkudelski 2001). Recently, 
another toxicity mechanism has been proposed in which STZ inhibits the 
activity of N-acetyl-β-D-glucosaminidase (O-GlcNAcase), the enzyme that 
removes N-acetylglucosamine from proteins, hence contributing to increase 
protein glycosilation in β cells (Konrad et al. 2001; He et al. 2009). Moreover, 
O-GlcNAcase from pancreatic islets was found to be more sensitive to STZ 
than that from other tissues (Konrad et al. 2001), providing supporting 
evidence for the β cell selectivity of STZ. 
The STZ-induced type 1 diabetic rat model displays the typical 
symptoms of type 1 DM present in humans (e.g. polyphagia, polydipsia and 
polyuria). Blood glucose levels rapidly increase within hours after the 
administration of a diabetogenic dose of STZ to adult rats, in parallel with a 
decrease in insulin levels (Burcelin et al. 1995). Food and water consumption 
increase in the first days and remain elevated for several weeks while 
weight gain is restrained (Wei et al. 2003). Hence, the STZ-diabetic rat is a 
very popular model for experimental type 1 DM and is used recurrently in 
addressing the pathophysiology of the disease and in characterizing the 
efficacy of antidiabetic interventions (e.g. Ferrannini et al. 1990; Akirav et al. 
2004; Iwasaki et al. 2005; Lo et al. 2006; Suthagar et al. 2009).  
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1.2 Overview of hepatic glucose and lipid 
metabolism  
Following meal digestion in the gastrointestinal tract (GIT), nutrients 
are absorbed to the blood and reach the liver via the portal vein. This event 
is consonant with the release of insulin from the pancreatic β cells into the 
portal vein, in response to glucose (and also protein and fatty acid) 
stimulation (Utzschneider et al. 2004). Under physiological conditions, the 
liver extracts 50-80% (Radziuk et al. 1994; Utzschneider et al. 2004) of portal 
vein insulin with the remainder reaching the systemic circulation. In the 
liver, insulin suppresses hepatic glucose production, which is active in the 
post absorptive or fasted state, and stimulates pathways for glucose 
disposal and storage as glycogen and lipids. The liver alone accounts for the 
extraction of one third of a glucose load, muscle and fat for another third 
and brain and red blood cells for the remaining third (Cherrington 1999). 
On the other hand, during fasting, the brain takes up about 80% of the 
glucose produced endogenously (Baron et al. 1988).  
 
1.2.1 Glucose disposal and storage 
Figure 1 depicts the fates of glucose in the liver, in the postprandial 
or absorptive state. Glucose enters the hepatocyte through the Glut-2 
transporter, which is primarily expressed in the liver but is also present in 
kidney, intestine and pancreatic β cells (Nordlie et al. 1999). Other dietary 
sugars like fructose or galactose also enter the liver through this transporter. 
The transport of glucose via Glut-2 is bidirectional; moreover Glut-2 has low 
affinity and high capacity for glucose facilitating both the efflux and uptake 
of glucose in the range of concentrations necessary for glucose homeostasis 
(Nordlie et al. 1999). 
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Figure 1  Schematic overview of the pathways for glucose disposal in the liver. Glycolysis, 
glycogenesis and de novo lipogenesis are presented and the key enzymes and 
glucose transporter involved are shown. For simplicity, some reactions in the 
pathways are omitted (discontinued arrows). (1) OAA is first converted to malate 
(and eventually further to pyruvate) in the cytosol prior to being transported back 
into the mitochondrion and resynthesized to OAA. Acetyl-CoA, acetyl coenzyme 
A; F6P, fructose-6-phosphate; FBP, fructose-1,6-bisphosphate; G1P, glucose-1-
phosphate; G6P, glucose-6-phosphate; Glut-2, glucose transporter 2; malonyl-
CoA, malonyl coenzyme A; OAA, oxaloacetate; TGs, triglycerides; UDPG, uridine 
diphosphate glucose. 
 
In the liver, the first reaction in glucose metabolism is the adenosine 
triphosphate (ATP)-dependent conversion of glucose to glucose-6-
phosphate (G6P) by hexokinase IV or glucokinase (GK). Glucokinase is 
expressed in the liver and pancreatic β cells and unlike the other 
Glucose
Glut-2
G6P G1P
Glycogen
F6P
FBP
Pyruvate Acetyl-coA
TCA 
cycle
Acetyl-CoA
Citrate
OAA
Mitochondrion
Hepatocyte (cytosol)
G
ly
co
ly
si
s
Glycogenesis
LipogenesisGlucokinase
Phosphofructokinase
Pyruvate
kinase
Pyruvate
dehydrogenase
UDPG
Glycogen synthase
Glucose
Citrate lyase
TGs
Acetyl-coA 
carboxylase
Fatty acid 
synthase
Malonyl-CoA
Pyruvate
Citrate OAA
(1)
8|Chapter 1 
 
hexokinases (I, II and III) it displays low affinity for the substrate. 
Furthermore, GK is not inhibited by physiological concentrations of the 
reaction product, G6P, and this allows the feed-forward activation of 
subsequent disposal fluxes (Agius 2008). In the liver, the control of GK 
activity is dependent in a regulatory protein (GKRP) that acts as an 
inhibitory competitor in regards to glucose (Agius 2008). It is widely 
accepted that under basal conditions of 5.5 mM glucose concentration, GK 
exists sequestered in the nucleus in association with GKRP and that GK is 
released and translocated to the cytosol under high glucose or low fructose 
concentration (Agius et al. 1993; de la Iglesia et al. 1999; Agius 2008). 
Fructose-1-phosphate, whose intrahepatic levels increase in the postprandial 
state, binds to GKRP causing the weakening of its interaction with GK, and 
this results on the release of the active GK (Iynedjian 2009). On the other 
hand, in the postabsorptive state, fructose-6-phosphate (F6P) binds to GKRP 
stimulating its interaction with GK (Iynedjian 2009), which is consequently 
imported back to the nucleus. This way GK degradation is prevented and at 
the same time a large stable pool of the enzyme is conserved for recruitment 
upon refeeding (Newgard 2004).  
Glucose uptake through Glut-2 is coordinated with its 
phosphorilation by GK (Figure 1) resulting in the formation of G6P, which 
can be directed to glycogen synthesis or glycolysis. 
 
1.2.1.1 Glycogen synthesis 
 Glycogen deposition occurs in the liver after a meal. The hepatic 
glycogen stores represent an important source of glucose to be released in 
the fasted state by the liver so that plasma glucose levels remain within the 
physiological range and whole-body energetic demands are fulfilled. Net 
glycogen synthesis results from the interplay between glycogen synthase 
(GS) and glycogen phosphorylase (GP) activities. In the biogenesis of 
glycogen, G6P is first converted to glucose-1-phosphate (G1P) by 
phosphogluco isomerase and subsequently to uridine diphosphate glucose 
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(UDPG) by UDPG pyrophosphorylase. Glycogen synthase then adds 
glucose residues from the UDPG donor to the growing glycogen molecule 
via α-1,4 bonds. 
The formation of glycogen is intimately related to glucose 
phosphorylation by GK. In fact, glycogen synthesis is sensitive to increases 
in GK activity secondary to glucose-induced translocation of GK (Agius et 
al. 1996). Furthermore, when GK translocates to the cytosol it is directed to 
the plasma membrane in a way that allows the coupling of glucose 
phosphorylation with glycogen synthesis (Jetton et al. 2001). The fact that 
GK overexpression enhances glycogen deposition (O'Doherty et al. 1996; 
Seoane et al. 1999; Morral et al. 2004), further demonstrates the dependence 
of glycogen synthesis on GK. The product of the GK reaction, G6P, is not 
only a precursor to glycogen but also a regulator itself of GS activity. 
Hepatic GS exists in an inactive form in the cytosol and it is activated and 
directed to the periphery of the cell via G6P stimulation (Ferrer et al. 2003). 
The binding of G6P to the phosphorylated (inactive) isoform of GS, causes a 
conformational change that makes it a better substrate for protein 
phosphatases, which then convert the enzyme to the active 
(dephosphorylated) isoform (Villar-Palasi et al. 1997; Ferrer et al. 2003). 
Insulin stimulates GS by increasing the protein phosphatase activity 
(Khandelwal et al. 1977; Newgard et al. 2000). The activity of GP, which 
catalyzes the breakdown of glycogen to G1P molecules, is also regulated by 
phosphorylation in a coordinated fashion with GS, with the 
dephosphorylated isoform being less active than the phosphorylated (Ferrer 
et al. 2003).  
The direct conversion of glucose to glycogen via GK and GS 
coordinated fluxes does not account for the whole of glycogen deposition in 
the absorptive state and a significant contribution from gluconeogenic 
precursors is required for efficient glycogen synthesis to occur (Newgard et 
al. 1983; Katz et al. 1984; Newgard et al. 1984). This latter route is known as 
the indirect pathway, where glucose is initially metabolized to 3-carbon 
intermediates followed by gluconeogenic re-synthesis into hexose 
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phosphate (Figure 2). This route also allows non-hexose precursors such as 
glycerol or gluconeogenic amino acids to be converted to glycogen. The 
relative contributions of both pathways depend on the nutritional and 
pathophysiological status of the organism, with the indirect pathway 
contribution to glycogen synthesis increasing with fasting (Shulman et al. 
1990; Hellerstein et al. 1995), type 1 DM (Hwang et al. 1995) or GK deficiency 
(Velho et al. 1996). 
 
 
 
Figure 2  Pathways for glycogen synthesis in the liver. By the direct pathway (orange 
arrow) glucose is converted to glycogen via glucokinase and glycogen synthase 
coordinated activities. Alternatively, glucose can be first metabolized to 3-carbon 
intermediates (mostly in the muscle) that are used in the liver to generate G6P for 
glycogen synthesis via the indirect pathway (blue arrow). DHAP, 
dihydroxyacetone phosphate; F6P, fructose-6-phosphate; FBP, fructose-1,6-
bisphosphate; G1P, glucose-1-phosphate; G6P, glucose-6-phosphate; G3P, 
glyceraldehyde 3-phosphate; UDPG, uridine diphosphate glucose. 
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1.2.1.2 Glycolysis and lipogenesis 
 Glycolysis refers to the series of cytosolic reactions that break down 
one glucose molecule to two pyruvate molecules. The first step in the 
glycolytic pathway is the highly regulated phosphorylation of glucose to 
G6P by GK, already overviewed. This reaction, together with the conversion 
of F6P to fructose-1,6-bisphosphate (FBP) catalyzed by phosphofructokinase 
(PFK) and the conversion of phosphoenolpyruvate (PEP) to pyruvate 
catalyzed by pyruvate kinase (PK) constitute the irreversible steps in 
glycolysis. The energy charge of the cell, as well as allosteric and 
transcriptional processes contribute to control the flux thourgh PFK and PK. 
Briefly, PFK and PK are stimulated by insulin, glucose and products from 
its early metabolism, while a high ratio of ATP to adenosine diphosphate 
(ADP) plus adenosine monophosphate decreases the activity of those 
enzymes (Newgard 2004).  
The most important activator of hepatic PFK is fructose-2,6-
bisphosphate (F2,6P2), which is degraded (to F6P and inorganic phosphate) 
and regenerated (from F6P and inorganic phosphate) by the bifunctional 
enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. In the fed 
state, xylulose-5-phosphate derived from glucose metabolization via the 
pentose phosphate pathway stimulates protein phosphatase 2A (PP2A) that 
dephosphorylates the bifunctional enzyme, favoring its kinase activity and 
the formation of F2,6P2 (Newgard 2004). Experiments in fasted rats showed 
that hepatic levels of F2,6P2 start to increase several hours after glucose 
administration or refeeding, when glycogen stores in the liver are near to 
replenishment (Kuwajima et al. 1984; Kuwajima et al. 1986; Holness et al. 
1988; Jin et al. 2003). Hence, under refeeding circumstances, stimulation of 
the glycolytic flux occurs after that of glycogen synthesis. Moreover, a 
positive correlation was observed between hepatic glycogen levels and the 
lipogenic rate after chow refeeding (Holness et al. 1988). Accordingly, when 
hepatic glycogen is depleted in humans by dietary intervention, excessive 
carbohydrate intake is disposed by high glucose oxidation rates and de novo 
lipid synthesis only after glycogen stores become saturated (Acheson et al. 
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1988). On the other hand, under natural feeding conditions, F2,6P2 levels 
rise in parallel with glycogen in the liver (Bois-Joyeux et al. 1986) suggesting 
the sequence of events may not be the same as in refeeding conditions.  
After the glycolytic phase, pyruvate enters the mitochondria and is 
oxidized to acetyl coenzyme A (acetyl-CoA) by pyruvate dehydrogenase 
multienzyme complex (PDH). This reaction links glycolysis to the 
tricarboxylic acid cycle (TCA cycle) and de novo lipogenesis (DNL). The 
activity of PDH is ruled by posphorylation (inhibition)-dephosphorylation 
(stimulation) mechanisms and inhibited by the end products acetyl-CoA 
and nicotinamide adenine dinucleotine in the reduced form (NADH) 
(Strumiło 2005). In rats, starvation, DM and low carbohydrate diet result in 
the inactivation of PDH whereas insulin and high carbohydrate loads 
activate PDH (Randle 1998). Furthermore, a decrease in circulating non-
esterified fatty acids (NEFA) is observed under those conditions (high 
insulin, low glucagon). Since the activity of PDH is inhibited by increased 
mitochondrial levels of acetyl-CoA and NADH from NEFA metabolism 
(Randle 1998; Holness et al. 2003), reduced NEFA levels permit more PDH 
flux and a greater potencial for glycolytic acetyl-CoA generation. In rats, the 
decrease in hepatic DNL rate during fasting (decline in insulin and glucose 
levels) is accompanied by a progressive reduction of PDH activity (Holness 
et al. 1990). In contrast, the flux through PDH relative to that of the TCA 
cycle is increased under simultaneous hyperinsulinemia and hyperglycemia 
conditions (Alves et al. 2011).  
The “first” reaction in the TCA cycle is the condensation of acetyl-
CoA with oxaloacetate (OAA) to yield citrate, catalyzed by citrate synthase. 
Citrate is common to both pathways downstream acetyl-CoA formation. 
Alternatively to following the TCA cycle reactions, citrate can be exported 
to the cytosol where citrate lyase (CL) reconverts it to acetyl-CoA, which can 
be used in DNL, and OAA that returns to the mitochondria in the form of 
either malate or pyruvate. The cytosolic conversion of OAA to malate and 
further to pyruvate requires the sequential activities of malate 
dehydrogenase and nicotinamide adenine dinucleotine phosphate (NADP)-
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malic enzyme. The latter reaction provides the majority of reducing 
equivalentes for DNL in the form of reduced NADP (NADPH). The 
remainder is produced in the pentose phosphate pathway by the activities 
of glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate 
dehydrogenase (6PGDH). 
In addition to glycolytically-derived pyruvate, acetyl-CoA molecules 
for the lipogenic pathway may be produced from amino acid catabolism, 
fatty acid oxidation or acetate from intestinal fermentation. Malonyl 
coenzyme A (malonyl-CoA) is formed by the carboxylation of acetyl-CoA 
catalyzed by acetyl-CoA carboxylase (ACC). Malonyl-CoA is a physiological 
inhibitor of carnitine palmitoyltransferase 1 (CPT1) (Ruderman et al. 1999), 
which transports fatty acids from the cytosol to the mitochondrial matrix for 
β oxidation. In this way, fatty acids from DNL are directed to esterification 
resulting on the synthesis of triglycerides (TGs).  
In humans, under normal conditions, daily hepatic DNL accounts 
only for a minor fraction of TG synthesis (3-7%) in the liver but this 
contribution is increased (up to 32%) by dietary (e.g. fructose, low fat-high 
carbohydrate diets) or hormonal intervention (e.g. insulin) (Hellerstein et al. 
1996). In rodents, the contribution of DNL to the hepatic TGs ranges from 
5% in 5-hour refed rats (Hellerstein et al. 1991) to 11% in 3-day ad libitum fed 
rats (Delgado et al. 2009a). Other studies report contributions up to 70% 
when the experiment was followed for two weeks, using a different rat 
specie (Lee et al. 2000; Bassilian et al. 2002). 
 
1.2.2 Lipids disposal and storage 
1.2.2.1 Brief overview of lipoprotein metabolism 
Lipids are different from other nutrients since, with the exception of 
short-chain fatty acids, they are not directly delivered to the portal 
circulation upon intestinal absorption. Instead, water-insoluble dietary 
lipids are processed within the enterocyte and packed into chylomicrons 
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that are absorbed to the lymphatic circulation prior to reaching the blood. 
Chylomicrons are part of the specialized family of plasma lipid-carriers, 
lipoproteins. These structures are spherical particles composed of a 
hydrophobic core (cholesterol esters and TGs) and a hydrophilic surface 
monolayer of phospholipids, cholesterol and apolipoproteins. Lipoproteins 
with distinct functions and compositions arise from the dynamic crosstalk 
between the liver and peripheral tissues through the bloodstream.  
The main function of chylomicrons is to transport diet-derived TGs 
to the tissues of destiny. After meals, the increase in plasma TGs is largely 
dependent on the chylomicron-TGs, although there is also a contribution 
from very low density lipoprotein (VLDL)-TGs (Frayn 2002). Chylomicron-
TGs are hydrolyzed by the endothelial enzyme lipoprotein lipase (LPL) and 
the resulting fatty acids are taken up by the tissues and stored (adipose 
tissue) or used for oxidation (skeletal muscle). Also by LPL activity, VLDL 
secreted by the liver deliver fatty acids to extra-hepatic tissues. Insulin is a 
potent activator of LPL, stimulating its expression and activity in the 
adipose tissue (Frayn 2002; Vergès 2009). Accordingly, in insulin-deficient 
mice, LPL activity is reduced hampering the storage of fat in adipocytes 
(Pighin et al. 2005). In untreated type 1 diabetic patients, the lack of insulin 
causes hypertriglyceridemia as a consequence of the reduced catabolism of 
TG-rich lipoproteins (Vergès 2009) and the same is observed in insulin-
deficient rats (Iwasaki et al. 2005). 
With the further removal of TGs, VLDL remnant particles are 
converted to the cholesterol-enriched intermediate density lipoproteins and 
low density lipoproteins, which supply cholesterol to essentially all cells. 
Conversely high density lipoproteins (HDL) are responsible for the reverse 
transport of cholesterol to the liver for excretion in the bile. The liver 
secretes these particles as lipid-poor lipoproteins. In the circulation, nascent 
HDL receive phospholipids and apolipoproteins from chylomicrons and 
VLDL, and take up cholesterol and phospholips from the peripheral tissues 
(Vergès 2009).  
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1.2.2.2 Hepatic TG dynamics and VLDL metabolism 
Besides DNL (see section 1.2.1.2), dietary and lipolytic sources 
contribute to the hepatic TG pool. As chylomicrons travel through the 
bloodstream they become depleted on TGs and the remnant particles are 
cleared from the blood by the liver through receptor-mediated endocytosis. 
Hence, dietary TGs reach the liver associated to the remnant chylomicrons. 
Hepatic lipase hydrolyses TGs from chylomicrons (and also other 
lipoproteins) releasing the fatty acids, which are re-esterified and stored as 
TGs in intra-hepatic lipid droplets (Sparks et al. 2009). 
In addition, fatty acids from adipose tissue lipolysis transported by 
plasma albumin also contribute to the hepatic TG pool. This inflow of NEFA 
is particularly high during fasting and decreases rapidly after meals as a 
result of insulin action on suppressing hormone sensitive lipase in the 
adipose tissue (Frayn 2002). This event, coupled with the stimulation of LPL 
causes the net storage of TGs in the adipocyte in the postprandial state.  
In the liver, TGs are packed along with cholesterol into VLDL and 
secreted to the bloodstream. A rate-limiting step in the formation of VLDL 
is the transfer of TGs to apolipoprotein B (apoB) by the microsomal transfer 
protein (MTP) (Kamagate et al. 2008). Insulin decreases VLDL secretion 
(Huang et al. 2009) by several mechanisms, including a direct inhibition of 
MTP gene expression and apoB synthesis (Sparks et al. 2009) and the 
suppression of NEFA release from adipose tissue as discussed above. 
Hence, and in accordance with the stimulation of DNL and of energy 
storage in general, insulin promotes the accumulation of TGs in the liver 
(Huang et al. 2009). 
 
1.2.3 Glucose production 
In the absence of exogenous glucose, provided by food intake, 
plasma glucose levels are maintained via endogenous glucose production 
(EGP). The liver is the main organ accounting for EGP but the kidney and 
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small intestine are also able to produce glucose and release it to the 
bloodstream (Mithieux et al. 2004), although their contribution only becomes 
significant in severe insulinopenic states such as prolonged fasting or 
diabetes (Mithieux et al. 2006). This capacity for glucose output relies on the 
activity of glucose-6-phosphatase (G6Pase), the enzyme that catalyzes the 
dephosphorylation of G6P to glucose. 
In the liver, G6P can originate from the release of glucosyl units from 
hepatic glycogen stores (glycogenolysis) or can be synthesized de novo in the 
process of gluconeogenesis. In healthy humans the gluconeogenic 
contribution to EGP increases with fasting from 40-55% in the postprandial 
state to 95% from the 42nd hour of fasting and onward (Chandramouli et al. 
1997; Roden et al. 2001). Parallel to this, hepatic glycogen stores decrease 
linearly in the first hours of fasting (Petersen et al. 1996) and are nearly 
depleted by the 42nd hour (Roden et al. 2001). 
Pathways to glucose production are dependent on substrate and 
hormonal inputs. The fall of glucose levels and the concomitant increase in 
the glucagon/insulin ratio observed in the fasted state translates into an 
increase in glycogenolysis and gluconeogenesis (Lefèvre 2004).  
 
1.2.3.1 Glycogenolysis 
As mentioned in section 1.2.1.1, net glycogen storage or breakdown 
depends on the activities of GS and GP. Those enzymes are regulated by 
reciprocal phosphorylation/dephosphorylation mechanisms. In catabolic 
states such as fasting or stress, cyclic adenosine monophosphate (cAMP)-
dependent protein kinase A (PKA) phosphorylates GS, inactivating it and 
conversely phosphorylates phosphorylase kinase that phosphorylates 
(activates) GP (Newgard et al. 2000). In addition, glycogen synthase kinase 3 
(GSK3) is also activated by PKA and contributes to further inactivate GS 
(Jope et al. 2004). 
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1.2.3.2 Gluconeogenesis 
The regulation of gluconeogenesis mainly occurs at a transcriptional 
level, in accordance with the slow transition from the fed to fasted state 
(Newgard 2004). The first step of gluconeogenesis is the conversion of 
pyruvate to PEP. This step actually involves the activity of two key 
enzymes: pyruvate carboxylase (PC) that generates OAA from pyruvate and 
PEP carboxykinase (PEPCK) that converts OAA to PEP. Under fasting 
conditions, it is the oxidation of fatty acids that fuels this energetically-
expensive conversion and at the same time provides allosteric regulators 
that favor it. Namely, acetyl-CoA stimulates PC and along with NADH and 
ATP (also by-products from the oxidation of fatty acids) inhibit PDH 
(Newgard 2004). Furthermore, the binding of glucagon to its cell receptor 
results in the conversion of ATP to cAMP that acts to stimulate the PEPCK 
gene expression (Gurney et al. 1994; Newgard 2004). The expression of the 
G6Pase gene is also increased by cAMP and, in addition, by variables 
associated with the diabetic condition like hyperglycemia and 
hyperlipidemia (Newgard 2004). The gene expression and activity of FBPase 
are also increased with fasting or insulinopenic diabetes but the underlying 
mechanisms are still unclear (Newgard 2004).  
 
1.3 Molecular aspects of insulin signaling 
 Insulin is a hormone that promotes anabolic processes. In the liver, 
insulin acts to stimulate glucose disposal and storage and inhibit glucose 
production as generally discussed in the previous sections. These effects are 
mediated by changes in enzyme activities or amounts as a consequence of 
the intracellular transduction of insulin’s signal. 
When insulin binds to its transmembrane receptor elicits a 
conformational change that results in the autophosphorylation of the 
receptor, which in turn mediates the phosphorylation of several 
intracellular substrate proteins on tyrosine residues (Garvey 2004). The 
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effects of insulin on cell function will depend on the substrate proteins 
involved and on the signaling pathways activated henceforward. Most of 
insulin’s metabolic effects result from a signaling pathway that involves the 
phosphorylation of the insulin receptor substrate (IRS) proteins and the 
sequential activation of phosphatidylinositol 3-kinase (PI3K) and Akt or 
protein kinase B (Akt/PKB).  
The following section introduces some of the most important 
signaling mechanisms and molecules implicated in insulin’s metabolic 
effects in the liver. 
 
1.3.1 Metabolic effects of insulin signaling in the liver 
In the liver, the PI3K pathway stimulates glycogen synthesis since 
Akt/PKB phosphorylates GSK3, inactivating it and hence stimulating GS 
activity (see also section 1.2.3.1) (Peak et al. 1998; Saltiel et al. 2001; Garvey 
2004).  
Another important hepatic metabolic consequence of the Akt/PKB 
pathway is the phosphorylation of forkhead box O1 (FoxO1) and the 
consequent export of that transcription factor from the nucleus to the 
cytosol. By this mechanism, the FoxO1-dependent gene expression of 
gluconeogenic enzymes PEPCK and G6Pase is decreased (Foufelle et al. 
2002; Garvey 2004; Postic et al. 2004). In addition, phosphorylation of FoxO1 
as a result of insulin signaling also prevents its interaction with peroxisome 
proliferative activated receptor γ co-activator 1, which is necessary for the 
transcription of the PEPCK and G6Pase genes (Postic et al. 2004). Moreover, 
since the nuclear activity of FoxO1 also accounts for the expression of MTP 
and apoB, insulin inhibition of FoxO1 translates into a decrease of VLDL 
secretion in the liver (Sparks et al. 2009).  
Conversely to the inhibition of FoxO1, insulin induces another 
transcription factor, the sterol regulatory element binding protein 1c 
(SREBP1c) probably also through the PI3K-Akt/PKB signaling pathway 
(Foufelle et al. 2002; Barthel et al. 2003). SREBP1c regulates gene expression 
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for GK, PK and most lipogenic genes, including the ones for fatty acid 
synthase multienzyme complex (FAS), ACC and CL (Foufelle et al. 2002; 
Garvey 2004). However, SREBP1c activity alone does not account for the 
stimulation of the glycolytic and lipogenic metabolic pathways and, with 
the exception of GK, most of the enzymes involved in those pathways are 
also induced by glucose via the carbohydrate responsive element binding 
protein (ChREBP) (Dentin et al. 2005). Under basal conditions, PKA 
phosphorylates ChREBP retaining it in the cytosol; conversely, under high 
glucose levels, xylulose-5-phosphate-stimulated PP2A dephosphorylates 
ChREBP allowing it to migrate to the nucleus (Towle 2005). 
 
1.4 Nuclear magnetic resonance spectroscopy 
methods in metabolism 
Metabolic phenotyping is emerging in the post-genomics and 
proteomics era in the context of linking cell metabolism – a fundamental 
parameter of cell function – to the DNA information and transcription 
(Chikayama et al. 2008). A comprehensive metabolic analysis provides an 
integrate profile of the pathophysiological status that results from the 
genomic, transcriptomic and proteomic variability, and is the basis for the 
development of a new field, metabonomics/metabolomics2 (Lindon et al. 
2007; Bain et al. 2009). Nuclear magnetic resonance (NMR) spectroscopy is a 
powerful and versatile technique for the study of cellular, tissue and whole-
body metabolism. In the context of metabonomics, NMR spectroscopy 
represents a quantitative, non-destructive tool that requires little sample 
preparation for the analysis of complex biological fluids, cells or even intact 
tissues. For such samples, a sizable array of metabolites can be identified 
                                                     
2 These two terms are used interchangeably in the scientific community. In its original 
definition “metabonomics” is the quantitative measurement of the dynamic multiparametric 
metabolic response of living systems to pathophysiological stimuli or genetic modification 
while “metabolomics” is the comprehensive and quantitative analysis of all metabolites in a 
system (Lindon et al. 2007). 
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and their concentrations measured from a single proton (1H) NMR 
spectrum. 
Moreover, NMR assessments can be performed in vivo, what 
represents a major breakthrough relative to the previously-established 
invasive approaches that required needle biopsies and catheterization 
(Roden et al. 2001). With in vivo 1H, carbon 13 (13C) and phosphorous 31 
NMR spectroscopy experiments, the metabolic profile of diverse metabolites 
can be determined in several organs includind liver, brain and muscle (e.g. 
Sinha et al. 2002; Goforth et al. 2003; Gruetter et al. 2003; Lanza et al. 2006; 
van Zijl et al. 2007) and followed in longitudinal studies to assess the 
dynamics of metabolite pools. Most interestingly, in the context of hepatic 
carbohydrate metabolism, the quantification of glycogen by in vivo 13C NMR 
spectroscopy is used in combination with tracer-based experiments and 
plasma turnover measurements providing a comprehensive insight into the 
metabolic fluxes (Roden et al. 1996; Bischof et al. 2002; Petersen et al. 2004).  
 
1.4.1 The use of stable isotopes to trace carbohydrate and lipid 
metabolism 
By definition, a metabolic tracer is a substance used to follow the 
biological transformation of an endogenous substrate (tracee). The tracer 
must be metabolically indistinguishable from the tracee but at the same time 
possess a unique property allowing for its detection. In the large majority of 
cases, tracers consist of synthetic substrate molecules where one or more of 
the atoms have been substituted by rare isotopes that can be detected by a 
specific technique. Stable isotopes such as 13C and deuterium (2H) can be 
detected by NMR and mass spectrometry and these approaches have 
largely replaced earlier tracer studies based on their radioactive 
counterparts (carbon 14 and tritium). In addition to being safer, stable 
isotope analytical methods have a key advantage over radioactive tracer 
detection in that they inherently provide positional labeling information. 
Equivalent information may be obtained with radioactive tracers, but it 
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involves highly tedious carbon-by-carbon degradation of the metabolite of 
interest. 
Isotopic labels at specific positions of any given precursor substrate 
are transferred to metabolic intermediates and products in a highly specific 
manner during the biochemical reactions within the organism. Thus, the 
fate of the labeled precursor is highly predictable depending on the 
metabolic pathway that it transverses. With NMR analysis of the product 
labeling pattern, different metabolic routes can be discriminated and 
measured.  
 
1.4.1.1 [U-13C]glucose as a tracer to glucose and glycogen metabolism 
Glucose kinetics can be addressed by enriching the plasmatic pool 
with [U-13C]glucose. This is easily achieved by supplementing a meal or a 
glucose solution with the tracer or even by delivering it directly to the 
bloodstream in more invasive infusion procedures. When [U-13C]glucose 
enters the disposal pathways, two important events occur to the plasmatic 
pool, (i) it becomes less enriched with the tracer as it is taken up by the cells 
and (ii) other 13C-enriched glucose isotopomers 3  arise from the 
metabolization (or recycling) of the tracer. The relative contribution of each 
isotopomer to the plasma glucose pool can be disclosed by 13C NMR 
spectroscopy and this information provides insight into the dynamics of 
whole-body glucose metabolism, which is sensitive to several 
pathophysiological conditions. 
Uptake of [U-13C]glucose is followed by its metabolization within the 
cells. For example, in the liver, the direct conversion of the tracer into 
glycogen renders [U-13C]UDPG and glycogen composed of [U-13C]glucosyl 
residues. If, on the other hand, glucose follows the glycolytic pathway, this 
results in the formation of two molecules of [U-13C]pyruvate. The glycolytic 
                                                     
3 Contraction of the words isotope and isomer, refers to molecules that differ one from the 
other solely by their isotopic composition. For example, considering the glucose molecule 
and the 13C isotope, each carbon may be 12C or 13C. Since there are 6 carbons in glucose, there 
are 26 = 64 possible isotopomers. 
22|Chapter 1 
 
processing is especially active in peripheral tissues like the muscle, where, 
under anaerobic conditions, pyruvate is further converted to lactate by 
lactate dehydrogenase. Lactate from muscle glycolysis then enters the 
bloodstream and is taken up by the liver, where it is reconverted to 
pyruvate that serves as a gluconeogenic substrate for glucose production. 
This sequence of events is named the Cori cycle. As a result of the glucose 
resynthesis from [U-13C]pyruvate, other isotopomers arise. In this process 
there is scrambling of the labeling due to pyruvate recycling (pyruvate → 
OAA → PEP → pyruvate) and racemization at the OAA/fumarate inter-
conversion. In consequence, several possible populations of glucose 
isotopomers from [U-13C]pyruvate can be predicted (Mendes et al. 2006) but 
[1,2-13C2]- and [1,2,3-13C3]glucose account for the majority (Perdigoto et al. 
2003), and the isotopomer analysis is thus much simplified. Moreover, those 
isotopomers can be distinguished from the [U-13C]glucose tracer by analysis 
of the C1 resonance in the 13C NMR spectrum of a glucose derivative 
(method applied in chapters 2 and 3).  
 
1.4.1.2 Deuterated water as a tracer to glucose and glycogen 
metabolism 
Deuterated water (2H2O) is a relatively inexpensive tracer. Upon 
administration it freely distributes within the tissues and rapidly 
equilibrates with total body water, thus allowing to follow whole-body 
metabolism (Murphy 2006). Deuterated water is easily administered both to 
humans and animals by adding it to the common drinking water in tracer 
amounts. Furthermore, 2H2O can be delivered to animals as an i.p. bolus 
that results in a steady state enrichment within 10 minutes (Turner et al. 
2003). Additionally, the subjects may be maintained under 2H2O 
administration for several days, making it suited for assessing metabolism 
both in short and long term studies in diverse experimental settings 
(Murphy 2006).  
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Glucose-6-phosphate is a common precursor to both glycogen and 
glucose. In the presence of 2H2O, G6P is labeled with 2H in several positions 
due to the incorporation of that isotope from body water in exchange and 
addition reactions of the G6P production pathways. This labeling is 
maintained in the glucose and glycogen molecules. Thus, a given positional 
2H enrichment in glucose or glycogen reflects the reaction accounting for 
incorporation from 2H2O in that position. Moreover, the positional 2H 
enrichment quantitatively reflects its respective reaction if isotopic steady 
state has been achieved (which occurs very fast with 2H2O) and the reaction 
is complete.  
A large body of studies has been performed in the past 15 years 
based on the 2H2O method and equations established by Landau and co-
workers (Landau et al. 1995; Landau et al. 1996). The exchange of protons 
with 2H from the 2H2O at the level of the G6P/F6P keto-enolic equilibrium 
results in the enrichment of G6P with 2H in position 2 (Figure 3). Because 
that isomerization is extensive and essentially complete, the G6P pool is 
enriched with 2H in position 2 regardless of its origin. Hence, 2H labeling of 
position 2 of glucose is assumed to reflect the total EGP, both via 
gluconeogenesis and glycogenolysis. In fact, in fasting conditions, when 
EGP is the only source of blood glucose, the 2H enrichment in position 2 of 
glucose is essentially that of body water both in humans (Landau et al. 1995; 
Jones et al. 2006a) and rats (Nunes et al. 2009). Likewise, both direct and 
indirect pathway precursors of glycogen become enriched with 2H from 
2H2O in position 2. On the other hand, 2H enrichment from 2H2O in position 
5 of G6P specifically and quantitatively reflects the contribution of 
gluconeogenesis from both pyruvate and glycerol. Incorporation of 2H in 
that position occurs at the level of the triose phosphates isomerization 
(Figure 3).  
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Figure 3  Reactions for glucose and glycogen labeling from 2H2O. Deuterium incorporation 
in position 2 of G3P (in blue) results in labeling of G6P in position 5. This labeling 
occurs when G6P is produced from either gluconeogenic precursor pyruvate or 
glycerol. Deuterium enrichment in position 2 (in orange) of G6P reflects both 
gluconeogenesis/indirect pathway and glycogenolysis/direct pathway due to the 
extensive G6P/F6P equilibrium. DHAP, dihydroxyacetone phosphate; F6P, 
fructose-6-phosphate. G3P, glyceraldehydes-3-phosphate; G6P, glucose-6-
phosphate. 
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1.4.1.3 Deuterated water as a tracer to de novo lipogenesis 
Fatty acid biosynthesis, as that of many other endogenous polymers, 
can be measured by mass isotopomer distribution analysis (MIDA). This 
method is based on the mathematics of combinatory probabilities and 
determines the true precursor enrichment by the analysis of the isotope 
distributions on the polymer end-product. For example, plasma VLDL 
isotopomer abundances can be quantified by mass spectrometry following 
the administration of 13C-enriched acetate (Hellerstein et al. 1996) or 2H2O 
(Murphy 2006) and the precursor (intracellular acetyl-CoA) enrichment 
determined by MIDA provides an estimation of hepatic DNL. 
Alternatively, the hepatic pool of acetyl-CoA can be sampled in vivo by the 
administration of a xenobiotic metabolized in the liver by acetylation. This 
strategy was developed by Hellerstein and colleagues (Hellerstein 1991; 
Hellerstein et al. 1991) and reports DNL values comparable with those from 
MIDA analysis.  
In the process of lipid biosynthesis, the incorporation of hydrogens (or 
deuterium) from the body water into the fatty acid molecule may occur 
directly or indirectly, through NADPH in the reduction steps or via the 
labeling of precursor acetyl-CoA. The methyl groups of the fatty acids in 
the TG molecule are derived from acetyl-CoA (Murphy 2006). Hence, a 
simple method for the quantification of DNL consists in determining the 
2H enrichment in the methyl group of TGs (by 2H NMR analysis of hepatic 
lipids) and relate that to the precursor enrichment in the presence of 2H2O 
(Delgado et al. 2009a).  
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2                                                                                                    
GLUCOSE PRODUCTION AND HEPATIC GLYCOGEN SYNTHESIS 
DURING A CARBOHYDRATE CHALLENGE IN RATS – EFFECT OF 
GALACTOSE 
2.1 Introduction 
The study of hepatic glycogen synthesis by the direct and indirect 
pathways is of central importance in the field of metabolic disorders like 
diabetes or obesity. Those contributions can be resolved in humans by 
supplementing a breakfast meal with 13C-enriched glucose and a xenobiotic 
glucuronide precursor such as paracetamol (Hellerstein et al. 1986; Delgado 
et al. 2009b). The 13C enrichment of UDPG, sampled via the urinary 
glucuronide, relative to that of 13C-enriched plasma glucose provides a 
measure of direct and indirect pathway contributions. Alternatively, the 
enrichment of UDPG position 5 from ingested 2H2O can be used to 
determine direct and indirect pathway contributions to glycogenic flux 
(Jones et al. 2006a). To date, none of these measurements have accounted for 
the effects of galactose that may be present in the breakfast meal. Although 
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it may be a minor component of the total meal carbohydrate intake, the fact 
that it is metabolized by liver (while dietary glucose is mostly metabolized 
by peripheral tissues) amplifies its effects on postprandial hepatic 
carbohydrate metabolism. For example, a 300 mL portion of reduced fat 
milk contains about 15 g of lactose or 7.5 g galactose – about 7.5% of the 
total carbohydrate from a typical breakfast meal containing ~100 grams of 
carbohydrate. Galactose aside, the liver accounts for about 20%, or 20 grams 
of glucose absorption from this meal. In this setting, the contribution of 
galactose to total hepatic carbohydrate uptake is 7.5/27.5 g, or 
approximately 27%. 
Galactose is metabolized to common intermediates of glucose 
metabolism via the Leloir pathway as shown in Figure 4 (Hellerstein et al. 
1988; Niewoehner et al. 1990; Niewoehner et al. 1992; Wehrli et al. 2007). 
After galactose phosphorylation to galactose-1-phosphate (Gal1P), 
galactose-1-phosphate uridyltransferase catalyses the transference of the 
UDP moiety from UDPG to Gal1P, producing UDP-galactose (UDPgal) and 
G1P. UDPgal is then converted to UDPG by UDP-galactose 4-epimerase. 
UDPG may then be converted to glycogen via GS or be metabolized to G1P. 
The extensive equilibration between G1P and G6P coupled to G6Pase 
activity allows the net conversion of galactose to hepatic glucose. 
All tracer measurements of direct and indirect pathway 
contributions to hepatic glycogen synthesis are based on the assumption 
that the labeled G6P precursor of one pathway is diluted by unlabeled G6P 
generated by the other. Thus, glucose tracers are metabolized to G6P via the 
direct pathway and are assumed to be diluted by G6P molecules generated 
by indirect pathway activity so that UDPG enrichment is less than that of 
the glucose precursor. With 2H2O, G6P derived via the indirect pathway is 
enriched in the fifth hydrogen to the same level as body water and this 
enrichment is assumed to be diluted by direct pathway G6P molecules that 
are not enriched in this position. In the presence of galactose, these 
assumptions are no longer valid since the conversion of galactose to UDPG 
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represents a hitherto undefined capacity for diluting UDPG enrichment 
from either 13C-glucose or 2H2O tracers.  
 
 
 
Figure 4 Schematic representation of pathways for glycogen synthesis and endogenous 
glucose production in the liver during a mixed glucose/galactose load. Glycogen 
sources include glucose (direct or indirect pathway), galactose and endogenous 
precursors. Sources of endogenous glucose production include gluconeogenesis 
(glucose load recycling plus endogenous precursors), galactose and glycogen. 
DHAP, dihydroxyacetone phosphate; G1P, glucose-1-phosphate; G3P, 
glyceraldehydes 3-phosphate; G6P, glucose-6-phosphate; Gal1P, galactose-1-
phosphate; UDPG, uridine diphosphate glucose; UDPGal, uridine diphosphate 
galactose. 
 
This chapter focuses on the effect of a small fraction of galactose, 
equivalent to that derived from a single glass of milk in a standard breakfast 
meal, on the estimates of direct and indirect pathways using current tracer 
methods. The experimental setting consisted of an oral glucose tolerance 
test (OGTT) performed to fasted rats, including [U-13C]glucose and 2H2O 
tracers. In the galactose experiments, these tracers were accompanied by [1-
13C]galactose so that its conversion to glycogen could be independently 
monitored. Additionally, in the same experiment, the glucose clearance 
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from the blood could be characterized by resolving the contributions from 
the load glucose, galactose and endogenous sources. 
 
2.2 Materials and methods 
2.2.1 Animal studies 
2.2.1.1 Animal housing 
Male Wistar rats (Charles Rivers, Spain) with approximately 8 weeks 
were used. Animals were subjected to a 12 hour light/12 hour dark cycle 
(lights on from 7 am to 7 pm) with free access to a standard chow diet (60% 
carbohydrates, 16% proteins, 3% lipids). At least five days of acclimatization 
were allowed before any intervention was performed on the animals.  
 
2.2.1.2 Animal protocols 
Rats (231 ± 5g) were fasted for 24 hours with free access to water. In 
order to attain proper body water 2H2O enrichment animals were injected 2 
mL of 2H2O in the i.p. cavity at the beginning of the study. Carbohydrate 
loads were also dissolved in 2H2O. A glucose load (2 g/kg, approximately 
2.6 mmol per animal) enriched to 10% with [U-13C]glucose was 
administered to the first group (GLU, N = 6) by oral gavage. The second 
group (GLU+GAL, N = 6) was administered the same dose of carbohydrate 
as glucose-galactose mixture consisting of 9 equivalents of glucose and 1 
equivalent of galactose. The glucose fraction was enriched to 10% with [U-
13C]glucose while the galactose fraction was enriched to 10% with [1-
13C]galactose. After administering the carbohydrate loads, plasma glucose 
was monitored from tail tip samples every 15 minutes until 180 minutes 
with an Accu-check Aviva (Roche, Portugal) glucometer. At 180 minutes, 
animals were anesthetized by injection of ketamine (100 mg/kg) in the i.p. 
cavity, the abdominal cavity was opened and ~5 mL of blood was collected 
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from the abdominal aorta. A small blood sample (0.5 mL) was reserved for 
determination of 2H2O body water enrichment and plasma insulin levels. 
The liver was excised and immediately freeze-clamped in liquid nitrogen. In 
order to determine the basal fasting liver glycogen content, 24-hour fasted 
animals (N = 5) were sacrificed without receiving a carbohydrate load. 
 
2.2.2 Metabolite analyses 
Whole blood was immediately treated with ZnSO4 0.15 M (1.5 mL 
per mL of blood) and Ba(OH)2 0.15 M (1.5 mL per mL of blood), centrifuged, 
and glucose on the supernatant extracted by passing through a sequential 
cationic and anionic ion-exchange columns. The effluent was lyophilized 
and glucose was derivatized to monoacetone glucose (MAG) as described 
below. Liver was lyophilized, and then pulverized to a fine powder and 
glycogen extracted by treatment with 30% KOH (8 mL per gram of liver dry 
weight, gdw) at 70ºC for 30 minutes. The mixture was treated with 6% 
Na2SO4 (4 mL per gdw) and 99.9% ethanol (to a final concentration of 70%, 
25 mL per gdw) and glycogen was allowed to precipitate at 4 ºC overnight. 
After centrifugation, the upper liquid phase was discarded and the solid 
residue dried. The residue was resuspended in 50 mM NaCH3COO pH 4.5, 
and 16 units of an aqueous solution of amyloglucosidase from Aspergillus 
niger (Sigma-Aldrich, Portugal) added. The sample was incubated at 55 ºC 
overnight, and then centrifuged and the upper liquid collected and 
lyophilized. Glucose obtained from liver glycogen enzymatic hydrolysis 
was quantified by a standard assay kit (Invitrogen, Spain). The percent 
glycogen synthesized over the experimental period was determined as the 
difference between the quantified glycogen for each animal and the mean 
value determined for the 24-hour fasted controls relative to the quantified 
glycogen. Insulin levels were determined by ELISA enzyme immunoassay 
accordingly with the supplier’s instructions (Mercodia, Sweden).  
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2.2.3 Synthesis of the glucose monoacetone derivative 
In order to optimize the signal resolution in the NMR spectra, 
glucose was converted into its monoacetone derivative. Briefly, the dried 
residue either from blood or liver glycogen preparations was suspended in 
10 mL (liver) or 5 mL (blood) acetone with 4% sulphuric acid. Acetone and 
sulphuric acid were enriched with deuterium to 2% as previously described 
(Jones et al. 2006b). The mixture was stirred overnight at room temperature 
to yield diacetone glucose. The acetonation reaction was quenched by 
adding 10 mL (liver) or 5 mL (blood) of water and adjusting the pH to 8 
with 1 M NaHCO3. Following acidification of the solution to pH 2.0 with 1 
M HCl, diacetone glucose was hydrolysed to MAG by incubation at 40 ºC 
for 5 hours. The solution pH was then increased to 8 with 1 M NaHCO3 and 
the samples were dried by rotary evaporation under vacuum. MAG in the 
residue was extracted with 4 mL of boiling ethyl acetate. Following 
evaporation of ethyl acetate, the residue was saved in a desiccator until 
NMR analysis.  
 
2.2.4 NMR Spectroscopy 
All spectra were analyzed with the NUTS PC-based NMR spectral 
analysis software (Acorn NMR Inc., USA). The peak areas were quantified 
using the curve fitting or the integration tool and the applied line 
broadening was 0.5 Hz for 1H NMR spectra, 1 Hz for 2H NMR spectra and 
0.2 Hz for 13C NMR spectra. 
 
2.2.4.1 2H NMR analysis of body water  
Body water 2H2O enrichments were determined from plasma by 2H 
NMR as described by Jones et al. (Jones et al. 2001) with adaptations. Briefly, 
10 µL of plasma were mixed with 1 mL of acetone. After centrifugation 0.6 
mL of the supernatant was collected and transferred to a 5 mm NMR tube. 
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2H NMR spectra were obtained at 25 ºC with a 11.7 T Varian Unity 500 
spectrometer (Agilent, USA) equipped with a 5 mm broadband probe with 
the observe coil tuned to 2H. Proton decoupled 2H NMR spectra were 
acquired with a 25° pulse, 4 seconds of acquisition time and 8 seconds of 
pulse delay. The number of scans was 24 and spectra typically looked like 
the one depicted in Figure 5. In order to determine the absolute 2H 
enrichment level of plasma samples a calibration curve was prepared from 
water standards enriched with 99% 2H2O from 1.3% to 3.3% (Figure 6).  
 
 
 
 
 
Figure 5 2H NMR spectrum showing the resonances for acetone and water. The water 
sample was enriched with 2H2O to 3.3% while acetone was used as internal 
standard. 
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Figure 6 Plot of the area of 2H water signals (normalized for the masses of sample and 
acetone; 2H-acetone signal area was set to 100) as a function of the 2H2O 
enrichment of water standards. The linear regression equation used to determine 
the 2H enrichment level of body water from plasma samples is shown.  
 
2.2.4.2 2H NMR analysis of MAG 
MAG was dissolved in 0.6 mL of 85% (v/v) acetonitrile in dimethyl 
sulfoxide (DMSO) or, alternatively, in 0.2 mL or 0.6 mL of 90% (v/v) 
acetonitrile in water with NaHCO3 (9 mg/mL), accordingly with the probe 
used. Proton-decoupled 2H NMR spectra of MAG samples were obtained at 
50 ºC with two alternative NMR spectrometers, a 11.7 T Varian Unity 500 
equipped with a 5 mm broadband probe and a 14.1 T Varian 600 (Agilent, 
USA) equipped with either a 3 mm or a 5 mm broadband probe. In all cases 
the observe coil was tuned to 2H and fully-relaxed spectra were acquired 
with a 90° pulse and 1.7 seconds of recycling time. The collection time 
ranged from 45 minutes to 12 hours according with sample size. In the 
Varian 600 system, field frequency stability was maintained via the Varian 
1H-Scout acquisition sequence. MAG 2H enrichments were quantified from 
the 2H NMR spectra by measuring the intensity of each signal of the MAG 
hexose moiety relative to the mean intensity of the two intramolecular 
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methyl reference signals at 1.28 and 1.40 ppm (Jones et al. 2006b). Each 
reference signal represents three equivalent hydrogens enriched to 2.5% 
with 2H (i.e. corresponding to 7.5% enrichment for a single hydrogen site). 
After each acquisition, the solvents were immediately removed by 
evaporation and the dried samples saved until 13C NMR analysis. 
 
2.2.4.3 1H and 13C NMR analyses of MAG 
Samples were dissolved in 0.2 mL of 90% (v/v) acetonitrile-d3 in 
water. Proton-decoupled 13C NMR spectra were acquired at 14.1 T with the 
Varian 600 spectrometer equipped with a 3 mm broadband probe. Spectra 
were obtained at 25 ºC. An acquisition time of 2.5 seconds and a pulse delay 
of 0.5 seconds were used and the number of acquisitions ranged from 5,000-
25,000. 1H NMR spectra were obtained in the same spectrometer equipped 
with a 3 mm indirect detection probe. Spectra were obtained at 25 ºC, using 
an acquisition time of 1.5 seconds and a pulse delay of 0.1 second. The 
number of acquisitions ranged from 22 to 512. 
The 13C enrichment level of MAG carbon 1 (13C1) was determined by 
1H NMR analysis of the hydrogen 1 signal (Figure 7). This resonance 
consists of a central doublet, D (from 1H-1H coupling to hydrogen 2 - 3JHH = 
3.8 Hz), representing hydrogens bound to 12C1, and a pair of satellite 
multiplets, SM (from heteronuclear direct 1H-13C coupling to 13C1 – 1JHC = 
184.5 Hz; 1H-1H coupling to hydrogen 2, and long range 1H-13C couplings to 
carbons 2 and 3 - nJHC, n>1), representing hydrogens bound to 13C1. The 13C1 
enrichment level was estimated as the intensity of the SM divided by the 
total resonance intensity i.e. SM + D as follows: 
 
Total 13C enrichment %  100  SMSMD 
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Figure 7 1H NMR spectrum of a MAG sample enriched with 13C1 isotopomers. The 
resonance for position 1 hydrogen is shown, it consists of a central dublet (D) 
representing hydrogens bound to 12C1 and two satellite multiplets (SM) 
representing hydrogens bound to 13C1. The expansion for one of the satellite 
multiplets is also shown. 
 
The fractional contribution of [1-13C]-, [1,2-13C2]-, [1,2,3-13C3]- and [U-
13C]hexose isotopomers to the 13C1 enrichment of MAG was determined 
from analysis of the carbon 1 multiplet signal in the 13C NMR spectrum as 
follows. The 7-line multiplet (Figure 10) can be resolved into a singlet 
component (C1S), representing [1-13C]MAG, a doublet component (C1D) 
representing the sum of [1,2-13C2]- and [1,2,3-13C3]MAG isotopomers, and a 
quartet component (C1Q), representing [U-13C]MAG. The fractional 
contribution of each isotopomer component to the total 13C1 signal (C1 total) 
was calculated by measuring the 13C signal intensity of each component 
relative to that of C1 total. To obtain 13C isotopomer excess enrichments, the 
fractional isotopomer contribution to the 13C1 signal was multiplied by the 
total 13C1 enrichment, as shown below. Since [1-13C]MAG enrichment (but 
not the other isotopomers) has a significant contribution from the 1.1% 
natural abundance 13C, this amount must be subtracted from the estimated 
[1-13C]MAG excess enrichment as shown below. 
 
1‐13CMAG  C1SC1 total   total 
13C1 enrichment  1.1% 
 
6.1 6.0 5.9 5.8 5.7 5.6 PPM
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1,2‐13C2  1,2,3‐13C3MAG  C1DC1 total   total 
13C1 enrichment 
 
U‐13CMAG  C1QC1 total  total 
13C1 enrichment 
 
2.2.5 Metabolic contributions parameters 
The non-hexose precursors or indirect pathway contribution to 
hepatic glycogen synthesis includes Cori cycle intermediates from 
metabolism of the glucose load as well as endogenous gluconeogenic 
precursors. The fractional contribution of non-hexose precursors to 
glycogen synthesis was calculated from the ratio of position 5 enrichment 
relative to that of position 2 (Landau et al. 1997) as shown in Equation 1. The 
balance represents the direct pathway flux from glucose as shown in 
Equation 2. The contribution of gluconeogenesis to plasma glucose was also 
calculated by Equation 1 and the hepatic glycogen’s contribution by 
Equation 2. 
 
Equation 1 
Non‐hexose precursors or gluconeogenesis %   100   H5H2 
 
Equation 2  
Direct Pathway or glycogenolysis %   100 – Non‐hexose precursors or gluconeogenesis 
 
Based on the absence of any significant levels of [1-13C]glucose 
isotopomers derived from the metabolism of [U-13C]glucose (Perdigoto et al. 
2003; Mendes et al. 2006; Sena et al. 2007), it was assumed that the 
enrichment levels of [1-13C]MAG derived from glycogen or blood glucose 
reflects the contribution from the [1-13C]galactose tracer in the load.  
From Equation 1 to Equation 6, hepatic glycogen synthesis from 
hexose and non-hexose precursors were resolved as shown in Figure 4. The 
hexose sources are resolved into glucose and galactose precursors while the 
gluconeogenic sources are resolved into recycled or indirect pathway 
carbons derived from the load and endogenous gluconeogenic precursors. 
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Since the fraction of galactose in the load was 10% enriched with [1-
13C]galactose, the percent contribution of galactose to total hepatic glycogen 
was estimated as the enrichment level of [1-13C]MAG multiplied by 10 with 
correction for the pre-existing residual unlabeled glycogen fraction (RG), as 
shown in Equation 3. The RG fraction was determined as the amount of 
residual glycogen measured in 24-hour fasted rats divided by the hepatic 
glycogen level at the end of each of the tracer load administrations. As for 
[1-13C]MAG, it was assumed that the enrichment levels of [U-13C]MAG 
derived from glycogen reflect the direct contribution from load glucose. 
Since enrichment of load glucose with [U-13C]glucose was also 10%, its 
contribution to hepatic glycogen was estimated as being 10 times [U-
13C]MAG enrichment, with correction for RG as shown in Equation 4. 
 
Equation 3 
Load galactose %  1‐13CMAG  10  11  RG   
 
Equation 4 
Load direct pathway glucose %  U‐13CMAG  10  11  RG 
 
The [1,2-13C2]- and [1,2,3-13C3]MAG isotopomer pair are assumed to 
be derived by gluconeogenic recycling of the glucose load via the Cori cycle 
and/or hepatic indirect pathway (Perdigoto et al. 2003; Mendes et al. 2006; 
Sena et al. 2007). In addition to the factor of 10 to account for the 10% [U-
13C]glucose precursor enrichment in the load, these isotopomer levels were 
multiplied by an additional factor of 1.5 to account for dilution at the level 
of the hepatic TCA cycle (Mendes et al. 2006), and corrected for residual 
unlabeled glycogen as shown in Equation 5. Isotopomers arising from 
indirect pathway metabolism of [1-13C]glucose formed via Leloir pathway 
metabolism of [1-13C]galactose were assumed to have negligible 
contributions to glycogen.  
 
Equation 5 
Load indirect pathway %  1,2‐13C2MAG  1,2,3‐13C3MAG  10  1.5  11  RG 
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The percent contribution of endogenous gluconeogenic sources was 
estimated as the difference between load contribution (Equation 3 to 
Equation 5) and 100 as shown in Equation 6. 
 
Equation 6  
Endogenous gluconeogenic %
 100  Load galactose  Load direct pathway glucose 
 Load indirect pathway 
 
Total non-hexose precursors contribution was also determined in an 
alternative way to that calculated by Equation 1 as the sum of endogenous 
gluconeogenic and load indirect contributions: 
 
Equation 7 
Non-hexose precursors %  Endogenous gluconeogenic  Load indirect pathway 
 
Plasma glucose consists of glucose absorbed from the GIT (gastric 
glucose) plus glucose from EGP. The latter includes recycling of glucose 
from the load, glucose derived from glycogen, endogenous gluconeogenic 
precursors, and galactose. Except for gastric glucose, all the other sources 
result in 2H enrichment of blood glucose in position 2. It is assumed that (i) 
hepatic G6P/F6P exchange is complete and (ii) there is negligible cycling of 
plasma glucose and hepatic G6P via GK and G6Pase. The contributions of 
load galactose and load glucose (both gastric and recycled) were 
determined similarly to those for hepatic glycogen, as shown in Equation 8 
to Equation 10. Likewise, the contribution of endogenous sources was 
determined as the difference to 100 as shown in Equation 11. 
 
Equation 8 
Load galactose %  1-13CMAG  10 
 
Equation 9 
Load gastric glucose %  U-13CMAG  10 
 
Equation 10 
Load recycled glucose %  1,2-13C2MAG  1,2,3-13C3MAG  10  1.5 
 
Equation 11  
Endogenous sources %  100  Load gastric glucose – Load recycled glucose – Load galactose 
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Endogenous sources can be further resolved into gluconeogenesis 
and glycogen by analysis of blood glucose 2H enrichment from 2H2O. The 
H5/H2 ratio corrected for the presence of gastric glucose (not labeled with 
2H) is a measure of the total gluconeogenic contribution to blood glucose 
(Equation 12), which includes that of the recycled load. The balance 
(Equation 13) represents the combined contributions of glycogen and 
galactose, since both originate glucose enriched with 2H in position 2 but 
not 5. The contribution of endogenous gluconeogenic precursors (Equation 
14) was determined by subtracting that of the recycled load (Equation 10) to 
the total gluconeogenesis (Equation 12). 
 
Equation 12 
Total gluconeogenesis %  100  Load gastric glucose   H5H2 
 
Equation 13 
Glycogen & galactose %  100  Load gastric glucose   1  H5H2   
 
Equation 14  
Endogenous gluconeogenesis %   Total gluconeogenesis   Recycled load glucose 
 
2.2.6 Statistics 
Data are expressed as means ± standard error of the mean (SEM). 
Statistical significance was determined by unpaired Student’s t test and 
defined as a p < 0.05 except when comparing more than two groups. In that 
case a one way analysis of variance (ANOVA) was performed and 
differences among means determined by Fisher’s least significant difference 
(LSD) test. 
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2.3 Results  
2.3.1 Plasma glucose levels during the carbohydrate challenge 
Plasma glucose levels over the experimental period are depicted in 
Figure 8. Baseline glycemia was not significantly different between the two 
groups (65 ± 4 mg/dL for animals assigned to the GLU group and 66 ± 5 
mg/dL for animals assigned to the GLU+GAL group). After the 
carbohydrate loads, blood glucose levels increased rapidly, peaking at 30 
minutes (182 ± 8 mg/dL for the GLU group and 169 ± 7 mg/dL for 
GLU+GAL group). Blood glucose levels returned to the normoglycemic 
range 75 minutes past the administration of the carbohydrate loads and at 3 
hours, glycemia was 87 ± 3 mg/dL for the GLU animals and 92 ± 4 mg/dL 
for the GLU+GAL animals (p = n.s.).  
 
 
 
Figure 8 Changes in blood glucose over the 180-minutes tolerance test. After a 24-hour 
fast, rats were administeraed 2H2O and a 2 g/kg oral hexose load with tracer 
amounts of [U-13C]glucose (GLU) or a 9:1 mixture of [U-13C]glucose and [1-
13C]galactose (GLU+GAL).  
 
The glycemic profile obtained following the oral administration of 
the carbohydrate loads matches other observations of conscious Sprague-
Dawley rats subjected to the same fasting period and hexose dose (Jin et al. 
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2003). The glycemic response was further assessed by calculating the area 
under the curve (AUC) for plasma glucose levels. These values were similar 
in both experimental groups. At the end of the experiment, insulin levels for 
the GLU group were 1.1 ± 0.4 µg/L and 2.4 ± 0.4 µg/L for the GLU+GAL 
group (p = 0.05). 
 
2.3.2 Hepatic glycogen content 
Figure 9 shows the hepatic glycogen content of control (24-hour 
fasted) and experimental rats, 180 minutes after the carbohydrate challenge.  
 
 
 
Figure 9 Hepatic glycogen content (µmol of glucosyl units per gram of liver dry weight) 
for 24h-fasted control rats and experimental groups. Groups are as described in 
the legend of Figure 8. Bars not sharing a common superscript letter are 
significantly different; statistical significance was accepted for a p < 0.05 
determined by one way ANOVA with Fisher’s LSD post test. 
 
In the 24-hour fasted controls, liver glycogen amounted to 6.0 ± 0.4 
µmol of glucosyl units/gdw (12 ± 0.5 µmol per liver). For animals that had 
been subjected to the carbohydrate challenges, hepatic glycogen levels were 
~8-10 fold higher: 59 ± 10 µmol of glucosyl units/gdw in the GLU group 
(net glycogen synthesis of 53 ± 10 µmol/gdw) and 41 ± 7 µmol of glucosyl 
units/gdw in the GLU+GAL group (net glycogen synthesis of 35 ± 7 
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µmol/gdw, p = n.s.). These amounts were lower4 than the range of 30 – 60 
µmol per gram of tissue reported by others for Sprague-Dawley rats 
weighing 100 – 200 g fasted for the same period prior to receiving either the 
same dose of glucose (Jin et al. 2003) or a somewhat lower (1 g/kg) load 
(Niewoehner et al. 1992). Glycogen synthesized during the 3-hour period 
represented 85 ± 4% of the total hepatic content for the GLU group and 83 ± 
2% for the GLU+GAL group, hence the pre-existing residual unlabeled 
glycogen fraction accounted for ~15% of total glycogen for both groups.  
 
2.3.3 2H enrichments 
Animals in both GLU and GLU+GAL groups attained matching 
2H2O body water precursor enrichments (Table 1). This ~2% enrichment 
level, coupled with the rates of glucose production and hepatic glycogen 
synthesis, provided sufficient amounts of 2H in the derivatized glycogen 
and glucose samples to generate 2H NMR spectra with acceptable signal-to-
noise ratios for precise quantification of positional 2H enrichment levels. 
This is illustrated by the representative 2H NMR spectra of Figure 10.  
 
Table 1: 2H enrichment levels of body water (BW) and position 2 of monoacetone glucose 
(MAG H2) derived from hepatic glycogen and blood glucose. Groups are as described in the 
legend of Figure 8. Liver and blood were collected 3 hours after the carbohydrate challenge. 
*Significantly different (p < 0.05) from BW in the same group (unpaired Student’s t test). 
 2H enrichments (%) 
BW 
MAG H2 
Blood glucose Hepatic glycogen 
GLU 2.02 ± 0.05 1.51 ± 0.13 * 1.48 ± 0.13 * 
GLU + GAL 2.15 ± 0.10 1.64 ± 0.17 * 1.24 ± 0.08 * 
 
                                                     
4  The result expressed as µmol/gdw is divided by 4 to yield the corresponding value 
expressed as µmol per gram of wet weight. Hence, the hepatic glycogen content after the 
carbohydrate loads is ~15 µmol/g for GLU group and ~10 µmol/g for GLU+GAL. 
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Figure 10 Representative 13C (left hand side) and 2H (right hand side) NMR spectra from 
monoacetone glucose derived from (A) hepatic glycogen and (B) blood glucose. 
The resonance for C1 is shown; the central singlet C1S represents [1-13C]MAG, the 
doublet component C1D represents the sum of [1,2-13C2]- and [1,2,3-13C3]MAG 
isotopomers, and the quartet component C1Q represents [U-13C]MAG. The 2H 
NMR spectra depict the resonances from H1 to H6S. Groups are as described in 
the legend of Figure 8. Liver and blood were collected 3 hours after the 
carbohydrate challenge. 
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Position 2 of both glycogen- and blood glucose-derived MAG is 
enriched with 2H from body water via its incorporation in the G6P common 
precursor in the G6P/F6P exchange. In both metabolites the 2H enrichment 
level of position 2 (2H2) was significantly lower than that of body water. 
This is due to the presence of unlabeled hepatic glycogen that was not 
completely depleted during the fasting period in the liver and of glucose 
from the oral load that remains in the blood at the end of the test. In the case 
of blood glucose the dilution effect caused by load glucose can completely 
account for the lower 2H2 enrichment of glucose in both experimental 
groups (see section 2.3.6). However, the dilution from residual glycogen 
doesn’t completely account for the reduced 2H2 enrichments observed in 
hepatic glycogen, especially in the GLU+GAL group (see section 2.3.5). 
Moreover, in the GLU+GAL group the 2H2 enrichment in hepatic glycogen 
tended to be lower (p = 0.06) than that in blood glucose demonstrating that 
the presence of galactose provides an additional dilution of the 2H2 
enrichment in glycogen.  
 
2.3.4 13C enrichments and isotopomer analysis 
The oral glucose or glucose + galactose loads enriched to 10% with 
[U-13C]glucose and [1-13C]galactose provided sufficient 13C enrichment of 
blood glucose and hepatic glycogen to generate 1H and 13C NMR spectra 
with acceptable 13C-signal intensities as shown in Figure 10. Thus, it was 
possible to precisely quantify 13C isotopomers from both [U-13C]glucose and 
[1-13C]galactose precursors. The 13C fractional enrichments and isotopomer 
levels derived by NMR analysis are shown in Table 2. 
Total glycogen 13C1 excess enrichment was not different between 
GLU and GLU+GAL groups, in agreement with the similar net glycogen 
synthesis amounts observed for the two groups by enzymatic 
measurements. The GLU group had no detectable excess enrichment from 
[1-13C]MAG isotopomer, in accordance with previous findings (Perdigoto et 
al. 2003; Mendes et al. 2006; Sena et al. 2007) while the GLU+GAL group had 
46|Chapter 2 
 
significant excess enrichment of [1-13C]MAG, reflecting the direct 
contribution of load galactose to hepatic glycogen. Excess enrichment levels 
of multiply-enriched glucose isotopomers ([1,2-13C2]- + [1,2,3-13C3]- and [U-
13C]MAG), which could not have been derived from [1-13C]galactose and 
therefore reflect only the contribution of load glucose metabolized via 
indirect pathway and/or Cori cycle, were significantly reduced in the 
GLU+GAL compared to GLU group.  
 
Table 2: 13C Isotopomer enrichment of monoacetone glucose (MAG) derived from hepatic 
glycogen and blood glucose. Groups are as described in the legend of Figure 8. Liver and 
blood were collected 3 hours after the carbohydrate challenge. *Significantly different (p < 
0.05) from GLU (unpaired Student’s t test). 
 
Excess 13C-isotopomer enrichments (%) 
Hepatic glycogen  Blood glucose 
13C1 
[1-13C] 
MAG 
[1,2-13C2]+ 
[1,2,313C3] 
MAG 
[U-13C] 
MAG 
 13C1 
[1-13C] 
MAG 
[1,2-13C2]+ 
[1,2,313C3] 
MAG 
[U-13C] 
MAG 
GLU 
3.89 ± 
0.50 
-0.06 ± 
0.05 
1.39 ± 
0.19 
2.56 ± 
0.29 
 
3.25 ± 
0.10 
0.16 ± 
0.05 
1.54 ± 
0.06 
1.55 ± 
0.15 
GLU + 
GAL 
4.39 ± 
0.49 
1.87 ± 
0.26 * 
0.86 ± 
0.08 * 
1.67 ± 
0.17 * 
 
3.33 ± 
0.25 
0.70 ± 
0.10* 
1.26 ± 
0.14 
1.30 ± 
0.07 
 
The total 13C1 excess enrichment in blood glucose was similar 
between GLU and GLU+GAL groups, indicating that after 3 hours the 
hexose load was cleared from the blood at the same extent in both cases. 
This observation is in agreement with the similar glycemic curves registered 
for the experimental groups throughout the test. Similarly to the 
observations for glycogen-derived MAG, the enrichment levels of the [1-
13C]MAG isotopomer in the GLU group were very close to the natural 
abundance but were significantly higher in the GLU+GAL group. This 
demonstrates that galactose in the load also contributed to blood glucose. 
The excess enrichment levels for the multiply-enriched isotopomers ([1,2-
13C2]- + [1,2,3-13C3]- and [U-13C]MAG) that reflect the contribution of load 
glucose to blood glucose were similar in both groups. 
Effect of galactose during a carbohydrate challenge|47 
2.3.5 Hepatic glycogen synthesis 
For animals that received the simple glucose load, position 2 
enrichment of glycogen was significantly less than that of body water (Table 
1). This is due in part to the presence of residual unlabeled glycogen prior to 
the introduction of 2H2O, as already discussed. When this is taken into 
account, the theoretical enrichment of glycogen position 2 (i.e. assuming 
complete exchange of position 2 hydrogen via G6P/F6P exchange) is ~85 % 
that of body water. The measured enrichment of position 2 was only 73 ± 
5% that of body water indicating that G6P/F6P exchange experienced by 
G6P en route to glycogen was extensive but not complete and/or that this 
group of animals had a higher residual glycogen content compared to the 
group where residual glycogen was determined. For GLU+GAL animals, 
glycogen position 2 enrichment relative to body water was significantly 
lower, amounting to only 58 ± 3% of body water 2H. The incorporation of 
galactose into glycogen via UDPG does not involve exchange of position 2 
hydrogen with body water, thus the lower position 2/body water 
enrichment ratios observed for the GLU+GAL compared to the GLU group 
are consistent with this mechanism.  
From the analysis of 2H and 13C enrichment distributions of hepatic 
glycogen, the principal sources of hepatic glycogen synthesis for GLU and 
GLU+GAL groups were estimated. Conversion of glucose to glycogen via 
both direct and indirect pathways was resolved. Formally, the indirect 
pathway includes intra-hepatic metabolism of glucose to glycogen via 3-
carbon intermediates as well as glucose metabolized via the Cori cycle. The 
Cori cycle can be considered as an indirect pathway where the glycolytic 
phase (glucose → pyruvate) occurs in peripheral tissues and the 
gluconeogenic phase (pyruvate → G6P) occurs in the liver. The direct 
pathway involves the conversion of plasma glucose to glycogen via hexose 
intermediates (Figure 4). Glucose absorbed from the oral load as well as 
unlabeled circulating glucose existing prior the carbohydrate administration 
contributes to the direct pathway. In addition to direct and indirect 
contributions of the load carbohydrates, the glycogenic contribution of 
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endogenous gluconeogenic precursors that were not derived from glucose 
recycling was also measured.  
For the GLU group, the direct pathway contribution from the load, 
as calculated from the dilution of [U-13C]glucose (Equation 4), accounted for 
less than one-third of all sources, see Table 3, matching the observations 
from Shulman et al. in a similar experimental setting (Shulman et al. 1985). 
The direct pathway contribution estimated by the 2H2O method was in 
excellent good agreement with that estimated by 13C isotopomer analysis 
(Table 4). Indirect pathway flux was dominated by unlabeled endogenous 
gluconeogenic precursors while indirect pathway/Cori cycle metabolism of 
the load glucose were subsidiary contributors as seen by the low abundance 
of [1,2-13C2]- plus [1,2,3-13C3]glucose isotopomers. 
When 10% of the oral glucose load was substituted by galactose, 
there were no significant changes in net glycogen synthesis, but glycogen 
sources were significantly modified. Although representing only 10% of the 
oral carbohydrate load, the galactose contributed about one-quarter of net 
hepatic glycogen synthesis. The 13C NMR analysis of glycogen-derived 
MAG indicates that the conversion of galactose to hepatic glycogen 
displaced contributions from both direct and indirect pathways of load 
glucose, but had no significant effect on the apparent endogenous 
gluconeogenic contribution to glycogen synthesis (Table 3). 
 
Table 3: Percent contributions of various sources to hepatic glycogen synthesis 3 hours after 
the carbohydrate challenge, as determined by the 13C isotopomer analysis of glycogen-
derived monoacetone glucose. The corresponding equations used to derive the source 
contributions are also indicated. Groups are as described in the legend of Figure 8. N.A., not 
applicable. *Significantly different (p < 0.05) from GLU (unpaired Student’s t test). 
 
Hexose Load (%) Endogenous 
Gluconeogenic 
(%) 
Total Non-
hexose 
precursors (%) 
Direct pathway 
glucose 
Indirect 
pathway 
Galactose 
Equation 4 Equation 5 Equation 3 Equation 6 Equation 7 
GLU 30 ± 3 24 ± 3 N.A. 47 ± 4 70 ± 3 
GLU + GAL 20 ± 3 * 16 ± 2 * 23 ± 4 41 ± 6 57 ± 5 * 
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Table 4: Percent contributions of various sources to hepatic glycogen synthesis 3 hours after 
the carbohydrate challenge, as determined by analysis of glycogen-derived monoacetone 
glucose 2H enrichment from 2H2O. The corresponding equations used to derive the source 
contributions are also indicated. Groups are as described in the legend of Figure 8. 
 Direct pathway glucose (%) Total Non-hexose precursors (%) 
 Equation 2 Equation 1 
GLU 32 ± 4 68 ± 3 
GLU + GAL 29 ± 6 71 ± 6 
 
2.3.6 Blood glucose sources 
Blood was collected at the end of the experimental period and the 
MAG derivative analysed by 1H, 13C and 2H NMR. Total gluconeogenesis 
(endogenous sources plus load glucose recycling), as estimated from the 
H5/H2 ratio in blood-derived MAG, contributed to 92 ± 4% of EGP in the 
GLU group and 95 ± 2% in the GLU+GAL group. These values were 
corrected for the presence of glucose from gastric absorption in order to 
determine the contributions to the overall blood glucose pool (Table 5). 
 
Table 5: Percent contributions of various endogenous sources to blood glucose 3 hours after 
the carbohydrate challenge, as determined by analysis of blood glucose-derived 
monoacetone glucose 2H enrichment from 2H2O. The corresponding equations used to derive 
the source contributions are also indicated. Groups are as described in the legend of Figure 8. 
 Gluconeogenesis (%)  
Glycogen & galactose (%) 
 Total Endogenous  
 Equation 12 Equation 14  Equation 13 
GLU 78 ± 4 55 ± 3  7 ± 3 
GLU + GAL 83 ± 1 62 ± 1  5 ± 2 
 
The 2H enrichment in position 2 of blood glucose relative to the 2H 
enrichment in the body water provides an estimation of the EGP 
contribution to the circulating glucose, assuming that plasma glucose 2H 
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enrichment by futile glucose/G6P cycling is negligible. In the GLU group 
this contribution was 75 ± 7%. That EGP accounted for such a large majority 
of plasma glucose under these conditions is surprising, since the glucose 
load would have been expected to suppress hepatic glucose output. In 
comparison, the contribution of the absorbed glucose from the load 
accounted for only 16 ± 1% of post-load plasma glucose (Table 6), which 
consistently adds up to the contribution from EGP to account for the overall 
blood glucose pool. Moreover, this indicates that most of the oral glucose 
load underwent rapid clearance. The presence of significant levels of 
recycled glucose isotopomers indicates that a substantial fraction of the 
cleared glucose was rapidly metabolized via the Cori cycle. Most 
surprisingly, about half of plasma glucose derived from endogenous 
gluconeogenesis that did not involved recycling of the glucose load (Table 
5).  
 
Table 6: Percent contributions of various sources to blood glucose 3 hours after the 
carbohydrate challenge, as determined by 13C isotopomer analysis of blood glucose-derived 
monoacetone glucose. The corresponding equations used to derive the source contributions 
are also indicated. Groups are as described in the legend of Figure 8. N.A., not applicable. 
 
Hexose Load (%)  
Endogenous sources (%) 
Gastric glucose Recycled glucose Galactose  
Equation 9 Equation 10 Equation 8  Equation 11 
GLU 16 ± 1 23 ± 1 N.A.  61 ± 1 
GLU + GAL 13 ± 1 20 ± 1 7 ± 1  60 ± 3 
 
For the animals receiving the carbohydrate mixture, the contribution 
of EGP to blood glucose as determined from the ratio between 2H 
enrichment in position 2 relative to the body water was 79 ± 7%, similar to 
the one determined for the GLU group. Gastric glucose accounted for the 
remainder blood glucose with a 13 ± 1% contribution (Table 6). In this group 
of animals, the contribution of recycled glucose and endogenous 
gluconeogenic precursors was essentially the same as in the glucose-fed 
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rats. The combined contributions from glycogen and galactose were similar 
to that of galactose by itself (see Table 5 and Table 6). These observations 
indicate that by 3 hours after the carbohydrate load, galactose that had been 
metabolized to G6P did not contribute significantly to hepatic glucose 
output and plasma glucose levels. 
 
2.4 Discussion 
2.4.1 Effect of galactose on direct and indirect pathway 
estimates with [U-13C]glucose and 2H2O tracers 
In this study, sources of hepatic glycogen synthesis following a load 
of pure glucose were quantified and compared with those following a load 
where 10% of the glucose was replaced by galactose. This proportion of 
galactose and glucose is representative of a breakfast meal containing a 
glass of skimmed milk – a standard source of protein for experimental 
breakfast meals. Given the rapid digestion of lactose and the fact that 
galactose is efficiently extracted and utilized by the liver, any effects of 
dietary galactose on direct/indirect pathway measurements are expected to 
be most pronounced in the initial stages of meal absorption. Interestingly, 
several studies with glucose tracers have shown that direct pathway 
contributions measured immediately after a mixed meal are significantly 
smaller than those measured 4-6 hours later (Shulman et al. 1990; Taylor et 
al. 1996). The study of Taylor et al. documents the presence of milk in the 
meal (Taylor et al. 1996), while the study of Shulman et al. (Shulman et al. 
1990) refers to a “standardized breakfast meal” which typically includes 
milk. By comparison, measurements performed during a glucose load 
infusion also show increases in direct pathway contributions over time 
(Stingl et al. 2006), but these changes are relatively modest when compared 
to those observed with meal studies. The hypothesis set for this study was 
that the uptake and metabolism of galactose from the breakfast meal could 
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account for unexpectedly low values of direct pathway fluxes in the early 
stages of absorption.  
The experimental model adopted was able to recapitulate that effect 
by replacing a small fraction of the glucose load with galactose. When the 
direct pathway contribution was measured with [U-13C]glucose, it reported 
a 30% contribution to hepatic glycogen synthesis for animals administered 
with glucose only. For animals that were administered with the 
glucose/galactose mixture, the direct pathway contribution reported by [U-
13C]glucose was significantly reduced by one-third to 20%. Since net 
glycogen accumulation was not significantly different to that of the glucose 
only group, this indicates that galactose competed against the direct 
pathway for glycogen synthesis. In addition, it was found that the indirect 
pathway contribution from load glucose was also reduced by one-third 
(24% to 16%). However, the apparent contribution from unlabeled 
gluconeogenic sources was not significantly altered by galactose 
metabolism. 
With the 2H2O method, the fractional contribution of indirect 
pathway flux to glycogen synthesis was estimated from the ratio of position 
5 enrichment to that of position 2 (H5/H2) and the direct pathway 
contribution is estimated as the balance. Since UDPG derived from 
galactose is not enriched with 2H in any position, this activity will 
systematically dilute all positional 2H enrichments of glycogen hence the 
H5/H2 ratio and direct/indirect pathway estimates based on this value will 
not be modified. In the absence of galactose, the direct pathway contribution 
obtained by this analysis (32%) matched the 30% estimate obtained with [U-
13C]glucose tracer. With galactose present, the observed H5/H2 ratio 
yielded an identical direct pathway contribution (29%) indicating that this 
analysis was insensitive to the contribution of galactose to glycogen 
synthesis. As predicted, the presence of galactose systematically reduced the 
2H enrichment in all positions of glycogen relative to that of body water. 
Assuming that the enrichment in position 2 of glycogen derived from 
glucose metabolism is equivalent to that of body water, then in theory, the 
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difference between the enrichment in position 2 of glycogen and that of the 
body water should correspond to the fraction derived from galactose. 
However, in this experimental setting this analysis has high uncertainty 
since equilibration of UDPG position 2 and body water hydrogens was 
incomplete and the amount of pre-existing unlabeled glycogen could not be 
directly determined. After adjusting for these parameters, the galactose 
contribution was estimated to be 18%, in fair agreement with the 23% 
estimate obtained directly with the [1-13C]galactose tracer.  
 
2.4.2 Dominance of the indirect pathway of glycogen synthesis 
A key finding of this study was that the indirect pathway was the 
dominant source of hepatic glycogen synthesis even after a pure glucose 
load. Both [U-13C]glucose and 2H2O tracers reported a ~70% indirect 
pathway contribution for the animals receiving the glucose only bolus. In a 
similar oral glucose test performed on 24-hour fasted rats, Jin et al. found an 
even higher indirect pathway contribution, accounting for ~90% of post-
load glycogen synthesis (Jin et al. 2003). 
In 24-hour fasted rats, hepatic glycogen is extensively depleted 
(Niewoehner et al. 1992; O'Doherty et al. 2000; Jin et al. 2003) therefore the 
maintenance of plasma glucose levels is almost completely dependent on 
gluconeogenesis. Following oral administration of a large glucose load, 
glucose disposal pathways must be activated while EGP from 
gluconeogenesis needs to be suppressed in order to maintain glucose 
homeostasis. In this setting, the diversion of gluconeogenic G6P flux from 
glucose to glycogen synthesis is a fast and effective means of suppressing 
EGP under these conditions. The observation that a significant fraction of 
synthesized glycogen was derived from endogenous gluconeogenic 
precursors is consistent with this mechanism. Moreover, this flux was 
maintained in the face of competition from galactose suggesting that under 
the conditions of our study, the diversion of gluconeogenic G6P to glycogen 
is somehow prioritized over other glycogenic fluxes. Under normal fasting-
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feeding conditions where the transition from negative to positive 
endogenous glucose balance is less abrupt, the gluconeogenic contribution 
to glycogen synthesis is present, but it accounts for a smaller fraction (~50%) 
of hepatic glycogen synthesis (Chapter 4).  
 
2.4.3 Conversion of the hexose load into hepatic glycogen 
For both the glucose and glucose-galactose loads, the synthesis of 
hepatic glycogen represented a very minor fraction of the total carbohydrate 
disposal. For example, out of the 2.6 mmol oral glucose load, only 68 µmol, 
or 2.6%, was converted to glycogen by all (direct plus indirect) pathways. 
With glucose and galactose loads, the fractional hepatic extraction of 
glucose to glycogen synthesis was significantly further reduced to 1.1%, (i.e. 
25 µmol of the 2.3 mmol load, p < 0.01 compared to the fraction from 
glucose only load). While the conversion of load galactose (~230 µmol) to 
glycogen was relatively more efficient, it nevertheless accounted for only 
7.4% of the total, amounting to ~15 µmol.  
 
2.4.4 Endogenous glucose production during the carbohydrate 
challenge 
One striking feature about the glucose dynamics during this 
experiment was the high contribution of EGP to plasma glucose levels a 
short time after the administration of a large glucose bolus. This was 
determined by a novel method based on the 2H enrichment level of plasma 
glucose position 2 from 2H2O and is dependent on the assumption that there 
is negligible cycling between plasma glucose and hepatic G6P. When this 
cycle is active, position 2 of plasma glucose can be enriched from 2H2O 
independently of EGP. Glucose/G6P cycling activity has been previously 
measured as an increased rate of [2-3H]glucose turnover relative to that of 
[U-14C]glucose (Dunn et al. 1976). In the 2H2O experiment, glucose/G6P 
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cycling activity would result in unlabeled glucose molecules, including 
those absorbed from the load, being enriched in position 2. This has two 
important and verifiable consequences on the 2H and 13C enrichment data. 
First, the EGP contribution to plasma glucose as measured by position 2 
enrichment from 2H2O would be overestimated while the contribution of 
absorbed glucose would be correspondingly underestimated. Therefore, the 
gastric glucose contribution as directly reported by the 13C tracer would be 
higher than that estimated by the 2H2O method (indeed if all plasma glucose 
underwent glucose/G6P cycling the apparent gastric glucose contribution 
would be zero). In fact, the gastric contribution reported by the [U-
13C]glucose tracer (13-16%) was comparable to the fraction of plasma 
glucose that was not labeled in position 2 from 2H2O (15-21%). The second 
consequence of glucose/G6P futile cycling would be to reduce the plasma 
glucose H5/H2 ratio compared to that of glycogen. Data from this 
experiment show that plasma glucose H5/H2 ratios were higher than those 
of glycogen indicating that there was no preferential enrichment of plasma 
glucose position 2 from 2H2O by glucose/G6P cycling. Based on these 
observations, it is conclude that in comparison to EGP activity, cycling 
between plasma glucose and hepatic G6P did not significantly contribute to 
plasma glucose enrichment from 2H2O. 
 
2.4.5 Estimation of gluconeogenesis and glycogenolysis with 
2H2O 
In these experiments effective glycogen synthesis was accompanied 
by a minor contribution of glycogenolysis to blood glucose. The estimation 
of glycogenolysis relies on the assumption that glucose derived from 
glycogen is enriched with 2H in position 2 but not 5. However, in this 
experiment the majority of glycogen was enriched in both positions 2 and 5, 
reflecting the high contribution from three carbon precursors and as a 
result, the calculations based on the 2H labeling pattern of blood glucose 
may underestimate the actual contribution from GP activity. However, since 
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the glycogenolytic contributions were very minor accounting for the 
glycogen precursor pool enriched beforehand does not significantly change 
the overall source contributions to plasma glucose5.     
 
2.5 Conclusions 
This study demonstrates that a relatively low amount of galactose, 
similar to what would be expected from a breakfast meal containing dairy 
products, has a significant effect on direct and indirect pathway estimates 
using current tracer methods. With 13C NMR isotopomer analysis of suitable 
13C-enriched glucose and galactose substrates, the galactose contribution to 
glycogen synthesis may be resolved from those of glucose and non-hexose 
precursors. When this is not possible or practical, galactose should be 
excluded from the dietary carbohydrate load.  
In terms of its overall effects on glucose metabolism and disposal, 
galactose utilization resulted in a decreased contribution of load glucose to 
hepatic glycogen synthesis but it had little effect on the clearance of glucose 
into peripheral tissues. 
 
 
 
 
                                                     
5 For example, considering that 85% of the hepatic glycogen was synthesized during the 3-
hour test and that of this fraction ~70% derived from the indirect pathway (i.e. non-hexose 
precursors), then about 60% of the total hepatic glycogen pool is labeled in both positions 2 
and 5. The contribution of glycogenolysis to the plasma glucose pool corrected by this factor 
yields ~11% compared to the original ~7% estimation. 
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3                                                                                                    
SOURCES OF BLOOD GLUCOSE AND HEPATIC GLYCOGEN 
SYNTHESIS DURING A GLUCOSE CHALLENGE IN DIABETIC 
RATS – EFFECT OF A SINGLE INSULIN DOSE. 
3.1 Introduction 
In the clinical setting, the OGTT is commonly used to discriminate 
among several pre-diabetic conditions although it is not applied to type 1 
diabetic patients (WHO 2006). Nonetheless, the OGTT is widely used in 
experimental animal models of type 1 DM in the context of evaluating and 
comparing the efficacy of antidiabetic agents. Sometimes, the intravenous or 
the i.p. routes are also used in animals to deliver a glucose load. Generally, 
the aim of the test is to evaluate the glycemic response over time as a 
measure of glucose disposal. The glucose tolerance test represents a very 
straightforward approach for assessing the antidiabetic efficacy of 
pharmacological agents (Marti et al. 2001) or dietary supplementation 
(Akhani et al. 2004; Lo et al. 2006), for example. 
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By introducing [U-13C]glucose and 2H2O in tracer amounts during 
the OGTT, load glucose clearance, pathways of glucose production and 
glycogen synthesis can be disclosed (see Chapter 2). Given that 
hyperglycemia in STZ-diabetic rats results in part from deficient glucose 
disposal (Wi et al. 1998) the tracer-enriched OGTT may provide insight on 
the underlying metabolic alterations and how they change with antidiabetic 
intervention. To address those questions the OGTT protocol presented in 
chapter 2 was performed on STZ-diabetic rats and STZ-diabetic rats 
previously injected with a single dose of insulin so that the effect of the drug 
on glucose disposal could be evaluated. Insulin was delivered by two 
different routes, the traditional s.c. route and the i.p. route, which results in 
higher hepatic insulinization (Mason et al. 2002). Hence, it was anticipated 
that any hepatic-specific insulin action in the context of glucose disposal 
would be detected and characterized under this experimental setting. 
 
3.2 Materials and methods 
3.2.1 Animal studies 
3.2.1.1 Animal housing 
As described in section 2.2.1.1. 
 
3.2.1.2 Animal protocols 
Rats (270 ± 3 g) were given a 50-65 mg/kg intra-peritoneal injection 
of STZ (Sigma-Aldrich, Portugal) dissolved in 10 mM citrate buffer pH 4.5 
to induce diabetes. Animals that did not develop hyperglycemia 1 day after 
the injection were given the same dose of STZ the following days up to a 
total of 3 doses. Animals were considered diabetic when glycemia was > 250 
mg/dL. 
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On the 20th and 21st days following the induction of diabetes, animals 
were fasted for 24 hours and then randomized into three groups. In two of 
the groups, rats were injected insulin (Actrapid®, Novo Nordisk, kindly 
donated by the Hospitais da Universidade de Coimbra) at a dose of 5 U/kg 
to the s.c. route (SC, N = 5) or the i.p. route (IP, N = 5). In the other group 
(STZ, N = 5), animals did not receive any injection. Thirty minutes after the 
insulin dose, all animals were administered 2H2O and gavaged a glucose 
load enriched to 10% with [U-13C]glucose and glycemia monitored for a 3-
hours period, as described in section 2.2.1.2. The GLU group in the 
experiment described in chapter 2 was used as non-diabetic control for the 
present experiment. In order to determine the basal fasting liver glycogen 
content a separate group of 24-hour fasted STZ-diabetic animals (N = 5) 
were sacrificed without receiving the glucose load. 
 
3.2.2 Metabolite analyses 
Glucose was extracted from the blood, hepatic glycogen isolated 
hydrolyzed to glucose and quantified, as described section 2.2.2. Glucose 
was converted to MAG as described in section 2.2.3. Exogenous (human) 
insulin levels were determined in the plasma obtained after centrifugation 
of a small blood sample by ELISA enzyme immunoassay (Mercodia, 
Sweden) accordingly with the supplier’s instructions. 
 
3.2.3 NMR spectroscopy 
As described in sections 2.2.4, 2.2.4.1, 2.2.4.2 and 2.2.4.3. 
 
3.2.4 Metabolic contributions parameters 
As described in section 2.2.5 
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3.2.5 Statistics 
As described in section 2.2.6. 
3.3 Results 
3.3.1 Induction of diabetes and performance during the OGTT 
Successful induction of diabetes was confirmed 4 days after STZ 
injection by the presence of typical symptoms like hyperglycemia (374 ± 17 
mg/mL), weight loss (weight represented ~80% of the initial), polydepsia 
and polyuria. On day 20, after 24 hours of fasting, the glycemia registered 
for the STZ was significantly higher than that found for control animals 
(Table 7).  
 
Table 7: Glycemia values registered at the beginning and at the end of the oral glucose 
tolerance test (OGTT); area under the curve (AUC) determined for the glycemia profiles in 
Figure 11; exogenous insulin and hepatic glycogen determined at the end of the OGTT. After 
a 24-hour fast STZ-diabetic rats (STZ), STZ-diabetic rats injected a single 5 U/kg insulin dose 
by the subcutaneous (SC) or intraperitoneal (IP) route, and non-diabetic controls (Control) 
were gavaged a 2 g/kg glucose load and sacrificed 3 hours after. Insulin was injected to 30 
minutes before the OGTT. Values not sharing a common superscript letter are significantly 
different; statistical significance was accepted for a p < 0.05 determined by one way ANOVA 
with Fisher’s LSD post test. N.D., not determined. 
 STZ SC IP Control 
Glycemia t0 (mg/dL) 172 ± 34 a 180 ± 42 a 121 ± 40 ab 65 ± 4 b 
Glycemia t180 (mg/dL) 297 ± 52 a 37 ± 5 b 34 ± 9 b 86 ± 3 b 
AUC t0→180 (arbitrary units) 432 ± 51 a 181 ± 40 b 211 ± 41 bc 328 ± 34 ac 
Exogenous insulin (mU/L) N. D. 29 ± 8 a 77 ± 24 a N. D. 
Hepatic glycogen (µmol/gdw) 236 ± 65 a 221 ± 77 a 199 ± 24 a 59 ± 10 b 
 
The glycemia variation over the OGTT experiment is depicted in 
Figure 11 and is expressed as percent from initial value (at time t = 0 
minutes). In all groups of animals, after the oral gavage of glucose, glycemia 
increased more than 100% in the first 30 minutes. In the STZ, that increment 
followed for another 30 minutes with the peak occurring at 60 minutes. On 
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the other hand, in the non-diabetic controls, SC and IP the glycemia for that 
time corresponds to the descending phase of the curve. Moreover, the 
injection of insulin to the diabetic animals translated into an increase of the 
slope of the descending part of the glycemia curve.  
 
 
 
Figure 11 Glycemia profiles (expressed as % from initial value) registered during the 180 
minutes of the oral glucose tolerance test. Experimental groups are as described in 
the legend of Table 7. 
 
Table 7 summarizes the performance of the different experiment 
groups subjected to the OGTT. The overall glycemia response during the 
OGTT was evaluated by determining the AUC corresponding to t0→180. The 
AUC for STZ tended to be higher than that of controls (p < 0.1). Both IP and 
SC groups displayed significantly lower AUC than STZ. Furthermore, the 
AUC for IP was similar to that of controls whereas in the SC group it was 
significantly lower. This observation is in agreement with higher peripheral 
glucose uptake in the case of the s.c. route relative to the i.p., in the first half 
of the test, as indicated by the marked decrease in glycemia (Figure 11). 
With time, glycemia for the IP group approached that of the SC and, at the 
end of the test, the glycemia values observed for both the IP and SC groups 
were similar and under the physiological range. On the other hand, by that 
time, non-diabetic controls had recovered from the oral glucose load and 
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again displayed glycemia within the physiological range, whereas in the 
STZ glycemia remained elevated. Exogenous insulin was quantified from 
the blood collected at the time of sacrifice and there were no significant 
differences between the values detected for IP and SC.  
All groups of STZ-diabetic rats displayed higher levels of hepatic 
glycogen relative to non-diabetic controls. However, contrarily to what was 
observed for controls (see chapter 2, section 2.3.2) after 24 hours of fasting, 
hepatic glycogen content was not nearly depleted in the STZ-diabetic rats, 
amounting to 373 ± 41 µmol/gdw. These values were not changed after the 
OGTT and when insulin was previously injected to the STZ-diabetic rats 
(SC and IP) glycogen levels in the liver were still similar to those of STZ. 
These observations indicate that, for the STZ-diabetic rats, there was no net 
glycogen synthesis in the liver in the context of the OGTT, even in the 
presence of insulin.  
 
3.3.2 13C and 2H metabolite enrichments 
The body water 2H enrichment level was determined from a small 
blood sample and was similar among all groups: 2.04 ± 0.06%, STZ; 1.80 ± 
0.10%, IP; 1.98 ± 0.15%, SC; and 2.01 ± 0.05%, Control. With this level of 
enrichment, the positional 2H enrichments obtained in blood glucose 
allowed for an adequate 2H NMR analysis in non-diabetic controls and STZ 
as shown in Figure 12. In those groups, 2H enrichment of blood glucose-
derived MAG was 1.51 ± 0.13% and 1.52 ± 0.16%, respectively. However, 
because in IP and SC groups little glucose could be extracted from the blood 
due to the hypoglycemia experienced by those animals, the 2H NMR spectra 
obtained in those cases didn’t have a signal to noise ratio adequate for a 
confident analysis.  
The 13C enrichment level at C1 of MAG from blood glucose was 4.35 
± 0.10% in the non-diabetic controls, similar to that determined in the STZ: 
4.62 ± 0.23%. In the diabetic animals injected with insulin prior the OGTT, 
the 13C enrichment levels in C1 of MAG from the blood were significantly 
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lower than the ones observed for the STZ and control groups: 2.27 ± 0.21%, 
SC; and 2.06 ± 0.25%, IP.  
 
 
 
Figure 12  Representative 13C (left hand side) and 2H (right hand side) NMR spectra from 
monoacetone glucose derived from blood glucose 3 hours after the oral glucose 
tolerance test. Experimental groups are as described in the legend of Table 7. The 
oral load was enriched with 2H2O and [U-13C]glucose tracers. The resonance for 
C1 is shown; the central singlet C1S represents [1-13C]MAG, the doublet 
component C1D represents the sum of [1,2-13C2]- and [1,2,3-13C3]MAG 
isotopomers, and the quartet component C1Q represents [U-13C]MAG. The 2H 
NMR spectra depicts the resonances from H1 to H6S.  
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to those we determined in the non-diabetic controls (5.50 ± 0.49%). In fact in 
the STZ, IP and SC groups, the 13C1 enrichment level was very close to the 
1.11% natural abundance: 1.40 ± 0.10%, in the STZ; 1.26 ± 0.06%, in the IP 
and 1.34 ± 0.04% in the SC. Hence, in these animals there was no efficient 
glycogen synthesis from the oral glucose load, in perfect agreement with the 
similar hepatic glycogen content prior and after the test as determined by 
the enzymatic measurement. 
 
3.3.3 Sources to blood glucose 
The relative contributions to blood glucose were calculated from the 
equations presented in section 2.2.5 and are shown in Table 8. To determine 
the concentration of glucose derived from each source, the percent 
contribution was multiplied by the glycemia registered at the end of the 
experiment. This analysis is depicted in Figure 13. 
 
Table 8: Percent contributions of various sources to blood glucose 3 hours after the glucose 
tolerance test. Experimental groups are as described in the legend of Table 7. The oral load 
was enriched with 2H2O and [U-13C]glucose tracers. The corresponding equations used to 
derive the source contributions are also indicated. Values not sharing a common superscript 
letter are significantly different; statistical significance was accepted for a p < 0.05 determined 
by one way ANOVA with Fisher’s LSD post test. N.D., not detectable.  
 Gastric Recycled Endogenous 
 % (Equation 9) % (Equation 10) % (Equation 11) 
Control 16 ± 1 a 23 ± 1 a 61 ± 1 a 
STZ 23 ± 4 a 13 ± 1 b 65 ± 5 a 
SC N.D. 9 ± 1 bc 91 ± 1 b 
IP N.D. 7 ± 2 c 93 ± 2 b 
 
3.3.3.1 Comparison between Control and STZ 
In the STZ, all the absolute contributions to blood glucose were 
elevated when compared to controls (Figure 13). Hence, both a reduced 
Effect of insulin during a glucose challenge in diabetic rats|65 
clearance of the oral load as well as an increased contribution from 
endogenous sources account for the hyperglycemic state of those animals. 
For this reason, the relative contributions of load glucose (gastric + recycled) 
and endogenous precursors to blood glucose were similar between STZ and 
Control (Table 8). These findings are in line with the observations from 
infusion studies by Wi et al where, one day after a 75 mg/kg STZ injection, 
hyperglycemia was associated with both increased glucose output and 
reduced clearance (Wi et al. 1998). Furthermore, those authors correlated the 
defects in glucose clearance with a decreased uptake of plasma glucose by 
the skeletal muscle. That mechanism also provides a good explanation for 
the present observations of reduced recycled glucose contribution in the 
STZ-diabetic rats since the apearence of recycled glucose relies largely on 
skeletal muscle uptake and metabolism of the parent [U-13C]glucose tracer. 
 
 
Figure 13  Contributions (expressed as glucose concentration) of gastric absorption, glucose 
load recycling and endogenous sources to blood glucose 3 hours after the glucose 
tolerance test. Experimental groups are as described in the legend of Table 7. The 
oral load was enriched with 2H2O and [U-13C]glucose tracers. A zoom for SC and 
IP groups is shown. For each source, bars not sharing a common letter are 
significantly different; statistical significance was accepted for a p < 0.05 
determined by one way ANOVA with Fisher’s LSD post test. 
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endogenous precursors and recycled load (78%), determined by analysis of 
13C isotopomer enrichment indicating that the enrichment of position 2 from 
2H2O was representative of net hepatic glucose output rather than futile 
glucose/G6P cycling. Moreover, the contribution of EGP to plasma glucose 
is similar to the 75 ± 7% determined for controls (see chapter 2). Finally, in 
both cases, gluconeogenesis dominated EGP as estimated by the H5/H2 
ratio: 0.89 ± 0.03 for STZ and 0.92 ± 0.04 for Control. 
 
3.3.3.2 Effect of the insulin dose 
Insulin administration to the STZ-diabetic rats in the IP and SC 
groups significantly altered glucose load disposal. In those groups the [U-
13C]glucose isotopomer was no longer detectable in the blood 3 hours after 
the oral gavage (see Figure 12), indicating that almost all of the glucose load 
had been cleared from the circulation. Additionally, the contribution of 
glucose from recycling of the load was significantly reduced relative to both 
STZ and Control groups. These observations, together with the absence of 
net glycogen synthesis in the liver, suggest that glucose may have been 
oxidized or stored as glycogen in the skeletal muscle. 
At the end of the test, more than 90% of blood glucose had derived 
from endogenous sources in the STZ-diabetic rats injected with insulin 
(Table 8). This contribution represented a glucose concentration similar to 
that observed in the non-diabetic controls, indicating that insulin reduced 
the contribution of EGP relative to the STZ-diabetic rats. 
Because of the poor signal to noise ratio that characterized most of 
the 2H NMR MAG spectra from blood glucose in SC and IP groups, the 
relative contributions of glycogenolysis and gluconeogenesis to EGP could 
not be quantified with confidence. Nevertheless, the similar intensities for 
H5 and H2 signals of blood glucose-derived MAG obtained from these 
animals (Figure 12) clearly indicate that gluconeogenesis was the main 
source of EGP in both cases. 
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3.3.4 Hepatic glycogen synthesis 
Hepatic glycogen synthesis in the setting of the OGTT was fully 
characterized in chapter 2 for the non-diabetic controls. In the case of STZ-
diabetic rats, there was no net glycogen synthesis in the liver. This was 
demonstrated by the similar glycogen content found in the liver of those 
animals before and after the OGTT, in contrast to what was observed for 
non-diabetic controls that had 10 times more glycogen after the test (see 
section 2.3.2). Insulin administration prior to the OGTT had no effect on the 
hepatic glycogen content. Furthermore, the percent 13C excess enrichment 
determined in the glycogen of rats from STZ, IP and SC groups was ~0.2%, 
much lower than the ~4% detected in the non-diabetic controls subjected to 
the same protocol. 
 
3.4 Discussion 
Without food intake blood glucose levels depend on EGP derived 
either from glycogenolysis or gluconeogenesis. The gluconeogenic 
contribution increases with the time of fasting. For example, in non-diabetic 
rats after 6 hours of fasting, gluconeogenesis accounts for about two thirds 
of EGP whereas after 24 hours of fasting that contribution represents over 
90% of EGP (Nunes et al. 2009). In the present studies (see also chapter 2) 
hepatic glycogen levels were highly depleted in control rats after the 24-
hour fast, in good agreement with high gluconeogenic activity.  
Unlike controls, the STZ-diabetic rats showed substantial levels of 
glycogen in the liver after the 24-hour fast. This has been previously 
reported by other authors (Friedmann et al. 1963; Ferrannini et al. 1990; 
Peroni et al. 1997). Apparently, these animals did not utilize hepatic 
glycogen stores during fasting, in accordance with the dominance of 
gluconeogenesis over glycogenolysis to EGP both in the post absorptive 
state and after 24 hours of fasting (Peroni et al. 1997). Interestingly, 
Friedmann et al showed that in diabetic rats, hepatic glycogen could be 
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depleted by prolonging the fasting period to 48 hours or by glucagon 
treatment and that refeeding after these interventions resulted in efficient 
hepatic glycogen synthesis, although the maximal glycogen levels still 
remain under those of non-diabetic controls (Friedmann et al. 1963).  
As expected, gluconeogenesis also dominated EGP in the diabetic 
animals, contributing to more than 60% of blood glucose at the end of the 
test. This percent contribution was similar to that observed for controls but 
the respective absolute contribution was much higher. In fact, all the 
absolute contributions to blood glucose were increased in the diabetic rats. 
The tracer-enriched OGTT protocol demonstrated that after the 
administration of the oral glucose load to STZ-diabetic rats, the contribution 
of load glucose adds to that from glucose production to account for the 
elevated blood glucose levels observed at the end of the test. These findings 
are in line with elevated EGP (Blondel et al. 1989; Peroni et al. 1997; Wan et 
al. 2000) and reduced glucose clearance (Wi et al. 1998) in the post 
absorptive state in STZ-diabetic rats.  
A single insulin injection prior to the glucose challenge altered the 
glycemia response of the STZ-diabetic rats, resulting in a rapid and 
pronounced decrease of plasma glucose levels. This enhanced glucose 
uptake from circulation resulted from two combined mechanisms. On the 
one hand, insulin reduced the absolute contribution of endogenous sources 
to the plasma glucose pool from the abnormally elevated values in the STZ-
diabetic rats to control levels. In addition, insulin strongly promoted 
glucose clearance. This last action is most probably a consequence of 
peripheral uptake rather than hepatic disposal and storage as no efficient 
glycogen synthesis was detected. The persistent hypoglycemia observed in 
the final minutes of the test is in agreement with the absence of glucagon 
counterregulation to insulin-induced hypoglycemia in the STZ-diabetic rats 
injected with insulin, by opposition to the glucagon response that follows 
normal insulin secretion in non-diabetic rats (Zhou et al. 2004).   
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3.5 Conclusions 
In STZ-diabetic rats both a deficient glucose clearance in peripheral 
tissues and an excessive glucose production contribute to the hyperglycemic 
state throughout the OGTT experiment. Hepatic glycogen serves as short-
term reservoir for endogenous gluconeognenic flux when fasted controls 
receive an oral glucose load. In this way, EGP may be rapidly suppressed. 
Data from these studies show that this mechanism is inoperative in the STZ-
diabetic rats. Insulin administration to STZ-diabetic rats reduced the 
contribution of EGP to plasma glucose and, most importantly, enhanced 
peripheral glucose disposal; but had no effect on diverting the 
gluconeogenic flux from EGP to hepatic glycogen synthesis during the 
OGTT. 
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4                                                                                                    
GLUCOSE PRODUCTION AND HEPATIC GLYCOGEN AND LIPID 
SYNTHESIS DURING AD LIBITUM FEEDING CONDITIONS IN 
RATS – EFFECT OF DIABETES 
4.1 Introduction 
In humans, direct and indirect pathway contributions to hepatic 
glycogen are quantified by analysis of plasma glucose and UDP-glucose 
enrichment following infusion of a glucose tracer as part of an intravenous 
glucose load (Hellerstein et al. 1995) with corrections for recycling of the 
labeled carbon (Magnusson et al. 1987). Alternatively, the tracer can also be 
given as part of a meal (Taylor et al. 1996; Bischof et al. 2002) to study the 
pathways of glycogen repletion under normal feeding conditions. This 
approach is poorly suited to study hepatic glycogen synthesis in ad libitum 
fed rats since they tend to feed intermittently over the entire dark period of 
the diurnal cycle (Benavides et al. 1998). While there have been studies of 
glycogen synthesis under artificial substrate delivery conditions such as 
glucose infusion (Katz et al. 1989) or after a glucose load (Newgard et al. 
72|Chapter 4 
 
1983; Shulman et al. 1985) there is no reported measurement of direct and 
indirect pathway activities in rats during their natural feeding routine. Since 
postprandial hepatic glycogen levels are sensitive to dietary composition 
(Gaíva et al. 2003; MacQueen et al. 2007), measurement of direct and indirect 
pathway activities under baseline conditions is essential for evaluating the 
effect of disease or other interventions on these fluxes. 
To quantify hepatic glycogen repletion via direct and indirect 
pathways during ad libitum feeding, the positional 2H-enrichment of hepatic 
glycogen was analyzed following the administration of 2H2O at the 
beginning and throughout the feeding cycle. The contribution of indirect 
pathways of hepatic glycogen synthesis was estimated by the ratio of 
glycogen 2H enrichment in position 5 relative to position 2 (H5/H2), see 
chapter 1. Moreover, the relative contributions of gluconeogenesis and 
glycogenolysis to EGP could also be disclosed by determining the H5/H2 
ratio in blood glucose. 
With the present 2H2O administration protocol it was also possible to 
determine the contribution of DNL to the hepatic TG pool. That fraction was 
determined by analysis the 2H enrichment in the methyl group of the 
hepatic TG relative to that of the body water as reported by Delgado et al. 
(Delgado et al. 2009a).  
The key advantages of this assay are the simplicity of tracer 
administration (no infusion catheters required) and that it can be applied to 
any substrate delivery setting including clamp studies, oral or i.p. glucose 
load and ad libitum feeding. In this study, this method was applied to define 
the effect of STZ-induced diabetes on hepatic pathways for glucose disposal 
and storage as glycogen or TG and also pathways for EGP in ad libitum fed 
rats.  
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4.2 Materials and methods 
4.2.1 Animal studies  
4.2.1.1 Animal housing 
As described in section 2.2.1.1. 
 
4.2.1.2 Animal protocols 
Rats (245 ± 4 g) were rendered diabetic by STZ injection as described 
in section 3.2.1.2. One group of animals consisted of non-diabetic control 
rats that were not injected with STZ (Control, N = 6). The other 3 groups 
consisted of STZ-diabetic rats studied at day 4 (STZ-4, N = 6), 10 (STZ-10, N 
= 8) or 20 (STZ-20, N = 8) after the induction of the disease. At 7 pm all 
animals received a loading dose of 99% 2H2O in saline by injection into the 
i.p. cavity. Assuming 70% body weight as water, the dose was calculated to 
enrich the body water to 2% or 3%. To maintain body water enrichment, 
their drinking water was enriched to 5% with 2H2O. At 8 am the next 
morning, animals were anesthetized by injection of ketamine (2 mL/kg) in 
the i.p. cavity, the abdominal cavity was opened and ~5 mL of blood were 
collected from the abdominal aorta. A small blood sample (0.5 mL) was 
reserved for determination of 2H2O body water enrichment and plasma 
insulin levels. The liver was excised and immediately freeze-clamped in 
liquid nitrogen.  
A group of control rats (N = 5) was sacrificed at 7 pm without 
receiving the 2H2O tracer and the livers harvested for determining the 
baseline glycogen and TG content.  
 
4.2.2 Metabolite analyses 
Glucose was extracted from the blood, hepatic glycogen isolated, 
hydrolyzed to glucose and quantified and plasma insulin levels quantified 
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as described section 2.2.2. Glucose was converted to MAG as described in 
2.2.3. Part of the lyophilized liver powder underwent lipid extraction 
accordingly with the method developed by Folch et al. (Folch et al. 1957). 
Briefly, approximately 1 g of powder was treated with 40 mL of 
chloroform:methanol (2:1, v:v). After centrifugation the liquid phase was 
recovered and 8 mL of NaCl (0.9%) were added, the solutions were 
vigorously mixed, centrifuged and the lower phase collected. Chloroform 
was evaporated under nitrogen flux and the lipid content stored at -20ºC 
until further analysis.  
 
4.2.3 NMR spectroscopy 
As described in sections 2.2.4, 2.2.4.1 and 2.2.4.2 
 
4.2.3.1 1H and 2H analysis of lipids 
Lipid samples were treated as described by Delgado et al (Delgado et 
al. 2009a). Briefly, lipids were dissolved in 0.6 mL of chloroform and 150 µL 
of a pyrazine-d4 solution were added as internal reference standard for 
quantification of hepatic TGs and determination of 2H methyl enrichment 
levels. 1H and 2H NMR spectra were acquired at 25 ºC using the Varian 600 
system equipped with a 5 mm broadband probe. 1H NMR spectra of lipid 
samples consisted of one scan obtained using an acquisition time of 3 
seconds and served for quantification of the hepatic TG content. 2H NMR 
spectra were obtained within 3 to 12 hours (depending on the amount of 
sample and 2H enrichment level) using a 90º pulse, an acquisition time of 5 
seconds and a pulse delay of 2 seconds. The amount of 1H-TG was 
determined by comparing the area of the methyl hydrogens with that of the 
pyrazine hydrogens in the 1H NMR spectrum of each sample and the 
amount of 2H-TG was determined by comparing the areas for those signals 
in the respective 2H NMR spectrum. Hence, the hepatic TG content was 
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calculated as the sum of 1H- and 2H-TG. The absolute 2H methyl enrichment 
was calculated as follows: 
 
2H methyl enrichment 
2H‐TG
2H‐TG  1H‐TG 
 
This quantification method was tested for linearity using a series of 
palmitic acid standards solutions prepared in chloroform from known 
amounts of [U-2H]palmitic acid so that enrichment levels ranged from 
0.035% to 0.40% (Figure 14).  
 
 
 
Figure 14 Plot of the theoretical 2H enrichment level of a series of palmitic acid standards 
prepared from palmitic acid and [U-2H]palmitic acid versus the 2H enrichment 
calculated as described. The linear regression equation is shown. 
 
4.2.4 Metabolic contributions parameters 
The percent contribution of gluconeogenesis to EGP and the indirect 
pathway contribution to glycogen synthesis were calculated from the 
H5/H2 ratio in the 2H NMR spectra of MAG from blood glucose and 
hepatic glycogen as shown in Equation 1 (page 37), while the contributions 
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of glycogenolysis to EGP and direct pathway to glycogen were calculated as 
the balance, as shown in Equation 2 (page 37). 
The contribution of newly-synthesized glycogen to the hepatic 
glycogen pool during overnight feeding was calculated from the ratio of 
glycogen position 2 to body water 2H-enrichments. Likewise, the 
contribution of newly synthesized TGs (DNL) to the hepatic TG pool was 
calculated as the ratio of 2H methyl enrichment to body water 2H 
enrichment. 
 
4.2.5 Statistics 
As described in section 2.2.6. 
 
4.3 Results 
4.3.1 Induction of diabetes 
In this study, STZ-diabetic rats were assayed in three early stages of 
the disease. The first stage corresponded to 4 days after STZ injection and 
the other two corresponded to 10 and 20 days. In all of those stages animals 
were profoundly hyperglycemic (Table 9). This observation is in agreement 
with the reduced levels of plasma insulin determined for STZ-10 and STZ-
20. Moreover, the hepatic glycogen content was reduced and the TG levels 
increased with the induction of diabetes by this method, in accordance with 
reports from other authors for SZT-diabetic rodent models (Pighin et al. 
2005; Fernandes et al. 2010). These alterations were observed 10 and 20 days 
after the injection of STZ, but not at 4 days. Hence, 4 days after STZ 
injection, although rats develop hyperglycemia they still have hepatic 
glycogen and TG levels comparable with controls.  
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Table 9: Glycemia, plasma insulin, hepatic glycogen and triglyceride content determined 
after an overnight feeding under 2H2O administration in non-diabetic controls (Control) and 
STZ-diabetic rats assayed 4 (STZ-4), 10 (STZ-10) and 20 days (STZ-20) after induction of 
diabetes. For each parameter, values not sharing a common superscript letter are 
significantly different; statistical significance was accepted for a p < 0.05 determined by one 
way ANOVA with Fisher’s LSD post test. N. D. not determined. 
 
Plasma Insulin  
(µg/L) 
Glycemia  
(mg/dL) 
Hepatic Glycogen 
(µmol/gdw) 
Hepatic Triglycerides  
(µmol/gdw) 
Control 5.3 ± 1 a 114 ± 4 a 907 ± 84 a 212 ± 22 a 
STZ-4 N. D. 385 ± 31 b 816 ± 61 a 216 ± 7 a 
STZ-10 0.5 ± 0.1 b 445 ± 31 b 407 ± 120 b 406 ± 39 b 
STZ-20 0.7 ± 0.2 b 549 ± 25 c 344 ± 52 b 358 ± 31 b 
 
4.3.2 Metabolite 2H enrichment levels 
Animals were kept under 2H2O administration overnight (~12 
hours). The body water 2H enrichment level was determined from a plasma 
sample at the end of that period and matched the target values (Table 10). 
For both blood and liver metabolites of interest, 2H NMR spectra with 
sufficient signal to noise for a reliable quantification of 2H excess enrichment 
were obtained (Figure 15 and Figure 17). This includes the hepatic TGs 
obtained for STZ-10 and STZ-20 groups, where the excess 2H enrichment 
levels were very low due to a vastly decreased DNL activity.  
 
Table 10: Body water (BW) and metabolite absolute 2H enrichment levels observed after an 
overnight feeding under 2H2O administration. Experimental groups are as described in the 
legend of Table 9. 
 2H enrichement (%) 
 Target BW BW H2 Blood Glucose H2 Glycogen Methyl-TG 
Control 3 2.90 ± 0.14 1.21 ± 0.15 0.99 ± 0.20 0.48 ± 0.06 
STZ-4 3 3.37 ± 0.26 1.05 ± 0.06 0.91 ± 0.15 0.24 ± 0.05 
STZ-10 2 1.63 ± 0.07 0.88 ± 0.09 1.19 ± 0.06 0.04 ± 0.007 
STZ-20 2 1.99 ± 0.08 0.78 ± 0.02 1.12 ±0.09 0.04 ± 0.004 
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Figure 15 Representative 2H NMR spectra of monoacetone glucose (MAG) showing the 
resonances for positions 1 to 6S. Blood was collected after an overnight feeding 
under 2H2O administration and glucose extracted and derivatized to MAG. 
Gluconeogenesis was estimated as the signal area of position 5 relative to position 
2. Experimental groups are as described in the legend of Table 9. 
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4.3.3 Metabolic parameters 
4.3.3.1 Sources of glucose production 
The 2H enrichment of position 2 of blood glucose relative to that of 
body water reflects the contribution of EGP to the circulating glucose. The 
remainder originates from absorption in the GIT. In non-diabetic controls, 
EGP accounted for 40 ± 4% of blood glucose and was similar to that 
determined in all STZ groups. Since STZ animals were hyperglycemic, they 
probably displayed higher rates of EGP coupled with increased food intake 
due to diabetes-related hyperphagia. Interestingly, the contribution of EGP to 
blood glucose in STZ-10 and STZ-20 was significantly higher than that 
observed for STZ-4, 46 ± 2% and 44 ± 5% vs 32 ± 2%, respectively. This likely 
reflects a weaker control (i.e. suppression) of EGP in animals that had been 
diabetic for a longer period. The STZ-10 and STZ-20 groups were additionally 
characterized by a significantly higher gluconeogenenic contribution to EGP 
compared to the STZ-4 group, which presented values comparable with non-
diabetic controls (Figure 16). 
 
 
 
Figure 16 Relative contributions of gluconeogenesis (white bars) and glycogenolysis (grey 
bars) to endogenous glucose production determined after an overnight feeding 
under 2H2O administration. Experimental groups are as described in the legend of 
Table 9. For each source, bars not sharing a common letter are significantly 
different; statistical significance was accepted for a p < 0.05 determined by one 
way ANOVA with Fisher’s LSD post test. 
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Figure 17 Representative 2H NMR spectra of monoacetone glucose (MAG) showing the 
resonances for positions 1 to 6S. Livers were harvested after an overnight feeding 
under 2H2O administration and glycogen extracted, hydrolyzed to glucose and 
derivatized to MAG. Indirect pathway was estimated as the signal area of 
position 5 relative to position 2. Experimental groups are as described in the 
legend of Table 9. 
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4.3.3.2 Hepatic glycogen synthesis 
In order to confirm that, under normal conditions, rats efficiently 
accumulate glycogen in the liver during feeding, hepatic glycogen content 
was quantified in non-diabetic controls at the beginning of the dark phase. 
In that group of animals, glycogen levels were 613 ± 75 µmol/gdw, 
significantly lower than the 907 ± 84 µmol/gdw determined in the morning 
(Table 9). This finding is in line with the circadian rhythm of hepatic 
glycogen, which increases during the dark phase and is consumed during 
the light phase under normal ad libitum feeding conditions (Lanza-Jacoby et 
al. 1986; Benavides et al. 1998). The net glycogen synthesis overnight 
represented about one third of the total hepatic glycogen content 
determined at the beginning of the light phase. This value is in excellent 
agreement with the estimation of glycogen synthesis from the 2H 
enrichment in glycogen position 2 relative to that in body water, which 
reported a 34 ± 7% contribution in controls (Table 11). In the STZ-4 group 
this contribution was similar to controls but it increased significantly in 
STZ-10 and STZ-20, representing in those cases more than half of the 
glycogen. The higher fractional synthesis values detected for the STZ-10 and 
STZ-20 groups are consistent with the smaller glycogen pool observed for 
those animals. In fact, the amount of glycogen synthesized during the 
experiment (total amount of glycogen × 2H2-Glycogen/2H-body water) was 
similar among the several groups.  
 
Table 11: Contribution of newly synthesized glycogen to the hepatic pool and amount of 
glycogen synthesized overnight determined after an overnight feeding under 2H2O 
administration. Experimental groups are as described in the legend of Table 9. For each 
parameter, values not sharing a common superscript letter are significantly different; 
statistical significance was accepted for a p < 0.05 determined by one way ANOVA with 
Fisher’s LSD post test. 
 Control STZ-4 STZ-10 STZ-20 
Glycogen synthesis 
(% contribution) 
34 ± 7 a 27 ± 4 a 63 ± 5 b 57 ± 8 b 
Overnight-synthesized 
glycogen (µmol/gdw) 
322 ± 87 a 212 ± 28 a 171 ± 31 a 206 ± 43 a 
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Despite the fact that the same amount of glycogen was synthesized 
overnight, the pathways for glycogen synthesis in the liver were altered in 
all STZ groups (Figure 18). In the STZ-4 group the indirect pathway was 
increased relative to controls and in STZ-10 and ST-20 groups it completely 
dominated glycogen synthesis in the liver. 
 
 
Figure 18 Direct (grey bar) and indirect (white bar) pathways for hepatic glycogen synthesis 
after an overnight feeding under 2H2O administration. Experimental groups are 
as described in the legend of Table 9. For each pathway, bars not sharing a 
common letter are significantly different; statistical significance was accepted for 
a p < 0.05 determined by one way ANOVA with Fisher’s LSD post test. 
 
4.3.3.3 Hepatic triglycerides and de novo lipogenesis 
Figure 19 depicts a representative 1H NMR spectrum obtained after 
the extraction of hepatic lipids by the Folch method. The resonance at ~0.8 
ppm represents the terminal methyl groups of fatty acid chains (Noula et al. 
2000; Ren et al. 2008) and was used to quantify the hepatic TG content by 
comparison with the internal pyrazine standard. In control rats, the amount 
of hepatic TGs at the beginning of the dark phase was 168 ± 17 µmol/gdw. 
After an overnight feeding the hepatic TG content was 212 ± 22 µmol/gdw 
(Table 9), which is not significantly different from that determined in the 
group of rats sacrificed at the beginning of the dark phase.  
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During feeding, TGs synthesized de novo are enriched with 2H from 
2H2O whereas those derived from the diet or adipose tissue lipolysis are 
unlabeled and therefore contribute to the dilution of the 2H labeling from 
DNL. To the extent that the hepatic TG pool has not turned over during the 
overnight feeding phase, the presence of unlabeled TGs in the liver prior to 
the administration of 2H2O also contributes to that dilution. The 2H-enriched 
TGs were quantified from analysis of the 2H NMR spectra of hepatic lipids 
(Figure 20).  
 
 
 
Figure 19 Representative 1H NMR spectrum of hepatic lipids obtained by Folch extraction 
from a diabetic rat 4 days after STZ injection. The solvent chloroform, the 
standard pyrazine and the methyl groups of TG are assigned to the respective 
resonances. 
 
As shown in Table 12, the contribution of DNL to the hepatic TG 
pool in the STZ-4 group was half of that determined for controls. In STZ-10 
and STZ-20 groups DNL represented no more than 2.5% of the hepatic TG 
pool. These findings indicate that the dietary and/or lipolytic contribution 
to hepatic TGs is increased in all STZ groups especially in the STZ-10 and 
STZ-20, in which the hepatic TG levels were about the double of those 
determined for the other groups (Table 9). 
8 6 4 2 PPM10
Chloroform
Pyrazine
Methyl-TG
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Figure 20 Representative 2H NMR spectra of hepatic lipidic extracts after an overnight 
feeding under 2H2O administration. The spectral regions show the solvent 
chloroform, the standard pyrazine and the methyl groups of TGs assigned to the 
respective resonances. Control, non-diabetic controls; STZ-4, STZ-10 and STZ-20, 
STZ diabetic rats assayed 4, 10 and 20 days after diabetes induction, respectively. 
 
Table 12: Contribution of de novo lipogenesis (DNL) to the hepatic triglyceride (TG) pool and 
amount of newly synthesized TGs determined after an overnight feeding under 2H2O 
administration. Experimental groups are as described in the legend of Table 9. For each 
parameter, values not sharing a common superscript letter are significantly different; 
statistical significance was accepted for a p < 0.05 determined by one way ANOVA with 
Fisher’s LSD post test. 
 Control STZ-4 STZ-10 STZ-20 
DNL (% contribution) 16.3 ± 1.7 a 7.3 ± 1.7 b 2.5 ± 0.4 c 2.0 ± 0.2 c 
9 8 7 2 1 PPM
Control
9 8 7 2 1 PPM
STZ-4
9 8 7 2 1 PPM 9 8 7 2 1 PPM
STZ-10 STZ-20
Chloroform
Pyrazine
Methyl-TG
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4.4 Discussion 
4.4.1 Addressing the absorptive state 
The circadian rhythm of the organism rules many biological functions. 
In the light cycle of rodents, the dark phase is characterized by high 
locomotive activity and oxygen consumption (Williams et al. 2000; Yamaoka et 
al. 2008) parallel to an increase in insulin levels (Benavides et al. 1998) and food 
and water intakes (Armstrong et al. 1980; Johnson et al. 1990; Benavides et al. 
1998). Perhaps not surprisingly, gene array experiments performed over a 24-
hour period clearly demonstrate that rat liver gene expression oscillates 
accordingly with the light cycle, including the expression of enzymes involved 
in carbohydrate and lipid metabolism (Almon et al. 2008). Hence, during 
feeding, pathways for glucose disposal and storage must be favoured against 
glucose production.  
The studies described on this chapter were designed to follow several 
metabolic insulin-dependent pathways during the natural feeding cycle of 
rats. The protocol consisted on keeping the animals under 2H2O 
administration overnight so that pathways for glucose production, hepatic 
glycogen and TG synthesis could be simultaneously traced in one single 
experimental setting by 2H NMR methods. With this methodological approach 
there is no interference with the animals’ natural feeding behaviour and hence 
the data obtained reflect the metabolic performance in the absorptive state 
under ad libitum conditions. The baseline measurements determined in non-
diabetic rats were sensitive to the STZ-induced type 1 DM, making this a 
valuable protocol for addressing the effect of any intervention in the context of 
diabetes.  
 
4.4.2 Sources to blood glucose and hepatic glycogen synthesis 
During the absorptive phase, blood glucose may be derived from 
both dietary absorption and endogenous production. In the present 
experimental setting, assuming the G6P/F6P exchange is complete and 
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there is no substancial glucose/G6P cycling, glucose from EGP is enriched 
with 2H in position 2 to the same level as body water and that enrichment is 
diluted by glucose derived from absorption. In the STZ-diabetic rats, the 
relative contributions of EGP and dietary sources to blood glucose were 
similar to those determined for non-diabetic controls, despite much higher 
glycemia values for the STZ-diabetic animals. Insulin deficiency is expected 
to result in higher endogenous contributions to feeding plasma glucose 
levels as a result of impaired EGP suppression. However, STZ-diabetic rats 
also eat more than controls (see also chapter 915, Table 14), due to the 
hyperphagia associated with the lack of hypothalamic insulin and leptin 
signalling (Sindelar et al. 1999; Akirav et al. 2004). This would translate into 
an increased uptake of dietary glucose. Therefore, the observation that EGP 
and dietary contributions to blood glucose levels in the hyperglycemic STZ 
rats were similar to those of normoglycemic controls may be explained by 
systematic increases in both EGP and glucose absorption rates for the STZ-
diabetic rats.  
In the non-diabetic controls, the 2H2O method indicated that 
immediately after an overnight feeding, gluconeogenesis accounts for the 
majority (approximately two thirds) of EGP. This is similar to estimates 
obtained after 6 hours of fasting in the same rat specie and using the same 
methodology as that described in these experiments (Nunes et al. 2009). 
Saadatian et al. report a somewhat lower (~50%) contribution of 
gluconeogenesis to EGP (Saadatian et al. 2000), using mass spectrometry 
methods. Taken together, these observations demonstrate that 
gluconeogenesis is continually active in non-diabetic free-feeding rats and 
does not appreciably change during the fed to fasted transition.  
In control rats only ~30% of the hepatic glycogen was synthesized 
overnight and of that fraction ~50% was enriched with 2H from 2H2O-enriched 
body water in both positions 5 and 2. The 2H2O method relies on the 
assumption that only glucose derived from gluconeogenesis is enriched with 
2H from 2H2O in both positions 5 and 2. But, because under the present 
experimental protocol 15% (30% × 50%) of the total hepatic glycogen was also 
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enriched with 2H in both positions 5 and 2, the contribution of glycogenolysis 
may be underestimated, but to a minor degree. Applying the 15% correction 
factor yields a 35% (instead of the 30%) contribution of glycogenolysis to EGP. 
Hence, under these circumstances, the 2H2O method is fairly reliable. 
However, in the case of diabetic rats studied 10 and 20 days after STZ 
injection, because of the high glycogen turnover (~60%) and the complete 
dominance of the indirect pathway (~95%), the majority of the glycogenolytic 
contribution to blood glucose is indistinguishable from the gluconeogenic 
contribution because the glucose derived from glycogen is labeled in both 5 
and 2 positions. Furthermore, since the amount of glycogen synthesized 
overnight was apparently the same in all groups, the reduced glycogen levels 
observed in the later stages of STZ-diabetes must be a consequence of 
excessive glycogen breakdown. Taken together, these observations indicate 
that, at least 10 days after induction of diabetes by STZ injection to rats, there 
was extensive glycogen degradation with simultaneous synthesis during the 
absorptive state (i.e. glycogen cycling).  
 
4.4.3 Estimation of de novo lipogenesis 
With the induction of diabetes there was a drastic reduction on the 
DNL contribution to the hepatic TG pool and this was immediately detected 4 
days after STZ injection. These observations are in line with Cohen’s (Cohen 
1987) experiments in perfused livers from control and STZ rats reporting that 
in the latter case the flux through pyruvate carboxylase is increased relative to 
that through pyruvate dehydrogenase resulting, amongst other things, in the 
recruitment of pyruvate into gluconeogenesis, rather than its oxidation to 
acetyl-CoA molecules for lipogenesis. 
The synthesis of TG de novo in the liver was estimated by 2H NMR 
analysis of the hepatic lipid content as the ratio of the 2H-methyl enrichment 
relative to that of body water. Although this estimation provides valuable 
insight on the hepatic lipid kinetics it is not an accurate quantification of the 
contribution of DNL to the hepatic TG content. Ideally, the 2H enrichment in 
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the methyl-TG should be compared to that of the precursor acetyl-CoA pool 
but that intermediate is scarce and difficult to isolate. Therefore, a necessary 
simplifying assumption is that the hepatic 2H acetyl-CoA enrichment is 
equivalent to that of body water. It is not know to what extent the acetyl-CoA 
methyl hydrogens directly exchange with those of water in the cellular 
environment, but it is well know that many of the key acetyl-CoA precursors – 
notably pyruvate – exchange extensively (Kuwajima et al. 1986) while others, 
such as fatty acids, involve the direct adition of water hydrogens to the methyl 
group when undergoing β-oxidation to acetyl-CoA. 
Under feeding conditions, pyruvate is considered to be the main 
source of acetyl-CoA (Cohen 1987) and the incorporation of 2H from body 
water in pyruvate is extensive (Kuwajima et al. 1986) but not necessarily 
complete (Silva et al. 2011). To the extent that the true acetyl-CoA 2H 
enrichment is less than that of body water, DNL contributions to the hepatic 
TG pool are systematically underestimated.  
Another factor affecting the estimations of DNL is the turnover of the 
hepatic TG pool. After 12 hours under 2H2O administration it is possible that 
the TGs did not turn over completely and hence pre-existing TGs may be 
accounting for the dilution of the 2H labelling in addition to the contribution of 
dietary and/or adipose tissue-derived TGs. Nonetheless, the DNL 
contribution determined in this experiment for non-diabetic controls was in 
the range of that found by Delgado et al. after 72 hours of 2H2O administration 
(Delgado et al. 2009a), suggesting the TG pool turned over during the 
overnight 2H2O protocol. In the case of the STZ diabetic rats, TG turnover may 
take longer given the higher hepatic pool.  
 
4.4.4 Progressive metabolic disruption in STZ-diabetes and 
relationship between carbohydrate and lipid metabolism 
Experimental diabetes was induced by injection of STZ in the i.p. 
cavity and rats studied 4, 10 and 20 days afterwards. In all cases, rats were 
profoundly hyperglycemic. This finding is consistent with the rapid 
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development of diabetic symptoms in the STZ-diabetic rat model (Burcelin 
et al. 1995; Sindelar et al. 1999; Wei et al. 2003). Furthermore, data from this 
study indicate that some metabolic pathways are altered in the first days 
following STZ injection and that those alterations are sustained afterwards. 
For example, at day 4 , the relative pathways to EGP were similar to controls 
and the contributions of the direct pathway to glycogen and DNL to hepatic 
TG – although reduced compred to controls – were not as low as those 
observed for the other STZ groups. In the later stages of diabetes (10 and 20 
days after STZ injection), the complete dominance of gluconeogenesis to 
both glycogen synthesis and glucose production correlates with the 
profound reduction of the lipogenic flux. Moreover, the elevated levels of 
TGs in the livers from 10- and 20-day STZ-diabetic rats suggest adipose 
tissue lipolysis is likely to be the dominant source for hepatic TGs. Among 
other things, the increased abundance of hepatic lipids helps to sustain high 
rates of gluconeogenesis and EGP.  
 
4.5 Conclusions 
The 2H2O protocol for the study of the absorptive phase under natural 
feeding conditions was successfully applied to both non-diabetic controls and 
STZ-diabetic rats. With one single experiment, it identified early alterations in 
hepatic carbohydrate and lipid metabolism following β cell destruction by 
STZ. Namely, DNL was profoundly reduced as early as 4 days after the 
induction of diabetes. By that time the indirect pathway to glycogen synthesis 
was already increased relative to controls but the contributions of 
glycogenolysis and gluconeogenesis to blood glucose were normal. In the later 
stages of STZ-diabetes, gluconeogenesis was the major source of both EGP and 
glycogen synthesis. The dominance of the gluconeogenic (indirect) pathway to 
glycogen synthesis and the rapid turnover of the hepatic pool via glycogen 
cycling translated into an extensive enrichment of hepatic glycogen positions 5 
and 2 from 2H2O. This likely resulted in an underestimation of the 
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glycogenolytic contribution to EGP as determined by the overnight 2H2O 
method. 
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5                                                                                                    
GLUCOSE PRODUCTION AND HEPATIC GLYCOGEN AND LIPID 
SYNTHESIS DURING AD LIBITUM FEEDING CONDITIONS IN 
RATS – EFFECT OF INSULIN REPLACEMENT  
5.1 Introduction 
Type 1 diabetic patients have insufficient pancreatic insulin secretion 
and thus must rely on exogenous insulin supply to avoid persistent 
hyperglycemia and related complications. With the conventional s.c. insulin 
treatment the peripheral tissues are the ones that receive most of the insulin 
dose. On the other hand, i.p. insulin administration is able to mimic the 
physiological insulin release, maintaining a portal/peripheral gradient 
concentration with insulin absorption occurring evenly through splanchnic 
and peripheral routes (Radziuk et al. 1994). In fact, under physiological 
conditions, insulin is secreted by the pancreas to the portal vein and the 
liver accounts for the extraction of a 50-80% fraction (Radziuk et al. 1994; 
Utzschneider et al. 2004).  
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There are some studies highlighting the relevance of i.p. insulin 
delivery in the context of diabetes treatment. Implanted insulin pumps that 
deliver insulin by i.p. infusion reduce the risk of hyperglycemia, and offer a 
better metabolic control compared with s.c. infusion pumps (Catargi 2004). 
Intraperitoneal insulin has also been administered to diabetic patients with 
end-stage renal disease undergoing continuous ambulatory peritoneal 
dialysis and this allowed for improving the glycemic control over 
conventional s.c. delivery (Nevalainen et al. 1997).  
Experiments in STZ-diabetic rats have demonstrated the beneficial 
effect of i.p. insulin on reducing glucose production, peripheral 
hyperinsulinemia, and improving glucose disposal relative to s.c. insulin 
(Mason et al. 2000; Wan et al. 2000). However, those studies were performed 
in post-absorptive conditions (after 5-6 hours of fast) and it would be of 
interest to evaluate the effect of i.p. insulin in natural feeding rats. 
During feeding, insulin stimulates the usage of glucose and its 
storage as glycogen and lipids in the liver. This is accomplished by diverse 
mechanisms through changes in enzyme activities and/or expression 
(overviewed in section 1.3.1). Since the liver is the organ targeted with i.p. 
insulin delivery, it can be hypothesized that the hepatic metabolic pathways 
will respond differently to the s.c. or i.p. insulin therapies. This chapter 
describes and discusses the experiments set to test that hypothesis. The 
methodological approach was the same described in chapter 4 to address 
hepatic insulin-dependent metabolic pathways during the absorptive state 
in rats. In addition, gene expression and enzyme activities for some key 
metabolic enzymes involved in those pathways were also assessed. The 
alterations detected in STZ-diabetes were recapitulated and in parallel the 
effect of insulin replacement during a short period was addressed. Insulin 
therapy began two weeks after the induction of diabetes, when the 
pathways for glucose production, hepatic glycogen and lipid synthesis were 
already severely disrupted (see chapter 4). 
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5.2 Materials and methods 
5.2.1 Animal studies 
5.2.1.1 Animal housing 
As described in section 2.2.1.1. 
 
5.2.1.2 Animal protocols 
Rats (280 ± 2 g) were rendered diabetic by STZ injection as described 
in section 3.2.1.2. Eight days after diabetes induction animals were assigned 
at random into 3 groups: one group of animals was administered a s.c. 
insulin injection at a dose of 15 U/kg twice a day at 8 am and 7 pm (group I-
SC, N = 9); a second group of animals received an i.p. insulin injection at the 
same dose and times as the I-SC group (group I-IP, N = 9); finally, a third 
group of animals received no treatment at all (group D, N = 7). Animals 
were kept under the insulin treatment protocol for 9 or 10 days. Blood 
glucose and TG levels were monitored throughout the experimental period 
with an Accu-check and Accutrend (Roche, Portugal) meters, respectively. 
At the end of the treatment period, 30 minutes after the night insulin 
injection, animals received a loading dose of 99% 2H2O in saline by injection 
into the i.p. cavity and the experiment proceeded as described in section 
4.2.1.2. Animals were sacrificed the next morning. Blood was collected for 
glucose extraction and NMR analysis and a small blood sample was 
reserved for determination of 2H2O enrichment levels, insulin and NEFA in 
the plasma. The liver was excised, immediately freeze-clamped in liquid 
nitrogen. A small liver sample was reserved for enzyme activities assays 
and real-time polymerase chain reaction (PCR) and the remainder 
lyophilized. Epididymal white adipose tissue (EWAT) was collected and 
weighted. 
The control group in the experiments described in chapter 4 was 
used in this study for sake of comparison. 
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5.2.2 Metabolite analyses 
Glucose was extracted from the blood, hepatic glycogen isolated, 
hydrolyzed to glucose and quantified and plasma insulin levels quantified 
as described section 2.2.2. Exogenous (human) insulin was quantified in the 
plasma as described in 3.2.2. Glucose was converted to MAG as described in 
section 2.2.3. Hepatic lipids were extracted as described in section 4.2.2. 
Plasma NEFA were determined enzymatically with NEFA-HR assay kit 
(Wako chemicals, Germany).  
 
5.2.3 NMR spectroscopy 
As described in sections 2.2.4, 2.2.4.1, 2.2.4.2 and 4.2.3.1 
 
5.2.4 Metabolic contributions parameters 
As described in section 4.2.4. 
 
5.2.5 Enzyme activities assays 
Enzyme activities assays were carried out as previously described 
(Metón et al. 1999; Caseras et al. 2000), with some modifications. Crude 
extracts for assaying enzyme activities were obtained by homogenization of 
the powdered frozen liver (1/5, w/v) using a PTA-7 Polytron (Kinematica 
GmbH, Switzerland) mixer (position 3, 30 seconds), and centrifugation at 
15,800 rcf for 40 minutes at 4 ºC. The homogenization buffer used in the 
assays for PFK, PK, G6PDH and 6PGDH activities consisted of 50 mM 
tris(hydroxymethyl)aminomethane (Tris)-HCl pH 7.5, 4 mM 
ethylenediaminetetracetic acid, 50 mM NaF, 0.5 mM phenylmethylsulfonyl 
fluoride, 1 mM 1,4-dithiothreitol and 250 mM sucrose. In the 
homogenization buffer used in the assay GK activity 100 mM KCl was also 
included and the crude extract filtered through a 1 mL Sephadex G 25 
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column after centrifugation. Assays for enzyme activities and total protein 
were adapted for automated measurement using a Cobas Mira S 
spectrophotometric analyzer (Hoffman-La Roche, Switzerland). All enzyme 
assays were carried out at 4 ºC and followed at 340 nm. For determining GK 
activity 5 µL of filtered sample extract were assayed in a final volume of 200 
µL containing 100 mM Tris-HCl pH 7.75, 7.5 mM MgCl2, 100 mM KCl, 1 
mM NADP, 2.5 mM 2-mercaptoethanol, 100 mM glucose and 1 mU/mL 
G6PDH. The reaction was triggered with the addition of 60 mM ATP and 
100 mM or 0.5 mM glucose. The GK activity was determined by subtracting 
the activity measured at 0.5 mM glucose from that measured at 100 mM 
glucose. PFK activity was assayed in a final volume of 200 µL containing 100 
mM Tris HCl pH 8.25, 5 mM MgCl2, 50 mM KCl, 0.15 mM NADH, 4 mM 
ammonium sulfate, 12 mM 2-mercaptoethanol, 10 mM F6P, 30 mM G6P, 
0.675 U/mL fructose bisphosphate aldolase, 5 U/mL triose-phosphate 
isomerase, 2 U/mL glycerol-3-phosphate dehydrogenase and 4 µL crude 
extract. The reaction was triggered after addition of 10 mM ATP. The 
specific assay conditions for PK activity were: 250 µL of final volume 
containing 70 mM glycylglycine pH 7.4, 10 mM MgCl2, 100 mM KCl, 0.15 
mM NADH, 2.8 mM phosphoenolpyruvate, 21 U/mL lactate 
dehydrogenase and 4 µL of sample. ADP (2.5 mM) was added to monitor 
the PK reaction. G6PDH activity was measured using 4 µL sample in a final 
volume of 200 µL containing 77.5 mM imidazole-HCl pH 7.7, 5 mM MgCl2, 
1 mM NADP and 1 mM G6P. The assay conditions for 6PGDH activity 
were: 82.7 mM imidazole-HCl pH 7.7, 3 mM MgCl2, 0.5 mM NADP, 2 mM 
6-phosphogluconate and 4 µL crude extract in a final volume of 200 µL. The 
total protein content was determined in Cobas Mira S at 600 nm by the 
Bradford method (Bio-rad, Spain) at room temperature in liver crude 
extracts using bovine serum albumin as a standard. 
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5.2.6 Real-time PCR 
Total messenger ribonucleic acid (mRNA) was isolated from frozen 
liver samples using the Speedtools Total RNA Extraction Kit (Biotools, 
Spain). Single strand complementary DNA (cDNA) templates for PCR 
amplification were synthesized from 1 µg of total mRNA by incubation with 
moloney murine leukemia virus reverse transcriptase (RT) (Promega 
Biotech Iberia SL, Spain) at 37 ºC for 1 hour, accordingly to supplier’s 
instructions. The RT reaction product was diluted 1/20 in milli-Q water and 
real-time quantitative PCR was performed in an ABI Prism 7000 Sequence 
Detection System (Applied Biosystems, Spain) using 0.4 µM of each primer, 
10 µL of SYBR Green (Applied Biosystems, Spain) and 1.6 µL of diluted 
cDNA. The temperature cycle protocol for amplification was: 50 °C for 2 
minutes, 95 °C for 10 minutes, followed by 48 cycles with 95 °C for 15 
seconds and 62 °C for 1 minute. 
The primer pairs used are listed in table 1 and were designed with 
Oligo Explorer 1.2 (Gene Link) except for PEPCK, reproduced from 
(Okamoto et al. 2008) and 18S, reproduced from (Palou et al. 2008). 
Ribosomal subunit 18 was chosen as the housekeeping gene to normalize 
expression levels of targets between different samples. Variations in gene 
expression were calculated by the standard ∆∆Ct method. For all pairs of 
primers linearity was confirmed with consecutive dilutions (from 1/10 to 
1/500) of a cDNA test sample. 
 
5.2.7 Statistics 
As described in section 2.2.6. 
 
 
 
 
 
 
Metabolic effects of insulin replacement in ad libitum fed diabetic rats |97 
 
Table 13: Sequence of primers used for the real-time PCR experiments. Genes: GK, 
glucokinase; PFK, phosphofructokinase; PK, pyruvate kinase; G6PDH, glucose-6-phosphate 
dehydrogenase; G6Pase, glucose-6-phosphatase; FBPase, fructose-1,6-biphosphatase; PEPCK, 
phosphoenolpyruvate carboxykinase; CL, citrate lyase; ACC1, acetyl-CoA carboxylase 1; 
FAS, fatty acid synthase; CPT1a, carnitine palmitoyltransferase 1a; SREBP1c, sterol 
regulatory element-binding protein 1c; ChREP, carbohydrate responsive element-binding 
protein; 18S, ribosomal subunit 18. 
 
Gene Primer sense (5’-3’) Primer anti-sense (5’-3’) 
Glycolysis and Pentose 
Phosphate Pathway 
  
GK ACCGACTGCGACATTGTGCG ACGTCCTCACTGCGGCTTTC 
PFK TGATGTCTACCGCAAAGGGC ACCGAACTGAAGGCCACCAC 
PK CTGGATGGGGCTGACTGTAT TCAAACAACTGGCGGTGGTA 
G6PDH CTATGCCCGCTCACGACTCA GGGCAAAGAACTCCTCTAGC 
Gluconeogenesis   
G6Pase  TGTGGTTGGGATACTGGGCT GATGGGGAAAGTGAGCCGCA 
FBPase GCTCAGCTCTATGGCATCGC CCGACACAAGGACACAGGTA 
PEPCK ATCGAAGGCATCATTTTTGG TGACCTTGCCCTTATGCTCT 
Lipid metabolism   
CL GGTTACTCCCGACACAGACT TCCATCCAGAGAGAGGTTGA 
ACC1 GGGCGTTGGGGGATAAGATT GGAAGAGTGGGGATACCTGC 
FAS CGGCGAGTCTATGCCACTAT ACACAGGGACCGAGTAATGC 
CPT1a ACCAACCCCAACATCCCTAA CCAAAAGACTGGCGCTGCTC 
Transcription factors   
SREBP1c GCCATCGACTACATCCGCTT CACTTCGCAGGGTCAGGTTCT 
ChREBP CCTGGAACCTGTCTTTGGGC TGGGTGGACTGGCTTTTCGT 
Housekeeping   
18S CGCGGTTCTATTTTGTTGGT AGTCGGCATCGTTTATGGTC 
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5.3 Results 
5.3.1 Induction of diabetes and animals’ performance during 
the insulin treatment protocol 
 Eight days after the injection of STZ, the body weight of the animals 
was significantly reduced to 261 ± 3 g (representing 93% of their initial weight) 
and blood glucose levels ranged from 394 to over 600 mg/dL, indicating the 
successful induction of type 1 DM. This was further confirmed by the reduced 
endogenous insulin levels determined at the end of the experiment for group 
D relative to the healthy controls (Table 14).  
Throughout the experimental follow-up, the animals in group D 
continued to lose weight, while the ones kept under insulin treatment tended 
to gain weight (Figure 21). At the end of the insulin replacement protocol, the 
body weight of untreated diabetic animals was 234 ± 10 g, significantly lower 
than the 288 ± 7 g and the 270 ± 5 g observed for I-SC and I-IP, respectively (p 
= 0.06, I-SC vs I-IP). Furthermore, the weight variation was quantified by the 
AUC in the weight vs time plot (Table 14), and was significantly increased for 
groups I-SC and I-IP relative to group D. Taken together, these observations 
demonstrate the positive effect of insulin on weight gain. Consistent with this 
finding, EWAT also increased with insulin treatment. 
As presented in Table 14, food and water consumption determined at 
the end of the experiment, were sensitive to the diabetic condition and also 
insulin treatment. In non-diabetic controls food consumption was 23 g/day, 
and water intake 35 mL/day, in good agreement with reports from several 
other authors (Havel et al. 1998; Dib 1999; Wei et al. 2003). As expected, 
diabetic animals ate and drank significantly more than controls. Insulin 
replacement decreased food (p < 0.05, D vs I-IP and p = 0.06 D vs I-SC) and 
water intakes in the treated diabetic rats, but the observed values were still 
higher than control levels.  
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Table 14: Biochemical and physiological parameters determined during the insulin replacement study 
in untreated STZ-diabetic rats (D), STZ-diabetic rats treated with insulin by subcutaneous (I-
SC) or intraperitoneal (I-IP) injection twice a day at a dose of 30 U/kg/day and non-diabetic 
controls (C). Glycemia and plasma triglyceride measurements were performed 2 hours after 
the morning insulin injection on the 8th day of insulin treatment. Food and water 
consumption were measured in the last 24 hours prior to the sacrifices. Weight evolution is 
expressed as the area under the curve (AUC) in the weight vs time plots, from days 0 to 10. 
All the other parameters correspond to post mortem measurements. For each parameter, 
values not sharing a common superscript letter are significantly different; statistical 
significance was accepted for a p < 0.05 determined by one way ANOVA with Fisher’s LSD 
post test. N. D., not determined, NEFA, non-esterified fatty acids, EWAT, epididimal white 
adipose tissue.  
 
Glycemia determined in the 8th day of the insulin treatment protocol, 2 
hours after the morning dose, was successfully reduced to control values in 
both I-SC and I-IP groups. However, glycemia observed after an overnight 
feeding (i.e. ~12 hours after the night insulin injection) was similar between 
treated and untreated STZ-diabetic rats and was on the hyperglycemic range 
(D, 563 ± 14 mg/dL; I-SC, 525 ± 38 mg/dL; and I-IP, 551 ± 20 mg/dL). 
Nonetheless, exogenous insulin was still detected in the plasma of animals 
from I-SC and I-IP groups in the morning.  
For the animals kept under insulin treatment, plasma TG levels were 
similar to control values whereas the untreated diabetic rats showed 
 D I-SC I-IP C 
Glycemia (mg/dL)  534 ± 22 a 90 ± 10 b 114 ± 22 b 105 ± 2 b 
Triglycerides (mg/dL)  249 ± 31 a 133 ± 10 b 116 ± 10 b 124 ± 7 b 
NEFA (mM) 0.586 ± 0.076 a 1.523 ± 0.176 b 1.150 ± 0.140 b 0.308 ± 0.047 a 
Exogenous insulin (mU/L) 1.18 ± 1.15 a 4.19 ± 1.02 b 3.87 ± 1.4 b N. D. 
Endogenous insulin (µg/L) 0.5 ± 0.2 a N. D. N. D 5.3 ± 1.1 b 
Hepatic glycogen (µmol/gdw) 320 ± 51 a 680 ± 56 b 814 ± 73 bc 907 ± 84  c 
Hepatic triglycerides (µmol/gdw) 319 ± 20 a 301 ± 15 a 287 ± 11 a 212 ± 22 b 
EWAT (g/100g) 0.30 ± 0.07 a 0.78 ± 0.09 b 0.92 ± 0.14 b N. D. 
Food intake (g/day) 40 ± 1 a 36 ± 2 ab 34 ± 0.3 b 23 ± 1 c 
Water intake (mL/day) 184 ± 14 a 113 ± 15 b 119 ± 10 b 35 ± 3 c 
Weight evolution (AUC0→10day) 229 ± 15 a 280 ± 6 b 268 ± 5 b N. D. 
100|Chapter 5 
 
significantly elevated plasma TGs, in agreement with reports from other 
authors (Dong et al. 2002; Mason et al. 2002; Iwasaki et al. 2005). The effect of 
insulin replacement on lowering the plasma TG levels may be a consequence 
of the enhanced chylomicron-TGs clearance by stimulation of LPL in the 
adipose tissue. This is consistent with the accumulation of fat as demonstrated 
by the higher content of EWAT in the insulin-treated diabetic animals relative 
to the untreated ones. In addition, insulin may also contribute to lower plasma 
TGs by inhibiting their hepatic secretion in VLDL. 
 
 
 
Figure 21 Plot of the animals’ body weight as a function of time during the insulin 
replacement period. Eight days after STZ injection, diabetic rats were left 
untreated (D) or injected a 15 U/kg insulin dose twice a day by the subcutaneous 
(I-SC) or intraperitoneal (I-IP) route.  
 
On the other hand, the concentration of NEFA in the plasma was 
similar between non-diabetic controls and untreated STZ-diabetic rats, and 
unlike reports from other authors (Wan et al. 2000; Dong et al. 2002), insulin 
replacement did not cause a reduction of NEFA values. Instead, and 
surprisingly, plasma NEFA concentration increased in the insulin-treated 
groups. This observation can be related to the larger mass of adipose tissue 
those animals presented. Actually, if plasma NEFA concentration is 
normalized for the mass of EWAT, the values for insulin treated rats tend to be 
lower than those for the STZ-diabetic rats. 
0 5 10
200
250
300
D
I-SC
I-IP
day of insulin replacement
bo
dy
 w
ei
g
ht
 (
g)
Metabolic effects of insulin replacement in ad libitum fed diabetic rats |101 
Similarly to the findings from the experiments described in chapter 4, 
hepatic glycogen content was reduced and TG levels increased in the 
untreated diabetic rats relative to controls. Insulin replacement in the I-IP 
group increased glycogen levels back to control values. On the other hand, in 
the I-SC group, although hepatic glycogen content was significantly higher 
than that observed for untreated diabetic rats, it was still lower than control 
levels. In contrast with observations from other authors (Shimomura et al. 
1999), hepatic TG content remained elevated in the diabetic rats receiving the 
insulin replacement treatments. 
 
5.3.2 2H enrichment levels and metabolic parameters  
After the insulin replacement period (9 or 10 days) all the animals 
were administered 2H2O and left to feed ad libitum overnight to trace the 
absorptive metabolism. The accurate body water 2H2O precursor 
enrichment was determined by 2H NMR analysis of plasma samples and 
reached the target value of 2% (Table 15). With these range of values, 
plasma glucose, hepatic glycogen and lipids were also enriched with 2H to 
levels that, coupled with the amount of sample recovered, allowed precise 
analysis by 2H NMR. All the STZ-diabetic rats had comparable 2H2O 
precursor enrichment levels. However, the insulin-treated rats, 2H 
enrichment in position 2 of blood glucose was higher than that of untreated 
STZ-diabetic rats, indicating insulin enhanced glucose turnover. On the 
other hand the 2H2 enrichment in glycogen was lower in the rats 
experiencing the insulin replacement protocol, consistent with the bigger 
hepatic glycogen pool. Insulin increased the absolute 2H enrichment in the 
methyl-TG, indicating a stimulation of the lipogenic pathway and reduction 
of the dietary and/or lipolytic contribution since the hepatic TG content was 
similar among all STZ-diabetic rats. 
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Table 15: Body water and metabolite absolute 2H enrichment levels observed after an 
overnight feeding under 2H2O administration. Groups are as described in the legend of Table 
14. For each parameter, values not sharing a common superscript letter are significantly 
different; statistical significance was accepted for a p < 0.05 determined by one way ANOVA 
with Fisher’s LSD post test.   
 2H enrichement (%) 
 Target BW BW 
H2 Blood 
Glucose 
H2 Glycogen Methyl-TG 
C 3 2.90 ± 0.14 1.21 ± 0.15 0.99 ± 0.20 0.48 ± 0.06 
D 2 1.93 ± 0.06 a 0.83 ± 0.06 a 1.21 ± 0.05 a 0.04 ± 0.01 a  
I-SC 2 1.97 ± 0.05 a 1.44 ± 0.05 b 0.66 ± 0.10 b 0.14 ± 0.01 b 
I-IP 2 1.96 ± 0.07 a 1.36 ± 0.06 b 0.72 ±0.13 b 0.16 ± 0.02 b 
 
5.3.2.1 Sources of glucose production 
Deuterium-enriched glucose molecules derive from EGP whereas 
unlabelled ones originate from the diet and subsequent gastrointestinal 
absorption to the blood stream. Hence, the contribution of EGP to blood 
glucose was assessed by the 2H enrichment of position 2 of blood glucose 
relative to that of body water (2H2/2H-BW). In non-diabetic control animals 
EGP accounted for 40 ± 4% of blood glucose. This contribution was similar 
to that observed for group D (44 ± 4%) because in these animals the 
increased food intake is parallel to higher rates of EGP (see discussion in 
chapter 4, section 4.4.2). In the cases where the animals were subjected to the 
insulin treatment protocols, the contribution of EGP to blood glucose was 
significantly higher reaching 73 ± 3% in group I-SC and 71 ± 5% in group I-
IP. The fact that insulin administration by both s.c. and i.p. routes translated 
into a higher contribution of EGP to blood glucose relative to that coming 
from the diet is consistent with the reduction on food intake and thus on the 
contribution of unlabeled dietary glucose. However, apparently, insulin did 
not efficiently reduce the rates of EGP under feeding conditions. 
Figure 22 represents the glycogenolytic and gluconeogenic 
contributions to EGP as determined by 2H NMR analysis of MAG derivative 
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from blood glucose. The H5/H2 ratio, which reflects the contribution of 
gluconeogenesis, was 0.95 ± 0.03 for the untreated diabetic animals, 
significantly higher than the 0.69 ± 0.04 observed for non-diabetic controls. 
When the STZ-diabetic animals were treated with insulin, the H5/H2 ratio 
was significantly reduced relative to group D and similar to that of healthy 
controls: 0.60 ± 0.03 for group I-SC and 0.62 ± 0.03 for group I-IP. 
 
 
 
Figure 22 Relative contributions of gluconeogenesis (white bars) and glycogenolysis (grey 
bars) to EGP determined after an overnight feeding under 2H2O administration. 
Groups are as described in the legend of Table 14. For each contribution, values 
not sharing a common letter are significantly different; statistical significance was 
accepted for a p < 0.05 determined by one way ANOVA with Fisher’s LSD post 
test.   
 
5.3.2.2 Hepatic glycogen synthesis 
The contribution of glycogen synthesized during the 2H2O 
administration protocol to the total hepatic glycogen pool is reflected in the 
2H enrichment in position 2 of glycogen relative to the body water’s. With 
insulin administration, the 2H2 enrichment in glycogen was significantly 
reduced (Table 15).  
Table 16 shows the data concerning hepatic glycogen synthesis 
during an overnight feeding after the insulin replacement protocol an also 
for non-diabetic controls. In the untreated STZ-diabetic rats more than half 
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of the hepatic glycogen was synthesized overnight, reproducing the 
observations from the experiments described in chapter 4. On the other 
hand, when the STZ-diabetic animals were treated with insulin, only one 
third of the hepatic glycogen was synthesized overnight, similar to the 
findings for the non-diabetic control animals. Because non-diabetic controls 
and insulin treated STZ-diabetic animals have higher glycogen levels the 
amount of glycogen synthesized overnight is actually similar in all groups. 
 
Table 16: Contribution of newly synthesized glycogen to the hepatic pool and amount of 
glycogen synthesized after an overnight feeding under 2H2O administration. Groups are as 
described in the legend of Table 14. For each parameter, values not sharing a common 
superscript letter are significantly different; statistical significance was accepted for a p < 0.05 
determined by one way ANOVA with Fisher’s LSD post test.   
 D I-SC I-IP C 
Glycogen synthesis 
(% contribution) 
58 ± 3 a 34 ± 5 b 35 ± 7 b 34 ± 7 b 
Overnight-synthesized  
glycogen (µmol/gdw) 
192 ± 35 a 236 ± 47 a 299 ± 64 a 322 ± 87 a 
 
 
 
Figure 23 Relative contributions of indirect (white bars) and direct (grey bars) pathways to 
hepatic glycogen synthesis determined after an overnight feeding under 2H2O 
administration. Groups are as described in the legend of Table 14. For each 
pathway, values not sharing a common letter are significantly different; statistical 
significance was accepted for a p < 0.05 determined by one way ANOVA with 
Fisher’s LSD post test.   
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The pathways for glycogen synthesis are depicted in Figure 23 and 
were altered by the induction of diabetes with the indirect pathway 
increasing from 54 ± 4% in the non-diabetic controls to 99 ± 1% in the 
untreated STZ-diabetic animals. Insulin treatment restored the 
direct/indirect pathways contributions to control levels with the indirect 
pathway accounting for 47 ± 2% in group I-SC and 49 ± 2% in group I-IP. 
 
5.3.2.3 Hepatic triglycerides and de novo lipogenesis 
In agreement with the observations from the experiments described 
in chapter 4, DNL was significantly reduced in group D when comparing to 
controls but the hepatic TG content was higher. This observation indicates 
that the contribution of dietary and/or lipolytic sources is increased in the 
diabetic rats. Insulin replacement to the diabetic rats significantly increased 
the contribution of DNL to the hepatic TG pool. The observation that the 
hepatic TG content was similar between the untreated and insulin-treated 
diabetic rats implies that the contribution of unlabeled dietary and/or 
lipolytic sources decreased with insulin treatment. Despite the enhancement 
of lipogenic TG synthesis, insulin replacement to diabetic rats did not 
translate into a complete restoration of the TG dynamics in the liver. 
 
Table 17: Contribution of de novo lipogenesis (DNL) to the hepatic triglyceride (TG) pool after 
an overnight feeding under 2H2O administration. Groups are as described in the legend of 
Table 14. For each parameter, values not sharing a common superscript letter are 
significantly different; statistical significance was accepted for a p < 0.05 determined by one 
way ANOVA with Fisher’s LSD post test.   
 D I-SC I-IP C 
DNL (% contribution) 2.2 ± 0.3 a 7.3 ± 0.7 b 8.2 ± 1.0 b 16.3 ± 1.7 c 
 
5.3.3 Changes in the gene expression and enzyme activities 
Table 18 shows the enzyme activities for GK, PFK, PK, G6PDH, and 
6PGDH measured from liver samples after the overnight feeding period 
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and the insulin replacement protocols. Figure 24 summarizes the changes in 
the expression of several hepatic genes involved in glucose and lipid 
metabolism relative to non-diabetic controls. 
 
Table 18: Enzyme activities (mU per mg of protein) determined in liver samples after an 
overnight feeding. Groups are as described in the legend of Table 14. For each enzyme 
activity, values not sharing a common superscript letter are significantly different; statistical 
significance was accepted for a p < 0.05 determined by one way ANOVA with Fisher’s LSD 
post test. GK, glucokinase; PFK, phosphofructokinase; PK, pyruvate kinase; G6PDH, glucose-
6-phosphate dehydrogenase; 6PGDH, 6-phosphogluconate dehydrogenase. 
 D I-SC I-IP C 
Glycolysis     
GK 0.050 ± 0.021 a 8.79 ± 0.27 b 7.48 ± 0.38 b 7.19 ± 0.96 b 
PFK 15.17 ± 1.02 a 16.93 ± 0.67 a 17.81 ± 1.15 a 22.48 ± 0.49 b 
PK 79.00 ± 15.69 a 463.6 ± 43.81 b 333.6 ± 33.88 c 814.7 ± 48.65 d 
Pentose Phosphate Pathway     
G6PDH 10.73 ± 0.56 a 20.96 ± 3.23 a 19.65 ± 1.70 a 97.88 ± 12.07 b 
6PGDH 11.49 ± 0.69 a 22.44 ± 1.62 b 19.71 ±0.76 b 43.24 ± 3.06 c 
 
5.3.3.1 Enzymes involved in glucose metabolism 
The relative mRNA levels of GK were significantly reduced in the 
STZ-diabetic animals but in both insulin-treated groups (I-SC and I-IP) the 
GK expression was similar to control levels. However, expression of the GK 
gene in the I-SC and I-IP groups was only modestly increased and thus was 
not significantly different from that of untreated diabetics. While the 
expression of the GK gene in the liver was not completely recovered with 
the insulin treatments, GK activity on the other hand, increased significantly 
to levels similar to controls (Table 18). PFK gene expression was similar 
among all study groups and its activity was similar for groups D, I-SC and 
I-IP. Moreover, in all the latter cases PFK activity was significantly lower 
than that measured for group C. The expression of the PK gene was 
significantly reduced in the STZ-diabetic animals but was completely 
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recovered to control levels in the I-SC and I-IP groups. Accordingly, the PK 
activity was significantly reduced in group D, relative to controls. Both 
insulin treatments resulted in significantly higher PK activities when 
comparing to diabetics, with the PK activity in the I-SC group being 
significantly higher than the one measured for I-IP, but these were however 
still significantly less than activities of controls. 
The hepatic gene expression of G6PDH was similar among all study 
groups. On the other hand, the activities of both G6PDH and 6PGDH were 
altered with diabetes and insulin replacement. In group D, both 
dehydrogenases’ activities were reduced when comparing to controls. 
Insulin replacement by both s.c. and i.p. routes resulted in a significant 
increase of G6PDH and 6PGDH activities, but these were still well below 
control levels.  
Considering the gluconeogenic enzymes in the untreated diabetic 
animals, PEPCK and FBPase gene expression was increased, while the 
expression of G6Pase remained similar to that of non-diabetic controls. 
Insulin treatment did not translate into a reduction on the expression of 
gluconeogenic enzymes. Instead, in the I-SC and I-IP groups, the expression 
of PEPCK, FBPase and G6Pase was similar to that determined for untreated 
diabetic rats.  
 
5.3.3.2 Enzymes involved in lipid metabolism 
The gene expression of CL was reduced in group D and recovered to 
control levels in I-SC and I-IP. This behaviour was also observed for the 
expression of the FAS gene. On the other hand, the ACC1 gene expression 
was similar between diabetics and controls. Insulin treatment resulted in a 
significant increase on the expression of the ACC1 gene in the I-IP group. In 
the I-SC group the ACC1 gene expression was similar to I-IP but not 
statistically different from groups D and C.  
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Figure 24 Gene expression (normalized for 18S and relative to controls, group C) of 
enzymes and transcription factors involved in carbohydrate and lipid metabolism 
determined after an overnight feeding in liver samples from groups D (white 
bars), I-SC (light grey bars), I-IP (dark grey bars), and C (black bars). Groups are 
as described in the legend of Table 14. Genes are as described in legend of Table 
13.For each gene, values not sharing a common superscript letter are significantly 
different; statistical significance was accepted for a p < 0.05 determined by one 
way ANOVA with Fisher’s LSD post test.  
 
The gene expression of CPT1a, the protein that transports fatty acids 
from the cytosol to the mitochondria for β-oxidation was increased in group 
D relative to controls (p < 0.05, unpaired t test). This observation, together 
with the reduced expression of the lipogenic genes CL and FAS suggests 
that the STZ-diabetic animals are experiencing a catabolic state, 
characterized by the oxidation of fatty acids by opposition to their synthesis 
via the lipogenic route. Furthermore, these data are in accordance with the 
upregulation of the gluconeogenic pathway, as determined by the elevated 
PEPCK and FBPase gene expression. In contrast to what was observed for 
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the regulation of the lipogenic genes expression, the expression of the 
CPT1a transporter did no approach control values with insulin treatment. 
Instead, CPT1a gene expression in the I-SC and I-IP groups was similar to 
that observed for diabetics. 
 
5.3.3.3 Transcription factors 
SREBP1c and ChREBP are two transcription factors involved in 
carbohydrate and lipid metabolism responding to insulin and glucose, 
respectively. While the mRNA levels for ChREBP were similar among all 
study groups, the ones for SREBP1c were significantly reduced in group D: 
With either insulin treatment, SREBP1c gene expression was restored to 
control levels but the observed levels were still not significantly different 
from those of group D. The induction of SREBP1c by insulin is in good 
agreement with the increased expression of the glycolytic and lipogenic 
enzymes in the insulin-treated diabetic rats. 
 
5.4 Discussion 
Chapter 4 established a 2H2O-based protocol for the study of the 
absorptive state. Those experiments pointed out the metabolic disruptions that 
take place with the induction of diabetes by STZ injection in regards to glucose 
production, hepatic glycogen and lipid synthesis. The study described in this 
chapter recapitulated those alterations and assessed the effect of insulin 
replacement on those pathways in two groups of rats receiving treatment for 9 
or 10 days to the i.p. or s.c. route. In addition, modifications on the gene 
expression and activities of several key enzymes were evaluated. Hence, these 
experiments allowed for a comprehensive study of hepatic metabolism by 
measuring the overall metabolic performance with the tracer-based approach 
and disclosing some regulatory aspects of hepatic glucose and lipid 
metabolism by gene expression and enzymology techniques. With these 
110|Chapter 5 
 
methods it was possible to identify the benefits and limitations of the insulin 
replacement protocol adopted. 
 
5.4.1 Alterations underlying the dominance of gluconeogenesis 
in STZ-diabetic rats 
In STZ-diabetic rats, both EGP and glycogen synthesis were dominated 
by the gluconeogenic flux. This was determined by the analysis of plasma 
glucose and hepatic glycogen 2H enrichment profile from 2H2O and confirmed 
by the increased expression of hepatic PEPCK and FBPase. The expression of 
G6Pase, although higher in the case of STZ-diabetic rats, was not statistically 
different from control levels. However, other authors (Hidaka et al. 2002) 
report that, in addition to PEPCK, G6Pase mRNA levels are increased in fed 
STZ-diabetic rats in a similar stage of the disease, relative to non-diabetic 
controls. The finding that in the present experimental setting, PEPCK gene 
expression was highly sensitive to insulinopenic STZ-diabetes (mRNA levels 
in diabetics were 7× higher than in controls) is consistent with the idea that 
insulin has a dominant action on the transcriptional regulation of PEPCK gene 
(Scott et al. 2003; Yabaluri et al. 2010).  
Gluconeogenesis from pyruvate is an energy-expensive pathway that 
is dependent on ATP and NADH. These can be derived from the β-oxidation 
of fatty acids in mitochondria. High rates of hepatic β-oxidation are supported 
by the increased expression of the CPT1a transporter and also by the increased 
availability of NEFA as a result of insulin deficiency in the STZ-diabetic rats.  
 
5.4.2 Alterations in hepatic lipid metabolism in STZ-diabetic 
rats 
Insulin deficiency impaired lipid uptake into adipose tissue in the 
STZ-diabetic rats as demonstrated by the reduced EWAT content and the 
elevated plasma TG levels. As a result, TGs not cleared by the adipocytes 
Metabolic effects of insulin replacement in ad libitum fed diabetic rats |111 
accumulated in the liver. The prevalence of hepatic TGs as a consequence of 
abnormal lipid metabolism by the adipose tissue rather than of hepatic de 
novo production was further demonstrated by the down regulation of the 
lipogenic enzymes (CL and FAS) and, consistently, the residual contribution 
of DNL to the hepatic TG pool as estimated by the 2H2O method. In this 
setting, it was anticipated that the NEFA flux from adipose tissue lipolysis 
would be increased, in agreement with the reduced levels of circulating 
insulin. The similar plasma NEFA concentration between diabetics and 
controls may be explained by the highly depleted TG stores in the adipose 
tissue. In accord with this, the EWAT content of diabetic rats represented 
only ~0.3% of the animals’ body weight, compared to the 0.6-1.2% range 
reported for non-diabetic controls (DiGirolamo et al. 1998; Wren et al. 2001; 
Takada et al. 2008).  
 
5.4.3 Metabolic control and limitations of the insulin 
replacement therapy 
Several biochemical and physiological parameters were improved by 
the insulin replacement protocols. For example, there was an increase in the 
animals’ body weight, in similar fashion to what was observed by other 
authors for STZ diabetic rats under a similar twice-daily insulin 
administration protocol (Suthagar et al. 2009) or under continuous insulin 
delivery by the use of infusion pumps (Wan et al. 2000). Likewise the 
deposition of fat in adipose tissue was increased as demonstrated by the 
higher content of EWAT. Moreover, the insulin-treated diabetic rats showed 
an alleviation of the symptoms associated with the disease, such as the 
hyperphagia and polydepsia. 
However, the metabolic evaluation by both the 2H2O tracer approach 
and gene expression and enzyme activities analyses suggests that the insulin 
treatment was in many aspects unable to revert the performance of diabetic 
animals back to that of controls. Insulin was administered as a rapid-acting 
formulation in two equal doses, one at the beginning of the dark phase (7 pm) 
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and the other at the beginning of the light phase (8 am). Prior to the 
administration of the morning insulin dose, glycemia was similar to that of 
untreated diabetic rats, in the hyperglycemic range. This indicates that the 
twice-daily insulin injection posology failed to afford normoglycemia 
throughout the complete day course. Under these circumstances, insulin 
action is no longer observed at the beginning of the light phase, in agreement 
with increased gluconeogenesis, fatty oxidation in the liver, and adipose tissue 
lipolysis as discussed below. 
Insulin replacement was able to normalize the relative contributions of 
gluconeogenesis and glycogenolysis to EGP. This finding is in line with 
reports from studies on controlled type 1 diabetic patients (Bischof et al. 2002). 
However, in the present experiment, the absolute fluxes of glycogenolysis and 
gluconeogenesis must remain elevated even after the treatment of the diabetic 
rats, accounting for the hyperglycemia observed in the morning. The gene 
expression analysis showed that, after an overnight feeding, the gluconeogenic 
enzymes were upregulated, supporting the increased absolute flux of 
gluconeogenesis in the insulin-treated diabetic rats.  
Despite the abnormalities in EGP the glycogenic and lipogenic 
pathways responded efficiently to insulin replacement in the diabetic rats, 
even in face of the incomplete insulinization throughout the day course. The 
restoration of GK gene expression and activity to control levels correlates very 
well with the increase in glycogen content in the liver. This effect is in 
accordance with the enhancement of glycogen synthesis in hepatocytes 
(O'Doherty et al. 1996; Seoane et al. 1999) and diabetic rats (Morral et al. 2004) 
overexpressing GK. In addition, in the diabetic rats, there was a complete 
recovery of the direct pathway flux with both insulin replacement protocols, 
contrarily to the observations for human type 1 diabetic patients that 
underwent intensive long-term insulin therapy where the fraction of glycogen 
synthesized by the indirect pathway remained dominant (Bischof et al. 2002). 
The stimulation of GK gene expression and activities parallel to those 
of PK and to the gene expression of several lipogenic enzymes, supports the 
coupling of glycolytic and DNL fluxes. With insulin treatment, the mRNA 
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levels of CL, ACC and FAS were increased to control levels or even higher (in 
the case of ACC). The increased gene expression of lipogenic enzymes in 
insulin-treated diabetic rats is in good agreement with the enhancement of 
DNL determined by 2H NMR methods and also with the stimulation of the 
dehydrogenases activities in the pentose phosphate pathway that generate 
NAPDH molecules for DNL.  
Nonetheless, DNL was not completely restored to control levels. In 
part, this was due to an important contribution from adipose tissue lipolysis to 
the hepatic TG pool, consistent with the elevated levels of circulating NEFA in 
the STZ-rats undergoing insulin replacement therapy. With both increased 
contribution from de novo production and adipose tissue lipolysis it was 
surprising that the hepatic TG content did not increase relative to the 
untreated diabetic rats. This finding can only be explained by concurrent 
lipogenesis and β-oxidation, which is actually supported by CPT1a expression 
levels in the range found for untreated diabetic rats and lower than those of 
controls. Evidence demonstrating the loss of reciprocal regulation between 
DNL and β-oxidation has been reported in hepatocytes overexpressing wild 
type and malonyl-CoA-insensitive (at a greater extent) CPT1a, even under 
feeding-like conditions of high insulin and high glucose (Akkaoui et al. 2009). 
Moreover the sensitivity of CPT1a to malonyl-CoA is decreased in diabetic 
rats and is only modestly reverted by acute administration of high insulin 
doses (Grantham et al. 1988). The present study provides additional evidence 
that lipogenesis and β-oxidation may occur simultaneously and furthermore 
insulin replacement may promote the cycling of lipids between those two 
pathways in the diabetic rats. 
 
5.4.4 Relevance of the intraperitoneal route 
Under physiological conditions, the liver receives insulin and nutrients 
by the portal vein during the absorptive phase. In these studies, the i.p. route 
was chosen as a strategy to target insulin to the liver and the absorptive phase 
was addressed after the insulin replacement period. It was anticipated that the 
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hepatic metabolic pathways would respond differently to the i.p. and s.c. 
routes of insulin administration. However, most of the effects observed in the 
fed state were independent of the route of administration. The only apparent 
difference was that when insulin was delivered to the i.p. route hepatic 
glycogen synthesis was further enhanced relative to the s.c. route. However, 
this observation was not supported by differently altered gene expression or 
enzyme activity of GK, which exerts high positive control over glycogen 
synthesis (Ferrer et al. 2003). It is possible that the lag phase between the last 
insulin injection and liver harvesting time prevented route-related effects to be 
noticed at the level of enzyme regulation. With continuous insulin diffusion 
pumps, the i.p. route resulted in increased stimulation of GK activity relative 
do s.c. and even non-diabetic controls (Mason et al. 2000). Interestingly, 
another study from the same group reports the activity of lipogenic enzymes 
is enhanced to the same extent by both routes (Mason et al. 2002). Hence, at 
least in the in the absorptive state, portal insulin is more relevant in the 
normalization of glycogen synthesis, probably via GK regulation.  
 
5.5 Conclusions 
Delivering insulin in two daily doses to either the s.c. or i.p. route was 
beneficial to the overall condition of STZ-diabetic rats. Glycolytic and 
lipogenic fluxes in the liver were highly responsive to the treatment but 
gluconeogenesis and lipid degradation could not be normalized, probably as a 
consequence of the insufficient insulinization throughout the whole day. 
Preferential hepatic action could not be clearly demonstrated for the i.p. route 
except for the higher glycogen content in the liver that, nonetheless, was not 
accompanied by other differential improvements. 
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6                                                                                                    
POLYMERIC NANOPARTICLES FOR INSULIN DELIVERY 
6.1 Introduction 
An important issue regarding the current insulin therapy is that its 
delivery by the s.c. route fails to recapitulate the hormone’s physiological 
release profile, since the portal to peripheral gradient is unmet under those 
circumstances. Oral insulin delivery would mimic the normal secretion of 
insulin because the drug would be largely absorbed to the portal vein. 
However, because of its peptide nature, oral insulin administration is 
hampered. Poor absorption and high enzymatic degradation of peptide and 
protein agents are the main barriers compromising their efficacy by the oral 
route (Pauletti et al. 1996; Uekama et al. 1998; Pinto Reis et al. 2006). Even 
after reaching circulation, these drugs are rapidly cleared from the blood, 
and their presence may also lead to immunological complications (Uekama 
et al. 1998). In this context, nanoparticles arise as specialized delivery 
systems being developed by several research groups with encouraging 
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results in regards to enhancing the oral efficacy of peptide drugs (e.g. 
Allémann et al. 1998; Bilati et al. 2005a; Pinto Reis et al. 2006).  
Nanoparticles are colloidal carriers ranging in size from 10 to 1000 
nm. They are used in drug formulation for facilitating the passage of drugs 
through the biological membranes, protecting drugs against degradation, 
controlling drug release and targeting to specific sites of action. Once in the 
body, nanoparticles are recognized as strange entities, undergo opsonisation 
(coating with opsonin protein) that flags them to phagocyte cells and are 
eventually delivered to organs of the reticuloendothelial system. Unloaded 
biodegradable nanoparticles are mainly taken up by the liver (42 to 80% of 
the administered dose), spleen (0,6 to 2%), lungs (0,7 to 3%) and to a less 
extent by the bone narrow (Allémann et al. 1993). This extensive uptake is 
advantageous when the therapeutic agent is intended to act on those organs 
and can thus be used as means of passive targeting drugs to the liver, for 
example.  
Concerning the above mentioned, a hypothesis can be set that 
physiological/portal delivery of insulin may be achieved by the 
nanoparticle strategy if: (i) the drug is successfully absorbed by the oral 
route; (ii) or passive liver targeting occurs even under the traditional s.c. 
administration. To test this hypothesis, nanoparticles with high insulin 
association were prepared from biodegradable and biocompatible materials 
and assayed for efficacy against the administration of free insulin. In the 
following paragraphs, some methodological considerations regarding the 
materials chosen to develop the nanoparticles are addressed. 
From the wide variety of polymers available for preparing 
nanoparticles, poly-lactide-co-glycolide (PLGA) has the advantage of being 
biodegradable.  
Among the various methods available for preparing nanoparticles, 
the nanoprecipitation technique employs mild conditions and is the most 
simple and straightforward. In this procedure a polymer is dissolved in an 
organic medium (typically acetone) and, upon contact of this solution with a 
non-solvent phase (typically water), the polymer immediately suffers 
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desolvation resulting in the formation of nanoparticles. In a second step the 
organic solvent is removed by evaporation and the nanoparticles are 
obtained as an aqueous colloidal suspension. The most common way to 
associate drugs to nanoparticles prepared by this methodology is to add the 
drug along with the polymer to the organic solvent. While this is a good 
procedure for hydrophobic molecules, it is not very suited for the 
formulation of hydrophilic compounds, such as insulin. Nonetheless, 
nanoprecipitation has been successfully used to prepare insulin-loaded 
PLGA nanoparticles by dissolving the drug in hydrochloride acid and then 
adding that solution to the polymer-containing acetonic phase (Barichello et 
al. 1999a, 1999b; Cui et al. 2007). Alternatively, Bilati et al using a modified 
nanoprecipitation method have obtained insulin-loaded PLGA 
nanoparticles by dissolving the drug and the polymer in DMSO or N-
methylpyrrolidone (Bilati et al. 2005b). In the authors’ method, the 
nanoparticles are recovered after centrifugation and successive washes with 
distilled water. 
Cyclodextrins (CD) are cyclic oligosaccharides consisting of several 
D-glucopyranose units linked to each other by α-1,4 bonds (Figure 25A). 
Natural occurring CDs are obtained from the enzymatic breakdown of 
starch by bacterial amylase cyclodextrin-glucosyl-tranferase and the most 
abundant are α-, β- and γ-CD, consisting of 6, 7 and 8 glucopyranose 
residues respectively. Cyclodextrins assume a cone shaped form (Figure 
25B) with the polar hydroxyl groups facing the outside, primary hydroxyl 
residues linked to C6 are in the narrowest face while secondary ones linked 
to C2 and C3 are localized on the wider face. These hydroxyl groups can 
suffer chemical modifications and be conjugated with other functional 
groups to alter the physicochemical properties of parent CD. Hence, CD and 
their derivatives cover a wide range of pharmaceutical applications and 
have been largely used in drug delivery as adjuvant to improve drug 
solubility, stability, and bioavailability (Loftsson et al. 2007). 
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                                       A                                                                       B 
                       
 
Figure 25 The chemical structure of β-CD. (A) Seven D-glucopyranose units linked by α-1,4 
bonds. (B) The cone shape configuration of β-CD, black dots represent carbon 
atoms and white dots oxygen atoms, hydrogen atoms are omitted. Reproduced 
from Loftsson et al. (Loftsson et al. 1996). 
 
About twenty years ago, new CD derivatives with amphiphilic 
character were synthesized by Zhang and co-workers (Zhang et al. 1991). 
Similar to polymers, these molecules are able to self-assemble into 
nanoparticles by the nanoprecipitation technique. This new amphiphile 
class of CD has extended the pharmaceutical potential of CD to the domain 
of the nanocarrier systems. Several chains can be grafted to the CD parent 
molecule at different positions (Duchêne et al. 1999), and recently, the 
thermolysin catalyzed transesterification of CD with vinyl esters allowed 
the synthetic procedure to be simplified to a quantitative one-step reaction 
(Pedersen et al. 2005; Choisnard et al. 2006).  
This chapter describes the preparation of insulin-loaded 
nanoparticles from PLGA and amphiphilic CD. The aim was to develop a 
new nanoparticle-based carrier for oral and/or s.c. administration of insulin 
that would translate in benefits with respect to the pharmacological 
response. From the most common α- β- and γ-CD, the latter is the less toxic 
(Loftsson et al. 2007) and was hence chosen to prepare an amphiphilic 
derivative to be included in the nanoparticle formulation. The amphiphilic 
CD consisted of a γ-CD backbone grafted with C10 chains from vinyl 
decanoate and was synthesized by enzyme catalysis. Insulin was not added 
to the polymer/amphipilic CD-containing solvent but rather to the non-
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solvent aqueous phase. Still, good association of insulin to the nanoparticles 
could be observed. The relevance of the nanosystem for insulin delivery in 
vivo, was studied in several experimental settings that aimed to evaluate the 
hypoglycemic response upon oral and s.c. administration to non-diabetic 
and STZ-diabetic rats. 
 
6.2 Materials and methods 
6.2.1 Synthesis and characterization of amphiphilic 
cyclodextrins 
Parent γ-CD (Roquette, France) was grafted C10 alkyl chains by a 
thermolysin-based catalysis as previously described (Choisnard et al. 2006). 
Briefly, ~1 g of γ-CD dissolved in 7.5 mL of DMSO plus 2.3 mL of vinyl 
decanoate (99%; TCI Europe nv, Interchim, France), were let to react at 45 ºC 
for 8 days in the presence of 1 g of thermolysin (Sigma Aldrich, France) 
previously immobilized in celite. At the end of the reaction, the celite-
thermolysin deposit was eliminated by centrifugation and cyclodextrin 
esters in the supernatant were precipitated by adding 20 mL of 35% (v/v) 
methanol in water. After centrifugation, the supernatant was discarded, the 
product solubilized in tetrahydrofuran and further purified by successive 
acetonitrile precipitation, filtration and re-solubilization in tetrahydrofuran. 
This procedure was repeated three times. Finally the γ-CD capric esters (γ-
CDC10) were dissolved in acetone and recovered as a white powder after 
drying under vacuum. MALDI-MS: m/z = 2399.11 (relative intensity, 33%; 
decanoate γ-CD ester with 7 chains + Na+); m/z = 2553,31 (relative intensity, 
100%; decanoate γ-CD ester with 8 chains + Na+); m/z = 2707.48 (relative 
intensity, 54%; decanoate γ-CD ester with 9 chains + Na+); m/z = 2861.66 
(relative intensity, 15%; decanoate γ-CD ester with 10 chains + Na+). 1H 
NMR (600 MHz; DMSO-d6): δ (ppm) = 0.85 (─CH2─CH2─(CH2)6─CH3), 1.24 
(─CH2─CH2─(CH2)6─CH3), 1.53 (─CH2─CH2─(CH2)6─CH3), 2.32 
(─CH2─CH2─(CH2)6─CH3), 3.49 (H4), 3.60 (H6), 3.66 (H5), 3.79 (H3), 4.43 
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(H2), 5.20 (H1). 13C NMR (600 MHz; DMSO-d6): δ (ppm) = 13.5 
(─CH2─CH2─(CH2)6─CH3), 22.0, 28.5 and 31.0 (─CH2─CH2─(CH2)6─CH3), 
24.0 (─CH2─CH2─(CH2)6─CH3), 33.2 (─CH2─CH2─(CH2)6─CH3), 59.8 (C6), 
69.5 (C3), 71.0 (C5), 72.7 (C2), 77.3 (C4), 172.7 (─CO─). This product was 
further characterized by heteronuclear multiple quantum coherence 
(HMQC) spectroscopy. 
 
6.2.2 Preparation of nanoparticles suspensions 
Nanoparticles were prepared by nanoprecipitation followed by 
solvent evaporation (Fessi et al. 1992). Typically, 5 mL of acetone containing 
the nanoparticle-forming material was poured over 6.5 mL of a polysorbate 
80 (Montanox® 80, Seppic, France) aqueous solution (0.015% m/v) under 
magnetic stirring, in a closed system thermostatized at 25 ºC. Nanoparticles 
were spontaneously formed, the organic solvent and part of the water were 
removed by evaporation under vacuum and particles were recovered as an 
aqueous colloidal suspension (approximately 5 mL). To prepare insulin-
loaded nanoparticles, 300 µL of an insulin commercial preparation 
(Actrapid®, Novo Nordisk, France) equivalent to 30 U of insulin were 
added to the aqueous phase prior nanoprecipitation to prevent possible 
denaturation resulting from contact with acetone. The organic solutions 
consisted of: (i) 5 mg of PLGA with a lactide-glycolide ratio of 50:50 
(Boehringer Ingelheim, Germany) per mL of acetone; (ii) 1 mg of γ-CDC10 
synthesized as previously described per mL of acetone; (iii) a mixture 
consisting of 5 mg PLGA plus 1 mg of γ-CDC10 per mL of acetone. To 
prepared coated nanoparticles, ethyl acrilate-methacrilic acid copolymer 
(Eudragit® L30D-55 30% aqueous dispersion, Evonik Röhm GmbH, 
Germany) was dissolved in acetone to prepare a 40 mg/mL mother solution 
and 1 mL of this solution was added to the nanoparticle suspension after the 
addition of the organic phase (iii) to the aqueous phase and prior to the 
evaporation of the solvents. 
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6.2.3 Nanoparticles characterization 
Particle size was determined in triplicate by quasi-elastic light 
scattering (QELS) using a Zetasizer 3000 instrument (10 mW HeNe laser at 
632.8 nm, K7132 correlator, Malvern). Nanosphere samples were diluted in 
distilled water in order to obtained adequate kcount readings for size 
measurements. The analyses took place at 25 ºC, at a reference angle of 90°, 
viscosity of 0.899x10-3 Pa.s, refractive index of 1.330. The polydispersity 
index (PI), which is a dimensionless measure of the broadness of the size 
distribution, and Z-average mean hydrodynamic diameter (Dh) of the 
particles were calculated using a cumulant algorithm with Zetasizer 3000 
software version V. 1.51. Dh was derived from the measured translational 
diffusion coefficient of the particles moving under Brownian motion.  
Morphology of the particles was address by transmission electron 
microscopy (TEM). 
 
6.2.4 Insulin quantification 
Insulin was quantified by high performance liquid chromatography 
(HPLC) with a method adapted from Sarmento et al. (Sarmento et al. 2006) 
as described. The samples were centrifuged at 17,000 rcf for 30 minutes at 20 
ºC. The supernatants were diluted in HCl 0.01 M to a final volume of 2 mL 
and filtered through 0.22 µm polyvinylidene fluoride filters6 prior to HPLC 
analysis. The chromatographic equipment consisted of a Prostar 230 ternary 
solvent delivery module (Agilent, USA) equipped with a reverse phase X-
Terra C-18 column, 5 µm, 4.6 mm × 250 mm (Waters, France) and a 
Interchrom C-18, 5 µm precolumn (Interchim, France) maintained at 31 ºC. 
A Prostar autosampler 400 (Agilent, USA) fitted a 50 µL loop was used for 
injections. Mobile phase A consisted of tri-distilled water with 0.1% 
                                                     
6 These filters were chosen because they display low protein retention by adsorption. Since 
standard insulin solutions used in the preparation of the calibration curve were also 
subjected to the same centrifugation-filtration procedure, any eventual insulin loss during 
the process is accounted for. 
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trifluoroacetic acid and mobile phase B of acetonitrile with 0.1% 
trifluoroacetic acid. Each analysis was performed over 18 minutes with a 
flow rate of 1 mL/minute, a linear gradient from 70:30 (A:B) to 60:40 (A:B) 
was applied in the first five minutes, the 60:40 (A:B) was maintained for 
another 8 minutes; system returned to the initial conditions in the final 5 
minutes. Insulin was detected at 210 nm with a Varian 9050 variable 
wavelength UV/Vis detector (Agilent, USA) and peak area integrated with 
Star Chromatography Workstation version 5.52 software. A typical 
chromatogram is depicted in Figure 26 and a calibration curve for insulin 
was set to determine insulin concentration in the supernatant (Figure 27).  
 
 
 
Figure 26 Typical chromatogram obtained for the 35 µg/mL insulin standard prepared by 
dilution of Actrapid® in HCl 0.01 M. The peaks were detected at 270 nm and 
correspond to insulin and cresol (included in the commercial preparation) as 
indicated.  
 
Standard solutions were prepared by dilution of the insulin 
commercial formulation in HCl 0.01 M. Insulin Association Efficacy (AE) 
was calculated indirectly as a difference of the amount found in the 
supernatant from the theoretical amount initially added as shown in 
Equation 15. This method was also used to determine the %AE after 
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dilution of the nanoparticle suspensions 1/5 in water and in the release 
studies in HCl 0.1 M. 
 
 
 
Figure 27 Calibration curve used for quantifying insulin in the supernatant of nanoparticles 
by HPLC. Standards were prepared from dilutions of a commercial insulin 
solution (Actrapid ®) in HCl 0.01M. The equation for the linear regression is 
show. 
 
Equation 15  
% 78   1   Insulin in supernatant :
µg
mL<  total volume of NS mL
initially added insulin µg   100              
 
A batch of nanoparticles from the PLGA-γ-CDC10 blend displaying 
93% AE was used to determine the amount of insulin that could be 
recovered from the formulations. A 200 µL aliquot was diluted 1/20 in HCl 
0.05 M, then 2 mL of this suspension was treated as described for the 
supernatant HPLC analysis and 95% of the theoretical amount of insulin 
added to the formulation could be recovered at the end of the procedure. 
 
6.2.5 Release assays in HCl 0.1 M 
Nanosphere suspensions were diluted 1/4 in centrifuge tubes with 
HCl (0.1 M, pH 1.2) and incubated in a water bath with the temperature set 
at 37 ºC. Every 30 minutes samples were centrifuged (5,500 rcf for 10 
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minutes) and the supernatants collect for HPLC analysis. The solid residue 
was resuspended in fresh HCl solution and again placed in the 
thermostatized bath. The release study followed for 2 hours.  
 
6.2.6 Animal procedures 
6.2.6.1 Animal housing 
As described in section 2.2.1.1. 
 
6.2.6.2 Study I. Non-diabetic controls, s.c. route 
Non-diabetic control rats (245 ± 9 g) were fasted overnight prior to 
the experiments and randomized into six groups (N = 5 per group) 
receiving the following treatments: CTRL, no treatment; ACTR, s.c. injection 
of Actrapid® solution in polysorbate 80 (0.015% m/v); PL-I, s.c. injection of 
insulin-loaded nanoparticles from PLGA; PL, s.c. injection of nanoparticles 
from PLGA; CDPL-I, s.c. injection of insulin-loaded nanoparticles from the 
PLGA-γ-CDC10 blend; CDPL, s.c. injection of nanoparticles from the PLGA-
γ-CDC10 blend. The formulations were administered at an insulin dose of 2.3 
U/kg or equivalent volume of placebo. Glycemia was monitored from the 
tail vein with a glucometer (Accu Check Performa, Roche Diagnostics, 
France) before treatment and henceforward at 0.25, 0.5, 1, 2, 4, 6 and 8 hours. 
Animals were allowed one week of recovery from this experiment and re-
randomized into groups for the next study. 
 
6.2.6.3 Study II. Non-diabetic controls, oral route 
In this assay animals were fasted overnight and assigned to the 
following groups: CTRL, oral gavage of tap water (N = 6); ACTR, oral 
gavage of Actrapid® solution in polysorbate 80 (0.015% m/v) (N = 8); 
PLCD, oral gavage of nanoparticles from the PLGA-γ-CDC10 blend (N = 8); 
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PLCD-I, oral gavage of insulin-loaded nanoparticles from the PLGA-γ-
CDC10 blend (N = 8). The formulations were administered at an insulin 
dosage of 100 U/kg or equivalent volume of placebo. Glycemia was 
monitored as described in study I, section 6.2.6.2 before treatment and 
henceforward at 0.5, 1, 2, 4, 6, 8, 10 and 24 hours.  
After reformulation experiments, this assay was applied to a 
separate group of animals (275 ± 3 g) to assess the efficacy of the Eudragit®-
coated nanoparticles. In this case, after an overnight fast, animals received 
an oral dose (100 U/kg) of insulin-loaded Eudragit®-coated nanoparticles 
from the PLGA-γ-CDC10 blend (NPL30D-I, N = 8) or alternatively an 
equivalent volume of placebo Eudragit®-coated nanoparticles from the 
PLGA-γ-CDC10 blend (NPL30D, N = 8). 
 
6.2.6.4 Study III. STZ-diabetic rats, s.c. route 
Diabetes was induced in a separate group of rats by STZ injection as 
described in section 3.2.1.2. Fifteen days after diabetes induction by STZ 
injection, animals (226 ± 6 g) were fasted overnight and randomized in two 
groups. One group (ACTR, N = 4) received an s.c. injection of an Actrapid® 
solution in polysorbate 80 (0.015% m/v) and the other (CDPL-I, N = 5) was 
injected insulin-loaded nanoparticles from the PLGA-γ-CDC10 blend. The 
insulin formulations were administered at a dose of 2.3 U/kg and glycemia 
monitored as described in study I, section 6.2.6.2. 
 
6.2.6.5 Study IV. STZ diabetic rats, OGTT 
Diabetes was induced in a separate group of rats by STZ injection as 
described in section 3.2.1.2. Twenty days after the induction of diabetes, 
animals (190 ± 7 g) were fasted for 24 hours and randomized in three 
groups. In two of the groups, rats were injected with insulin formulations 30 
minutes before the OGTT while another group was not given any injection, 
STZ (N = 5). Insulin was administered at a dose of 5 U/kg as a solution of 
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Actrapid® in polysorbate 80 (0.015% m/v), ACTR (N = 4) or as a suspension 
of insulin-loaded nanoparticles from PLGA-γ-CDC10 blend, CDPL-I (N = 4). 
The glucose load was prepared at a dose of 2 g/kg and glycemia was 
monitored over a 3-hour period as described in chapter 2.  
 
6.2.7 Statistics 
As described in section 2.2.6. A two-way ANOVA with Bonferroni 
post tests was used to analyze glycemia profiles. The area above the curve 
(AAC) was calculated by setting a cutoff at 100%.  
 
6.3 Results  
6.3.1 Synthesis of amphiphilic cyclodextrin 
Cyclodextrin esters were obtained by enzymatic synthesis as a 
mixture of over- and under-acylated species with the substitution degree 
ranging from 7 to 10 acylations (m/z, 2399.11–2861.66). The signals in the 
MALDI-MS analysis were separated by 154 mass units, corresponding to 
the molecular mass of the decanoate chain. The most abundant species in 
the mixture was acylated with 8 C10 chains. This profile may represent one 
or more acylations per glucopyranose unit that composes the CD. The 
presence of species with 9 and 10 acylations indicates some glucopyranose 
units were acylated in at least three carbons. Acylation can occur via the 
primary C6 hydroxyl or the secondary C2 and C3 hydroxyls. Enzymatic 
catalysis is reported to lead mainly to acylation in C2 however, the grafting 
of other positions is not to be excluded (Pedersen et al. 2005; Choisnard et al. 
2006). The NMR analyses of the γ-CDC10 product (Figure 28 and Figure 29) 
further clarified the substitution profiles in the mixture, namely in what 
concerns the positions that were attacked during the transesterification 
reaction.  
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Figure 28 HMQC spectrum of γ-CD in DMSO-d6. The 1H/13C correlations are identified for 
each position of the hexose unit. 
 
 
Figure 29  HMQC spectrum of γ-CDC10 ester mixture in DMSO-d6. The hexose moiety of the 
esters is shown and the 1H/13C correlations are identified for each position of the 
hexose unit. 
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The H6/C6 correlaction in the HMQC spectrum of the the γ-CDC10 
ester mixture was similar to the one observed for the parent γ-CD. Hence, 
substitution in position 6 is unlikely to have occurred. The most significant 
shift from the parent γ-CD was observed for the H2 resonance, which 
moved downfield from 3.30 to 4.42 ppm, translating in an altered H2/C2 
correlation. This downfield shift is consistent with a strong deshielding 
effect due the ester function in the C2 position. All the other positions 
experienced a modest downfield shift in 1H, which indicates the presence of 
an additional electronegative environment in the vicinity of H3, H4 and H5 
and is consistent with the C2 acylation. Nonetheless, the presence of species 
with 9 and 10 acylations implies that C3 was also acylated at least to some 
extent. The presence of an extra correlation peak at 4.59/70.43 ppm supports 
the presence of species acylated in C3, with the H3 moving downfield from 
3.59 ppm in the parent γ-CD and from 3.78 ppm in the C2 acylated species.  
 
                                A                                                               B 
 
 
Figure 30 (A) Chemical structure of the γ-CDC10 amphiphilic cyclodextrin. By enzyme 
catalysis 10-carbon alkyl chains were grafted in positions 2 and 3. (B) Three 
dimensional representation of the amphiphile, consisting of a hydrophilic head 
(primary face of the CD cone) and 8 hydrophobic tails in the secondary face. 
In sum, the γ-CDC10 product consisted of a mixture of esters derived 
from acylation of the parent γ-CD mainly in C2 and at less extent also in C3. 
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The proposed structure is depicted in Figure 30. This product showed self-
assembly properties compatible with the formation of nanoparticles as 
presented in section 6.3.2. 
 
6.3.2 Nanoparticle preparation and characterization 
Nanoparticles were prepared by the solvent displacement 
procedure. The nanoparticle-forming material was dissolved in acetone and 
upon contact of this organic solution with the aqueous phase nanoparticles 
immediately assembled as a consequence of the desolvation process. This 
observation was verified for all three organic solutions: PLGA (5 mg/mL), 
γ-CDC10 (1 mg/mL) and the PLGA-γ-CDC10 (5:1 mg/mL) blend. Size 
measurements by QELS (Table 19) confirmed the presence of monodisperse 
particle size distributions in the nano range. Despite the differences on the 
composition of the organic phase, all the uncoated formulations rendered 
nanoparticles of similar sizes. The average mean diameter ranged from 112 
to 126 nm. Moreover, these observations indicate that PLGA and γ-CDC10 
co-nanoprecipitated in formulation from the PLGA-γ-CDC10 blend and this 
was further confirmed by TEM photographs (Figure 31) that show spherical 
particles in good agreement with the size measurements by QELS. 
As described in section 6.2.2, insulin-loaded nanoparticles were 
prepared by adding a commercially available insulin formulation 
(Actrapid®) to the system. This formulation consists of an aqueous neutral 
solution of insulin and because its contact with acetone resulted in 
immediate turbidity observed by the naked eye, suggesting the integrity of 
the protein to be compromised, Actrapid® was added to the aqueous phase. 
When the nanoparticles were prepared from γ-CDC10 alone, ~80% of the 
insulin added to the system could be recovered in the aqueous supernatant 
after centrifugation, with less than 20% remaining associated to the particles 
(Table 19). On the other hand, excellent association efficacy (~90%) was 
observed for the PLGA formulation, which was maintained for the PLGA-γ-
CDC10 blend (Table 19).  
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Table 19: Particle sizes (mean diameter in nm), polydispersity indexes (PI) and insulin 
association efficacy (% from initial, %AE) for the three organic phases studied, which 
consisted of the following acetonic solutions: 5 mg/mL PLGA with a lactide-glycolide ratio 
of 50:50 (PLGA); 1 mg/mL γ-CD esters from 10 carbon-alkyl chains (γ-CDC10); and 5 mg/mL 
PLGA plus 1 mg/mL of γ-CDC10 (PLGA-γ-CDC10). (1) Coating was performed with 
Eudragit® L30D55 after nanoparticle assembly using the specified organic phase. (2) Insulin 
was not detected in the supernatant after centrifugation of the nanoparticle suspensions. 
 
Placebo Nanoparticles  Insulin-loaded Nanoparticles 
Size PI  Size PI % AE 
Uncoated Nanoparticles       
PLGA 117.4 ± 3.3 0.1 ± 0.01  112.4 ± 5.8 0.1 ± 0.001 88.1 ± 5.1 
γ-CDC10 118.3 ± 0.6 0.09 ± 0.03  126.5 ± 7.3 0.07 ± 0.01 19.0 ± 1.4 
PLGA-γ-CDC10 122.7 ± 3.5 0.09 ± 0.007  115.8 ± 5.4 0.1 ± 0.007 92.0 ± 1.0 
Coated nanoparticles (1)       
PLGA-γ-CDC10 167.5 ± 2.5 0.1 ± 0.01  186.5 ± 0.5 0.09 ± 0.007 N.D. (2) 
 
 
 
Figure 31  TEM photography for insulin-loaded nanoparticles prepared from the PLGA-γ-
CDC10 blend. 
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When Eudragit® was added to the preformed nanoparticles there 
was a slight increase in particle size but the monodispersity of the 
population distribution was maintained, supporting the efficient coating of 
the nanoparticles. Moreover, coating seemed to strengthen the interactions 
between insulin and the nanoparticles since the %AE was virtually 100 as a 
result of no insulin being detect in the supernatants after centrifugation of 
the suspensions. 
 
6.3.3 Dilution and release assays 
When the uncoated nanoparticle suspensions were diluted in water, 
the %AE was maintained relative to that initially determined (Figure 32). 
This indicated that the interaction between insulin and the carrier was not 
disrupted upon simple dilution. These results, together with the particle 
size measurements and %AE determinations before dilution suggest that 
both formulations from PLGA and the PLGA-γ-CDC10 blend have similar 
characteristics in regards to the interaction with insulin.  
 
 
 
Figure 32 Percente association efficacy (%AE) after dilution of the nanoparticle suspensions 
in water. Nanoparticles were prepared by nanoprecipitation followed by solvent 
evaporation, the organic phase consisted of PLGA (5 mg/mL) or a PLGA-γ-CDC10 
mixture (5:1 mg/mL) in acetone and the aqueous phase was polysorbate 80 
0.015% (m/v), insulin was added to the aqueous phase. 
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With the oral route of administration in mind, studies were 
performed to investigate the release profile of insulin in acidic medium as 
an indication for the possible resistance of the system during the GIT transit. 
As depicted in Figure 33, the coating with Eudragit® improved association 
of insulin to the nanoparticles after HCl treatment. This effect was expected 
since Eudragit® L30D55 is resistant to acid environment, dissolving at a pH 
value superior to 5.5. 
 
 
 
Figure 33 Release studies in HCl 0.1 M, pH 1.2 performed at 37 ºC. Coated (NPL30D-I) and 
uncoated (CDPL-I) insulin-loaded nanoparticles from the PLGA-γ-CDC10 blend 
were diluted 1/4 in HCl and insulin released to the medium quantified by HPLC. 
 
6.3.4 Biological activity of the nanoparticle formulations 
Insulin not associated to the particles remains in the aqueous phase 
of the suspensions. Thus, when determining the dosage for administration it 
was taken into consideration the total (free plus nanoparticle-associated) 
amount of insulin present in the suspensions. Since only a residual amount 
of insulin was found in the supernatant fraction of the suspensions, most of 
it being associated to the particles, the in vivo effect of the formulations is 
assumed to be mostly due to the nanoparticle-associated insulin.  
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6.3.4.1 Subcutaneous administration to non-diabetic rats 
After the overnight fasting period, the glycemia observed for the 
animals was 88 ± 2 mg/dL. Figure 34 shows the glycemia profiles 
(expressed as percent from the initial value) for all experimental groups 
following the injection of insulin or placebo formulations.  
 
 
 
Figure 34 Glycemia profiles for non-diabetic rats after an overnight fasting. Insulin and 
placebo formulations were administered by the subcutaneous route at time t = 0 
hours at a dose of 5 U/kg or equivalent volume. CTRL, control rats not 
administered with any formulation; PL, rats administered sham nanoparticles 
from PLGA; CDPL, rats administered sham nanoparticles from the PLGA-γ-
CDC10 blend; ACTR, rats administered the commercial insulin formulation 
Actrapid®; PL-I, rats administered insulin-loaded nanoparticles form PLGA; 
CDPL-I, rats administered insulin-loaded nanoparticles from the PLGA-γ-CDC10 
blend. See text for statistical differences. 
 
Animals that were injected with placebo formulations (PL and CDPL 
groups) presented glycemia profiles similar to controls, maintaining the 
initial blood glucose levels throughout the experimental period with a slight 
initial increment attributed to manipulation-induced stress. This 
observation demonstrates that the formulations per se don’t elicit 
hypoglycemic response. Also the AAC, which is a measure of the overall 
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± 17, PL; and 51 ± 16, CDPL), further supporting the lack of pharmacological 
effect of the sham nanoparticles. On the other hand, when insulin 
formulations were administered to the animals, the hypoglycemic effect was 
immediate, overcoming the initial stress-induced raise in glycemia, 
although statistically significant differences were only attained from 0.5 
hours onward. The AAC for all the insulin formulations were significantly 
higher than controls and placebo formulations, as expected. 
When animals were injected with the standard insulin formulation 
(Actrapid®), glycemia decreased progressively until a minimum value (29 ± 
6 mg/dL) observed at time t = 2 hours, and 2 hours later animals had regain 
normoglycemia. Furthermore, the glycemia curve for ACTR group was 
characterized by a peak-like shape with a minimum at t = 2 hours. In 
contrast, for both nanoparticle formulations, the negative peak was 
smoothen and the curves assumed a rounder shape, enlarging the interval 
for the minimum, which in these cases was sustained from t = 0.5 hours 
(corresponding to 45 ± 6 mg/dL, PL-I and 39 ± 3 mg/dL, CDPL-I) to t = 2 
hours (corresponding to 43 ± 5 mg/dL, PL-I and 36 ± 2 mg/dL, CDPL-I). 
These observations suggest both formulations from PLGA and PLGA-γ-
CDC10 blend were able to modulate insulin’s hypoglycemic effect that was 
sustained during that interval. These results are in good agreement with 
Barichello et al. experiments, in which the authors observe a similar 
sustentation for the minimum glycemia following the s.c. injection of 
insulin-loaded nanoparticles from PLGA (Barichello et al. 1999b). Moreover, 
it was observed an earlier onset on the hypoglycemic effect for animals 
administered the formulation containing γ-CDC10 along with PLGA (p < 
0.01 vs ACTR at t = 0.5 hours) as well as a prolonged effect, still detected 6 
hours past the injection (p < 0.05 vs all other groups). Additionally, the AAC 
for CDPL-I was 282 ± 24, significantly higher than that observed for PL-I 
(172 ± 29) and ACTR (199 ± 22) groups. On the other hand, the AAC for PL-I 
was not statistically different from that of ACTR. 
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6.3.4.2 Oral administration to non-diabetic rats 
Data from the s.c. administration assay support the inclusion of the 
γ-CDC10 in the nanoparticle core as a means to enhance insulin’s biological 
effect. The next step was to investigate whether that formulation would 
prove beneficial in the oral administration of insulin. As depicted in Figure 
35, following the oral administration of the CDPL-I formulation to overnight 
fasted rats, no hypoglycemic effect was observed. In fact, all the test groups 
showed similar glycemic profiles throughout the experimental period 
maintaining a constant glycemia. Hence, the nanoparticle formulation was 
unable to protect insulin through the GIT.  
 
 
 
Figure 35 Glycemia profiles for non-diabetic rats after an overnight fasting. Insulin and 
placebo formulations were administered by oral gavage at time t = 0 hours at a 
dose of 100 U/kg. CTRL, CDPL, ACTR, CDPL-I as describe in the legend of 
Figure 34. 
 
Reformulation studies led to the coating of nanoparticles from the 
PLGA-γ-CDC10 blend with a copolymer from ethyl acrilate and methacrilic 
acid, which is specific for enteric delivery. Upon oral administration of the 
coated nanoparticles still no hypoglycemic effect was detected against the 
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sham nanoparticles (Figure 36) suggesting that this strategy failed to protect 
insulin from degradation in the GIT. 
 
 
Figure 36 Glycemia profiles for non-diabetic rats after an overnight fasting. Insulin-loaded 
(NPL30D-I) and sham (NPL30D) nanoparticles from the PLGA-γ-CDC10 blend 
coated with Eudragit® were administered by oral gavage at time t = 0 hours at a 
dose of 100 U/kg.  
 
6.3.4.3 Subcutaneous administration to STZ-diabetic rats 
Since the CDPL-I formulation improved insulin’s hypoglycemic 
effect when delivered to the s.c. route in non-diabetic control rats, it was 
then evaluated the effect on an animal model of type 1 DM, the STZ-diabetic 
rat. After an overnight fast the glycemia for STZ-diabetic rats was 224 ± 27 
mg/dL, significantly higher than that observed for the non-diabetic rats in 
study I. Upon the injection of the commercial insulin formulation, glycemia 
decreased progressively but, unlike the observations for the non-diabetic 
controls that could rapidly recover from the insulin-induce hypoglycemia, 
this lowering effect was sustained up until t = 4 hours. As discussed in 
chapter 3, this is probably due to the lack of appropriate glucagon response 
in the diabetic rats (Zhou et al. 2004). When the animals received the 
nanoparticle formulation instead of Actrapid®, there were no significant 
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changes in the glycemic response. In fact, the AAC were similar for both 
ACTR (399 ± 48) and CDPL-I (283 ± 41) groups.  
 
 
 
Figure 37 Glycemia profiles for STZ diabetic rats after an overnight fasting. Insulin 
formulations were administered by subcutaneous injection at time t = 0 hours at a 
dose of 2.3 U/kg. ACTR and CDPL-I as in legend of Figure 34. 
 
6.3.4.4 Oral glucose tolerance test in STZ-diabetic rats 
The performance during the OGTT is an indicator of the glucose 
disposal capacity. This test was performed in STZ-diabetic rats to establish 
the effect of insulin formulations under those circumstances. Insulin 
injection prior to the OGTT successfully prevented the raise in glycemia 
observed for the STZ-diabetic rats not injected with the hormone (Figure 
38). This effect was independent of the formulation. In fact, the AUC 
determined for ACTR (116 ± 10) was similar to that of CDPL-I (98 ± 12) and 
both were significantly lower than that of STZ-diabetic animals (339 ± 51).  
At the beginning of the study, glycemia values after 24 hours of 
fasting were 252 ± 29 mg/dL for the STZ-diabetic rats, significantly higher 
than those observed for non-diabetic controls (65 ± 4 mg/dL, see chapter 2). 
Three hours after the oral glucose load, glycemia in the STZ group remained 
elevated (336 ± 41 mg/dL) when comparing with ACTR and CDPL-I 
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groups. For the animals in the latter groups, glycemia descended to 53 ± 10 
mg/dL and 94 ± 27 mg/dL, respectively (p = n.s.). The range observed for 
the animals injected with the commercial insulin formulation was under 
that observed for non-diabetic controls in chapter 2 (86 ± 3 mg/dL, p < 0.01). 
This difficulty of STZ-diabetic rats to recover from insulin-induced 
hypoglycemia had already been observed in the studies described in 
chapter 3. Interestingly, the STZ-diabetic rats administered the nanoparticle 
formulation displayed a glycemia value within the physiological range at 
the end of the test. This effect may be related with the sustained release of 
insulin to the blood and is in good agreement with the observations from 
study I. 
 
 
 
Figure 38 Glycemia curves recorded during the OGTT performed in 24-hour fasted STZ-
dibetic rats. Insulin formulations were administered by subcutaneous injection 30 
minutes prior to the test at a dose of 5 U/kg. STZ, STZ-diabetic rats not injected 
with any formulation, ACTR and CDPL-I as in legend of Figure 34. 
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6.4 Discussion 
6.4.1 Formulation considerations 
This chapter presented the formulation development study for 
improving insulin delivery by the use of alternative delivery systems. A 
novel formulation for insulin delivery was obtained by combining two 
strategies in the pharmaceutical technology field: the use of polymeric 
nanoparticles and modified cyclodextrins. An important achievement of this 
work was the preparation of nanoparticles from two different materials 
with the ability to self-assemble individually. The nanoprecipitation 
technique allowed for both the PLGA polymer and the amphiphilic CD 
derivative γ-CDC10 to co-nanoprecipitate and form mixed nanoparticles. 
This system presented excellent association of insulin, which was due to the 
presence of the polymer in the matrix of the nanoparticle.  
 
6.4.2 Biological relevance for the inclusion of γ-CDC10 in the 
insulin nanoparticles 
The biological relevance of polymeric (from PLGA only) and mixed 
(from the PLGA-γ-CDC10 blend) formulations was first investigated in non-
diabetic controls. Those assays showed that both the nanoparticle 
formulations were able to modulate insulin action towards a more sustained 
hypoglycemic response in contrast with the peak observed when insulin 
was administered as a simple solution. This effect may result from a 
progressive release of insulin associated to the particles and/or a 
progressive absorption of the particles from the subcutaneous region to the 
blood stream. Following s.c. administration, nanoparticles and drugs are 
subjected to an absorption barrier eventually reaching systemic circulation 
via the blood capillaries or lymph vessels. Polymeric (Owens III et al. 2006) 
and CD esters-based (Gèze et al. 2007) nanoparticles accumulate mainly in 
liver and spleen upon intravenous injection. On the other hand, studies with 
solid lipid nanoparticles (Reddy et al. 2005) indicate that, in the case of s.c. 
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injection, deposition of nanoparticles in the administration site is 
responsible for delaying and lowering tissue accumulation. In this 
experiment it could be observed a rapid hypoglycemic effect following the 
subcutaneous administration of the insulin-loaded nanoparticles, which is 
consistent with progressive release of the drug from the carrier to the blood, 
with the latter remaining at the administration site, similarly to the reports 
from studies with solid lipid nanoparticles. On the other hand, the late effect 
detected at 6 hours could be attributed to insulin released from 
nanoparticles that reach the blood after a delayed absorption. It is possible 
that the presence of γ-CDC10 in the formulation promoted the passage of the 
nanoparticles to the blood allowing for the 6th hour-effect to be noted for 
this system and not for the one prepared from PLGA alone. Since many CD 
derivatives are used in drug delivery as means to promote drug absorption 
(Sharma et al. 2005) it can be hypothesized that the CD esters in the 
nanoparticles may act as absorption enhancers.  
 
6.4.3 Insulin-carrier interactions and the oral delivery 
The excellent association of insulin to the nanoparticles was not 
compromised when the formulations were diluted in water, under those 
circumstances ~90% of the amount added to the system remain associated 
to the carrier. However, upon the s.c. injection of the nanoparticle 
formulations to non-diabetic rats, most of the biological effect was observed 
in the first 2 hours, suggesting the interactions between insulin and the 
nanoparticle carrier are easily broken in vivo resulting in the fast (although 
sustained) release of the drug from the carrier. When insulin was added to a 
pre-formulated suspension of sham nanoparticles the resulting association 
efficacy was similar to that observed when the nanoparticles were prepared 
in the presence of insulin. Taken together these observations support 
adsorption interactions between insulin and hydrophilic PLGA to be the 
major forces accounting for the drug’s association to the nanoparticle 
system. This behavior most probably is a consequence of the 
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nanoprecipitation method, which employs very mild conditions. In other 
words, nanoparticles fail to afford a sufficient protection of the drug 
because the adsorption interactions accounting for insulin’s association to 
the carrier can be easily disrupted in vivo. Moreover, the weak nature of the 
insulin-carrier interaction is in perfect agreement with the lack of efficacy 
upon oral administration of the nanoparticles.  
On the other hand, there are some reports on the efficient delivery of 
insulin by the oral route by means of PLGA-based particles. For example, 
Cui et al. prepared insulin-loaded PLGA nanoparticles by nanoprecipitation 
and afforded to avoid the initial burst effect (i.e. the rapid release of insulin) 
by including a cellulose derivative for enteric coating in the formulation 
(Cui et al. 2007). Alternatively, Naha et al. report that microparticles 
prepared by the double emulsion method coated with Eudragit® effectively 
deliver insulin to the oral route (Naha et al. 2008). The coating strategy was 
also pursued in the studies described in this chapter. Eudragit® L30D55 was 
used as enteric coating but, despite the reduction on insulin release in acidic 
medium in vitro, the coated formulations did not translate into any 
hypoglycemic effect upon oral administration. Manufacture aspects such as 
the method of nanoparticle preparation or the amount of polymers in the 
system may be preventing the oral efficacy of the formulation, relative to 
the experiments from Cui et al. and Naha et al. above mentioned. However, 
increasing the PLGA concentration or the amount of coating material 
compromised the formation of nanoparticles by the method described in 
this chapter. 
 
6.4.4 Effect of insulin nanoparticles in the STZ-diabetic rat 
When the mixed nanoparticles from PLGA and γ-CDC10 were tested 
in STZ-diabetic rats, no differences could be observed when comparing its 
effect with that of the commercial insulin formulation. In the STZ-diabetic 
rat, the hypoglycemic period following insulin injection was longer than 
that observed in non-diabetic controls. These animals take more time to 
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recover from insulin-induced hypoglycemia because of the lack of 
appropriate glucagon response to hypoglycemia (Zhou et al. 2004; Cui et al. 
2007). In their studies, Zhou et al. demonstrate that for normal glucagon 
secretion to occur both hypoglycemia and a discontinuation of the insulin 
signal to the α cell (switch off hypothesis) are required (Zhou et al. 2004). 
Hence, because the physiology of the STZ-diabetic rats is quite distinct from 
that of non-diabetics a single insulin injection translates into different 
kinetics in the hypoglycemic response. Thus, the nanoparticle-induced 
sustained and prolonged hypoglycemic response that was observed in the 
case of the non-diabetic controls was probably masked in the STZ-diabetic 
rats due to the already prolonged insulin-induced hypoglycemia.  
The efficacy of the nanoparticles was yet investigated in the context 
of a glucose challenge and again no clear benefits could be attributed to the 
nanoparticle formulation for insulin delivery in STZ-diabetic rats.  
 
6.5 Conclusions 
A novel nanoparticle system for s.c. insulin delivery with high 
insulin association efficacy was successfully prepared form a mixture of 
PLGA and an amphiphilic cyclodextrin derivative (γ-CDC10). The biological 
action of insulin could be enhanced by the use of the formulation, especially 
when the cyclodextrin derivative was present. This effect was observed in 
non-diabetic control rats but not in STZ-diabetic animals. The findings from 
these experiments were strongly dependent on the animal model used. 
Because of the altered physiology of the STZ-diabetic rat, modest 
improvements in insulin delivery such as the ones observed in these studies 
may not be detected. 
In drug development, animal studies usually follow an exhaustive 
set of assays that have established an optimized formulation. In these 
studies, animal experiments were moved slightly upstream and re-
formulation was done in accordance with inputs from animal studies. This 
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allowed for re-addressing the oral route with the coating approach that 
unfortunately didn’t prove to be effective. Nonetheless, the nanoparticles 
from PLGA and γ-CDC10 promise to be a good carrier for insulin delivery 
and further formulation development should be undertaken aiming to 
strengthen the interaction between insulin and the nanoparticle matrix. For 
example, other preparation method or coating material may be envisaged. 
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CONCLUDING REMARKS 
Insulin is an absorptive state hormone acting in many target organs 
to promote energy storage. In the liver, insulin stimulates glycogen and 
lipid synthesis and inhibits glucose output after meals. These studies 
addressed postprandial hepatic metabolism in control and diabetic rats. In 
all the experiments, hyperglycemia in diabetic rats was accompanied by 
weight loss, consistent with impairments in glucose disposal and energy 
storage. Tracer-based experiments and NMR spectroscopy methods 
provided insight into the mechanisms underlying the metabolic disruptions 
resulting from the lack of insulin action.  
The transition from fasted to fed state is a rapid event and efficient 
short-term mechanisms must operate to readjust the hepatic metabolic 
fluxes from a positive glucose output to net storage under those 
circumstances. This setting was investigated in the carbohydrate challenge 
experiments described in chapters 2 and 3. In non-diabetic control rats, the 
gluconeogenic flux accounting to maintain EGP during the fasting period 
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was diverted to glycogen synthesis and this actually constituted the major 
source of glycogen in the context of the glucose challenge. Direct conversion 
of load glucose contributed to ~30% of the glycogen synthesis but this 
fraction was reduced when other preferential substrate such as galactose 
was present. Hence, hepatic glycogen is a highly dynamic pool that 
constitutes a “first line” response in the recuperation of glucose homeostasis 
after nutritional challenges. Efficient glycogen deposition was parallel to a 
rapid clearence of glucose from the blood, and at the end of the test, EGP 
accounted for the majority (~75%) of plasma glucose in non-diabetic rats. 
This mechanism is necessary to avoid hypoglycemia resulting from a 
continuous glucose uptake from the blood. Under natural feeding 
conditions, with constant glucose provision from food intake, EGP 
contributed to only 40% of plasma glucose. 
Diabetic rats have high rates of EGP essentially due to unrestrained 
gluconeogenesis.  Their hepatic glycogen levels do not fall during fasting 
demonstrating an inability to mobilize hepatic glycogen stores for glucose 
production. Nonetheless, under normal feeding conditions there was a 
significant turnover of hepatic glycogen in the diabetic rats, indicating that a 
futile cycle of glycogen breakdown and synthesis is taking place. In non-
diabetic controls the depletion/replenishment are harmonized with the 
fasting/(re)feeding cycles but that dynamic is no longer observed in the 
diabetics. Without insulin, the hepatic glycogen pool was unresponsive to 
fasting, at least in the 24-hour period. Moreover, it also lost the capacity to 
receive the gluconeogenic flux in response to a glucose load. 
In diabetic rats, inefficient glycogen deposition after a glucose load 
was parallel to elevated EGP and reduced clearance form the blood, 
resulting in persistent hyperglycemia at the end of the 3-hour glucose 
tolerance test. A single insulin dose had no effect on improving glycogen 
synthesis in that context but efficiently controlled the contribution of EGP to 
plasma glucose levels. However, the most striking action of insulin was to 
stimulate peripheral glucose uptake. As a consequence, plasma glucose 
Concluding remarks|147 
levels decreased drastically and the animals were in fact hypoglycemic for 
at least 3-hours after the load. 
After a period of insulin replacement for 10 days, pathways for 
energy storage were enhanced but diabetic animals still experienced 
abnormal catabolic events like high gluconeogenic and lipolytic fluxes 
during feeding. This could be a consequence of insufficient or inappropriate 
insulinization and other therapeutic protocols should be studied to 
determine whether an efficient glycemic control by insulin replacement is 
able to normalize all the metabolic disruptions in diabetic rats. With the 
insulin treatments applied, the pathways for hepatic glycogen synthesis in 
the diabetic rats were restored to control levels but the hepatic glycogen 
content was only completely recovered when insulin was delivered to the 
i.p. route. Thus, targeting insulin to the liver translated into differential 
benefits on the hepatic glycogen storage. TG metabolism was also sensitive 
to insulin replacement, which translated into a reduction of plasma TGs and 
an increase in de novo hepatic TGs. 
In the context of insulin formulation development, animal studies 
are simple and straightforward assays that measure a specific 
pharmacological response, which in the case of insulin typically is the 
hypoglycemic effect. These assays are important in establishing the 
biological interest of a particular formulation and should be integrated with 
formulation re-assessments for optimizing drug delivery. In the 
experimental work of this thesis, a novel nanoparticle formulation for 
insulin delivery was developed and its biological relevance demonstrated in 
a simple animal experimental setting, but those findings were not 
reproduced when a more complex diabetic rat model was studied and 
further formulation development is required. After 
formulation/reformulation studies, animal experiments should include the 
assays for addressing the hepatic metabolic effects of insulin in the 
postabsorptive state to determine whether liver-targeted insulin action can 
be afforded. 
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